taurine has been researched along with Disease Models, Animal in 368 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Experimental data suggest strongly that taurine could have beneficial effects in type 1 diabetes mellitus, and could generally reduce organ lipid peroxidation and plasma lipids." | 8.83 | Taurine supplementation and diabetes mellitus. ( Franconi, F; Ghirlanda, G; Loizzo, A; Seghieri, G, 2006) |
| "As a non-toxic endogenous antioxidant, the semi-essential amino acid taurine is a potential attenuator of oxidative damage such as that produced by ischaemia-reperfusion injury." | 8.82 | The therapeutic role of taurine in ischaemia-reperfusion injury. ( Kelly, CJ; Kingston, R; Murray, P, 2004) |
| "The study employed a rat model to examine the effects of taurine (Tau) on prevention and therapy of non-alcoholic fatty liver disease (NAFLD)." | 8.02 | Taurine Reduces Liver Damage in Non-Alcoholic Fatty Liver Disease Model in Rats by Down-Regulating IL-9 and Tumor Growth Factor TGF-β. ( Chen, XQ; Huang, L; Lan, LC; Liang, G; Lv, ZL; Shan, QW; Tang, Q; Yang, MX; Yao, Z; Zhu, FL, 2021) |
| " We aimed to evaluate the protective role of taurine (TAU), a beta amino acid with antioxidant activity, against DOXO-induced cardiotoxicity in a rat model." | 7.91 | Protective effect of taurine against doxorubicin-induced cardiotoxicity in rats: echocardiographical and histological findings. ( Barış, VÖ; Erdem, A; Gedikli, E; Müftüoğlu, S; Yersal, N, 2019) |
| "Several off-label studies have shown that acamprosate can provide some clinical benefits in youth with Fragile X Syndrome (FXS), an autism spectrum disorder caused by loss of function of the highly conserved FMR1 gene." | 7.88 | Acamprosate rescues neuronal defects in the Drosophila model of Fragile X Syndrome. ( Bantel, AP; Hutson, RL; Tessier, CR; Thompson, RL, 2018) |
| "Taurine (2-aminoethansulfolic amino acid) exerts neuroprotective actions in experimental stroke." | 7.88 | Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat. ( Jin, R; Li, G; Liu, S; Wang, M; Xiao, AY, 2018) |
| " Furthermore, we assessed the therapeutic effects of taurine on ovalbumin (OVA)-induced allergic rhinitis (AR) animal models." | 7.85 | The potential protective role of taurine against experimental allergic inflammation. ( Jeong, HJ; Kim, HM; Nam, SY, 2017) |
| "This study investigated the protective effect of subacute pre-adminsitration of either selenium (Se), taurine (Tau), or both drugs in combination against experimentally induced myocardial infarction (MI) in rats and illustrates the possible mechanisms of action." | 7.85 | A synergistic protective effect of selenium and taurine against experimentally induced myocardial infarction in rats. ( Dallak, M, 2017) |
| "Latrunculin A microperfusion of the hippocampus induces acute epileptic seizures and long-term biochemical changes leading to spontaneous seizures." | 7.80 | Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. ( Loureiro, AI; Sierra-Marcuño, G; Sierra-Paredes, G; Soares-da-Silva, P; Wright, LC, 2014) |
| "The aim of this study was to investigate the protective effects of taurine (Tau) on experimental acute pancreatitis (AP) in a rat model by measuring cytokines and oxidant stress markers." | 7.79 | The protective effects of taurine on experimental acute pancreatitis in a rat model. ( Agilli, M; Akay, C; Akgul, EO; Aydin, I; Cakir, E; Eken, A; Eyi, YE; Kaldirim, U; Ozkan, Y; Oztas, E; Oztosun, M; Poyrazoglu, Y; Tuncer, SK; Yaman, H; Yasar, M; Yildirim, AO, 2013) |
| "Taurine is reported to reduce tissue damage induced by inflammation and to protect the brain against experimental stroke." | 7.78 | Anti-inflammatory mechanism of taurine against ischemic stroke is related to down-regulation of PARP and NF-κB. ( Gu, Y; Sun, M; Xu, C; Zhao, Y, 2012) |
| "The effects of taurine supplementation on the serum cholesterol levels and the progression of atherosclerosis were investigated in the hyperlipidemia- and atherosclerosis-prone Japanese (LAP) quail." | 7.76 | Prevention of hypercholesterolemia and atherosclerosis in the hyperlipidemia- and atherosclerosis-prone Japanese (LAP) quail by taurine supplementation. ( Fukuda, N; Murakami, S; Nasu, T; Sakono, M; Sakurai, T; Tomoike, H, 2010) |
| "Our results suggest that taurine attenuates endoplasmic reticulum stress-induced apoptosis in the lungs of rats after limb ischemia reperfusion." | 7.76 | Taurine protects against lung damage following limb ischemia reperfusion in the rat by attenuating endoplasmic reticulum stress-induced apoptosis. ( Cao, G; Gao, J; Han, S; Lu, H; Men, X; Pu, J; Yu, H; Zhang, L, 2010) |
| " Glycine or muscimol reduced bicuculline-induced allodynia regardless of the administration site, whereas intrathecal taurine reduced bicuculline-induced allodynia." | 7.76 | Intracisternal or intrathecal glycine, taurine, or muscimol inhibit bicuculline-induced allodynia and thermal hyperalgesia in mice. ( Lee, IO; Lim, ES, 2010) |
| "An experimental model based on kainic acid (KA) injections replicates many phenomenological features of human temporal lobe epilepsy, the most common type of epilepsy in adults." | 7.75 | Prevention of epilepsy by taurine treatments in mice experimental model. ( Auladell, C; Camins, A; Duque, D; Junyent, F; Pallàs, M; Romero, R; Utrera, J, 2009) |
| "To study the effects of different doses of taurine (Tau) on calcium ion concentration ([Ca2+]i) and ATPase on cardiocyte membrane of diastole heart failure rats." | 7.75 | [Antagonism for different doses of taurine on calcium overload in myocardial cells of diastole heart failure rat model]. ( Qu, Y; Zhang, Q; Zhang, T; Zhang, X, 2009) |
| "To observe and compare the effect of taurine on contractions of aortic rings isolated from normal (NC) and insulin resistance (IR) Sprague-Dawley rats, and to explore its underlying mechanism(s)." | 7.74 | Effects of taurine on aortic rings isolated from fructose-fed insulin resistance Sprague-Dawley rat are changed. ( Li, J; Liang, Y; Niu, L; Wu, D; Xue, W; Zhang, M, 2008) |
| "We examined the effects of peritoneal instillation (INST, 5-ml solution) with taurolidine (TAURO) or polihexanide (POLI-LS) on intestinal microcirculation using intravital microscopy (IVM) in experimental endotoxemia (15 mg/kg lipopolysaccharide i." | 7.74 | Peritoneal instillation of taurolidine or polihexanide modulates intestinal microcirculation in experimental endotoxemia. ( Frieling, H; Gründling, M; Kanellopoulou, T; Lauer, KS; Lehmann, C; Meissner, K; Pavlovic, D; Usichenko, T; Wendt, M, 2007) |
| "The effects of dietary taurine on the experimental colitis induced by dextran sulfate sodium (DSS) in mice were evaluated." | 7.74 | Attenuation by dietary taurine of dextran sulfate sodium-induced colitis in mice and of THP-1-induced damage to intestinal Caco-2 cell monolayers. ( Fujisawa, M; Hori, M; Ishimoto, Y; Kakuta, S; Nambu, A; Ozaki, H; Satsu, H; Shimizu, M; Totsuka, M; Zhao, Z, 2008) |
| " We investigated whether taurine, an endogenous antioxidant and vasodilator, could attenuate the deleterious effects of endotoxin in a mouse model of sepsis." | 7.74 | The effect of taurine on mesenteric blood flow and organ injury in sepsis. ( Akbiyik, F; Atilla, P; Balkanci, ZD; Cakar, N; Erdem, A; Guc, MO; Iskit, AB; Sevgili, AM, 2008) |
| "Taurolidine is a broad-spectrum, non antibiotic antimicrobial agent, not previously tested against the common causes of bacterial keratitis." | 7.73 | Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. ( Gurkan, T; Oguz, E; Oguz, H; Ozbilge, H, 2005) |
| "The higher bursting pressures and tissue hydroxyproline levels in the rats given taurolidine showed the positive effect of taurolidine on anastomotic strength in secondary peritonitis." | 7.73 | Effect of peritoneal lavage with taurolidine on primary colonic anastomosis in a rat model of secondary peritonitis. ( Akkuş, A; Barişik, NO; Bildik, N; Cevik, A; Gülmen, M; Oztürk, E; Sad, O, 2006) |
| " The aim of this study was to investigate the effects of taurine on oxidative capacity and fibrosis in experimental chronic rat pancreatic fibrosis." | 7.73 | Antioxidant treatment with taurine ameliorates chronic pancreatitis in an experimental rat model. ( Akay, C; Comert, B; Deveci, S; Inal, V; Isik, AT; Mas, MR; Mas, N; Tasci, I; Yamanel, L, 2006) |
| "To explore the molecular mechanism of neural tube defects (NTDs) caused by hyperglycemia and thiadiazole and the antagonistic effect of taurine." | 7.72 | [Study of teratogenicity of hyperglycemia on neural tube defects and antagonistic effect of taurine]. ( Che, JH; Li, SR; Mao, DW; Tan, WH; Zhao, YP, 2004) |
| "Intravenous injection of chloramine derivatives of amino acids and taurine reduced the mortality rate in mice with thrombosis induced by intravenous injection of ADP or collagen-epinephrine mixture." | 7.71 | Antithrombotic activity of N,N-dichlorotaurine on mouse model of thrombosis in vivo. ( Chudina, NA; Fesenko, OD; Murina, MA; Roshchupkin, DI; Sergienko, VI, 2002) |
| "The effects of taurine on insulin sensitivity were examined in a model rat of insulin resistance and type 2 diabetes-the Otsuka Long-Evans Tokushima Fatty (OLETF) rat." | 7.70 | Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes. ( Harada, N; Minami, A; Nakaya, Y; Niwa, Y; Ohnaka, M; Sakamoto, S, 2000) |
| "Taurine and niacin have been previously found to block the accumulation of collagen in lung in the multidose bleomycin hamster model of pulmonary fibrosis." | 7.69 | Dietary supplementation with taurine and niacin prevents the increase in lung collagen cross-links in the multidose bleomycin hamster model of pulmonary fibrosis. ( Blaisdell, RJ; Giri, SN; Schiedt, MJ, 1994) |
| "The early-weaned pig develops intestinal atrophy and provides a readily accessible animal model for determining the role of dietary supplementation of glutamine (Gln, a major fuel for enterocytes) in preventing intestinal damage." | 7.69 | Dietary glutamine supplementation prevents jejunal atrophy in weaned pigs. ( Knabe, DA; Meier, SA; Wu, G, 1996) |
| "The therapeutic effects of 2-aminoethanesulfonic acid (taurine) were tested in animals with congestive heart failure (HF) simulated by aortic valve damage." | 7.68 | [Use of taurine in the treatment of experimental congestive heart failure]. ( Elizarova, EP; Fetisova, NI; Mit'kina, LI; Orlova, TsR; Ryff, IM, 1991) |
| " Severe hyponatremia and hypoosmolality induced profound decreases in levels of brain electrolytes, amino acids (especially taurine), and creatine." | 7.67 | Adaptive decreases in amino acids (taurine in particular), creatine, and electrolytes prevent cerebral edema in chronically hyponatremic mice: rapid correction (experimental model of central pontine myelinolysis) causes dehydration and shrinkage of brain. ( Hauhart, RE; Nelson, JS; Thurston, JH, 1987) |
| "Myocardial taurine levels were correlated with pulmonary wedge pressure (PWP) in dogs with congestive heart failure (CHF)." | 7.65 | A relation between myocardial taurine contest and pulmonary wedge pressure in dogs with heart failure. ( Bressler, R; Frangakis, CJ; Grosso, DS; Newman, WH, 1977) |
| "Taurine is a sulfur-containing amino acid that is present in mammalian tissues in millimolar concentrations." | 6.52 | Role of taurine in the pathogenesis of obesity. ( Murakami, S, 2015) |
| "Atherosclerosis is the underlying mechanism of cardiovascular disease including myocardial infarctions, strokes and peripheral artery disease and remains a major cause of morbidity and mortality worldwide." | 6.50 | Taurine and atherosclerosis. ( Murakami, S, 2014) |
| "Oral taurine treatment has been studied extensively as a hypotensive agent." | 6.41 | Treatment of hypertension with oral taurine: experimental and clinical studies. ( Lombardini, JB; Militante, JD, 2002) |
| "Taurine treatment normalized the expression levels of γ-glutamyl ligase C/M, GS, OPLAH, and glyoxalase-1, and reversed HCU-induced deficits in protein glutathionylation by acting to double GSH levels relative to controls." | 5.48 | Taurine treatment prevents derangement of the hepatic γ-glutamyl cycle and methylglyoxal metabolism in a mouse model of classical homocystinuria: regulatory crosstalk between thiol and sulfinic acid metabolism. ( Aivazidis, S; Allen, RH; Harris, PS; Jiang, H; Kim, E; Maclean, KN; Petersen, DR; Roede, JR; Shearn, CT; Stabler, SP, 2018) |
| "Treatment with taurine prevents gut mucosal damage and inhibits intestinal epithelial cell apoptosis following intestinal IR in a rat." | 5.43 | Effect of taurine on intestinal recovery following intestinal ischemia-reperfusion injury in a rat. ( Aranovich, I; Ben Shahar, Y; Berkowitz, D; Bitterman, A; Bitterman, N; Chepurov, D; Coran, AG; Pollak, Y; Sukhotnik, I, 2016) |
| "Taurine has also been shown to reduce lenticular oxidative stress." | 5.39 | Effects of magnesium taurate on the onset and progression of galactose-induced experimental cataract: in vivo and in vitro evaluation. ( Abdul Rahman, TH; Agarwal, P; Agarwal, R; Ahmad Fisol, NF; Awaludin, NA; Bakar, NS; Iezhitsa, I; Mohamed Ahmed Salama, MS; Mohd Ismail, N; Ozerov, A; Spasov, A, 2013) |
| "Maternal obesity is associated with obesity and metabolic disorders in offspring." | 5.39 | Effects of taurine supplementation on hepatic markers of inflammation and lipid metabolism in mothers and offspring in the setting of maternal obesity. ( Gray, C; Li, M; Reynolds, CM; Sloboda, DM; Vickers, MH, 2013) |
| "Taurine is an inhibitory neurotransmitter and is one of the most abundant amino acids present in the mammalian nervous system." | 5.39 | The mechanism of taurine protection against endoplasmic reticulum stress in an animal stroke model of cerebral artery occlusion and stroke-related conditions in primary neuronal cell culture. ( Chen, PC; Gharibani, PM; Ma, Z; Menzie, J; Modi, J; Pan, C; Prentice, H; Tao, R; Wu, JY, 2013) |
| "Taurine is an organic acid, which has a very important function in the human body." | 5.37 | Effects of taurine on reperfusion injury. ( Akdemir, O; Arslan, Z; Hede, Y; Lineaweaver, WC; Songur, E; Zhang, F, 2011) |
| "Taurine treatment alleviated the oxidative injury of the kidney, improved SOD and GSH-Px activities, as well as the mitochondrial membrane injury, with lesser crystal depositions in the kidney." | 5.35 | Taurine protected kidney from oxidative injury through mitochondrial-linked pathway in a rat model of nephrolithiasis. ( Deng, YL; Li, CY; Sun, BH, 2009) |
| "Paraoxonase activity has been reported to decrease in several situations associated with atherosclerosis and oxidative stress." | 5.34 | High-dose taurine supplementation increases serum paraoxonase and arylesterase activities in experimental hypothyroidism. ( Dirican, M; Sarandöl, E; Taş, S, 2007) |
| "Ischemia-reperfusion injury is of major clinical relevance during liver transplantation." | 5.33 | Taurine protects against ischemia-reperfusion injury in rabbit livers. ( Jiang, H; Li, J; Meng, F; Qiao, H; Sun, X; Tong, L, 2006) |
| "Taurolidine has significant antineoplastic activity against MM in vitro and in vivo, in part, due to tumor cell apoptosis." | 5.32 | The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. ( Calabresi, P; Monfils, B; Nici, L, 2004) |
| "Acute pancreatitis was induced by administering three subcutaneous injections of cerulein (40 microg/kg body weight) at 1-hour intervals, while taurine was administered intravenously at graded doses (30, 100, or 300 mg/kg, respectively) following the first cerulein injection." | 5.31 | Effects of taurine on cerulein-induced acute pancreatitis in the rat. ( Ahn, BO; Hyun, JH; Kim, CD; Kim, KH; Kim, WB; Kim, YS; Lee, G; Lee, HS; Oh, TY; Son, MW, 2001) |
| "Taurine treated rats showed levels of MDA not different from untreated rats after RS; also no differences were observed concerning enzyme concentrations and ammonia levels." | 5.30 | No beneficial effects of taurine application on oxygen free radical production after hemorrhagic shock in rats. ( Isselhard, W; Minor, T; Niessen, F, 1998) |
| "Neither streptozotocin diabetes nor taurine in the diet appeared to affect the weight of the lenses." | 5.30 | Modelling cortical cataractogenesis 21: in diabetic rat lenses taurine supplementation partially reduces damage resulting from osmotic compensation leading to osmolyte loss and antioxidant depletion. ( Dzialoszynski, T; Linklater, HA; Mitton, KP; Sanford, SE; Starkey, K; Trevithick, JR, 1999) |
| " A number of studies provide the evidence that taurine has the efficient action to reduce plasma and liver cholesterol concentrations, especially to decrease VLDL and LDL cholesterol in hypercholesterolemia animal induced by high cholesterol diet." | 4.88 | The effect of taurine on cholesterol metabolism. ( Chang, P; Chen, W; Guo, JX, 2012) |
| "Experimental data suggest strongly that taurine could have beneficial effects in type 1 diabetes mellitus, and could generally reduce organ lipid peroxidation and plasma lipids." | 4.83 | Taurine supplementation and diabetes mellitus. ( Franconi, F; Ghirlanda, G; Loizzo, A; Seghieri, G, 2006) |
| "As a non-toxic endogenous antioxidant, the semi-essential amino acid taurine is a potential attenuator of oxidative damage such as that produced by ischaemia-reperfusion injury." | 4.82 | The therapeutic role of taurine in ischaemia-reperfusion injury. ( Kelly, CJ; Kingston, R; Murray, P, 2004) |
| " The presentations were (1) Pharmacological validation of a new animal model of alcoholism, by Rainer Spanagel; (2) Persisting loss of control as main criterion for alcohol addiction in rats and mice, by Jochen Wolffgramm; (3) Role of NMDA receptor subunits associated with protein kinase C in the prevention of alcohol dependence, by Minoru Narita; (4) Long-term follow up of continued naltrexone treatment, by David Sinclair; (5) Pharmacological treatment trials with dopaminergic and serotonergic substances: Myths or facts? by Gerhard A." | 4.81 | Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials. ( Boening, JA; Lesch, OM; Mason, BJ; Narita, M; Sinclair, D; Spanagel, R; Wiesbeck, GA; Wolffgramm, J, 2001) |
| " These included cortisol, 3-hydroxybutyric acid, taurine, esculin and uric acid, which are closely associated with osteoporosis." | 4.31 | Metabolomics analysis of the potential mechanism of Yi-Guan-Jian decoction to reverse bone loss in glucocorticoid-induced osteoporosis. ( Jia, F; Li, J; Li, X; Su, X; Sun, R; Yin, M; Zhou, D, 2023) |
| "In the histological examination, on the 3rd, 7th and 21st days, inflammation was found to be reduced in the groups given taurine and apocynin on the 3rd day." | 4.12 | Effects of taurine and apocynin on the zone of stasis. ( Abbas Ali Noma, S; Fırat, C; Öcük, Ö; Özhan, O; Parlakpınar, H; Ulu, A; Vardı, N; Yıldız, A, 2022) |
| "The study employed a rat model to examine the effects of taurine (Tau) on prevention and therapy of non-alcoholic fatty liver disease (NAFLD)." | 4.02 | Taurine Reduces Liver Damage in Non-Alcoholic Fatty Liver Disease Model in Rats by Down-Regulating IL-9 and Tumor Growth Factor TGF-β. ( Chen, XQ; Huang, L; Lan, LC; Liang, G; Lv, ZL; Shan, QW; Tang, Q; Yang, MX; Yao, Z; Zhu, FL, 2021) |
| " L-glutamine supplementation failed to rectify taurine biosynthesis or CSAD protein expression, but worsened CKD (proteinuria in NxT 12." | 4.02 | Hepatic cysteine sulphinic acid decarboxylase depletion and defective taurine metabolism in a rat partial nephrectomy model of chronic kidney disease. ( Abbasian, N; Bevington, A; Brown, J; Bursnall, D; Ghaderi-Najafabadi, M; Pawluczyk, I; Seymour, AM; Watson, E; Yu Si, L, 2021) |
| "These findings suggest that glutathione depletion with BSO may be a useful model to mimic ARN and dietary intake of taurine, may have an important role in decelerating the process of cataract formation." | 4.02 | Taurine supplementation protects lens against glutathione depletion. ( Kerry, Z; Ozsarlak-Sozer, G; Sevin, G; Sozer, N, 2021) |
| "Endothelin-1 (ET-1), a potent vasoconstrictor, plays a significant role in the pathophysiology of ocular conditions like glaucoma." | 3.96 | Magnesium acetyltaurate protects against endothelin-1 induced RGC loss by reducing neuroinflammation in Sprague dawley rats. ( Agarwal, P; Agarwal, R; Iezhitsa, I; Ismail, NM; Nor Arfuzir, NN, 2020) |
| "We investigated the antidepressant effect of creatine (CRE) and taurine (TAU) mixtures on behavioural changes and biomarkers in stress-induced depression in Drosophila melanogaster and a mouse model." | 3.96 | Creatine and taurine mixtures alleviate depressive-like behaviour in Drosophila melanogaster and mice via regulating Akt and ERK/BDNF pathways. ( Hong, KB; Jo, K; Kim, S; Suh, HJ, 2020) |
| " We aimed to evaluate the protective role of taurine (TAU), a beta amino acid with antioxidant activity, against DOXO-induced cardiotoxicity in a rat model." | 3.91 | Protective effect of taurine against doxorubicin-induced cardiotoxicity in rats: echocardiographical and histological findings. ( Barış, VÖ; Erdem, A; Gedikli, E; Müftüoğlu, S; Yersal, N, 2019) |
| "Several off-label studies have shown that acamprosate can provide some clinical benefits in youth with Fragile X Syndrome (FXS), an autism spectrum disorder caused by loss of function of the highly conserved FMR1 gene." | 3.88 | Acamprosate rescues neuronal defects in the Drosophila model of Fragile X Syndrome. ( Bantel, AP; Hutson, RL; Tessier, CR; Thompson, RL, 2018) |
| "Taurine (2-aminoethansulfolic amino acid) exerts neuroprotective actions in experimental stroke." | 3.88 | Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat. ( Jin, R; Li, G; Liu, S; Wang, M; Xiao, AY, 2018) |
| " Furthermore, we assessed the therapeutic effects of taurine on ovalbumin (OVA)-induced allergic rhinitis (AR) animal models." | 3.85 | The potential protective role of taurine against experimental allergic inflammation. ( Jeong, HJ; Kim, HM; Nam, SY, 2017) |
| "This study investigated the protective effect of subacute pre-adminsitration of either selenium (Se), taurine (Tau), or both drugs in combination against experimentally induced myocardial infarction (MI) in rats and illustrates the possible mechanisms of action." | 3.85 | A synergistic protective effect of selenium and taurine against experimentally induced myocardial infarction in rats. ( Dallak, M, 2017) |
| "Emerging evidence has suggested that hydrogen sulfide (H2S) may alleviate the cellular damage associated with cerebral ischemia/reperfusion (I/R) injury." | 3.85 | The administration of hydrogen sulphide prior to ischemic reperfusion has neuroprotective effects in an acute stroke model. ( Choi, CG; Choi, Y; Ha, HK; Ham, SJ; Jeon, SB; Jung, SC; Kim, J; Kim, JK; Kim, KW; Kim, ST; Kwon, JI; Shim, WH; Sung, YS; Woo, CW; Woo, DC, 2017) |
| " The purpose of this study was to evaluate the neuroprotective potential of RGC death induced by the in vivo transient increase in intraocular pressure (IOP) of a combined treatment with forskolin, homotaurine, and L-carnosine." | 3.81 | Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury. ( Adornetto, A; Bagetta, G; Cavaliere, F; Corasaniti, MT; Morrone, LA; Nucci, C; Rusciano, D; Russo, R; Varano, GP, 2015) |
| "Latrunculin A microperfusion of the hippocampus induces acute epileptic seizures and long-term biochemical changes leading to spontaneous seizures." | 3.80 | Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. ( Loureiro, AI; Sierra-Marcuño, G; Sierra-Paredes, G; Soares-da-Silva, P; Wright, LC, 2014) |
| "The aim of this study was to investigate the protective effects of taurine (Tau) on experimental acute pancreatitis (AP) in a rat model by measuring cytokines and oxidant stress markers." | 3.79 | The protective effects of taurine on experimental acute pancreatitis in a rat model. ( Agilli, M; Akay, C; Akgul, EO; Aydin, I; Cakir, E; Eken, A; Eyi, YE; Kaldirim, U; Ozkan, Y; Oztas, E; Oztosun, M; Poyrazoglu, Y; Tuncer, SK; Yaman, H; Yasar, M; Yildirim, AO, 2013) |
| "Taurine is reported to reduce tissue damage induced by inflammation and to protect the brain against experimental stroke." | 3.78 | Anti-inflammatory mechanism of taurine against ischemic stroke is related to down-regulation of PARP and NF-κB. ( Gu, Y; Sun, M; Xu, C; Zhao, Y, 2012) |
| "The aim of the present study was to evaluate the preventive effects of taurine (TAU) supplementation upon monosodium glutamate (MSG)-induced obesity." | 3.77 | Taurine prevents fat deposition and ameliorates plasma lipid profile in monosodium glutamate-obese rats. ( Balbo, SL; Bonfleur, ML; Boschero, AC; Carneiro, EM; Nardelli, TR; Ribeiro, RA; Vanzela, EC, 2011) |
| "Taurine alleviated mechanical allodynia, mechanical hyperalgesia, and thermal hyperalgesia in CCI rats and suppressed mechanical allodynia and hyperalgesia in diabetic rats." | 3.77 | Antinociceptive effect of intrathecal administration of taurine in rat models of neuropathic pain. ( Hara, K; Haranishi, Y; Sata, T; Terada, T, 2011) |
| "The effects of taurine supplementation on the serum cholesterol levels and the progression of atherosclerosis were investigated in the hyperlipidemia- and atherosclerosis-prone Japanese (LAP) quail." | 3.76 | Prevention of hypercholesterolemia and atherosclerosis in the hyperlipidemia- and atherosclerosis-prone Japanese (LAP) quail by taurine supplementation. ( Fukuda, N; Murakami, S; Nasu, T; Sakono, M; Sakurai, T; Tomoike, H, 2010) |
| "Our results suggest that taurine attenuates endoplasmic reticulum stress-induced apoptosis in the lungs of rats after limb ischemia reperfusion." | 3.76 | Taurine protects against lung damage following limb ischemia reperfusion in the rat by attenuating endoplasmic reticulum stress-induced apoptosis. ( Cao, G; Gao, J; Han, S; Lu, H; Men, X; Pu, J; Yu, H; Zhang, L, 2010) |
| " Food and Drug Administration (FDA) for use in the treatment of alcohol abuse and alcoholism--disulfiram, naltrexone, and acamprosate." | 3.76 | Pharmacotherapies for alcoholism: the old and the new. ( Olive, MF, 2010) |
| " Glycine or muscimol reduced bicuculline-induced allodynia regardless of the administration site, whereas intrathecal taurine reduced bicuculline-induced allodynia." | 3.76 | Intracisternal or intrathecal glycine, taurine, or muscimol inhibit bicuculline-induced allodynia and thermal hyperalgesia in mice. ( Lee, IO; Lim, ES, 2010) |
| "An experimental model based on kainic acid (KA) injections replicates many phenomenological features of human temporal lobe epilepsy, the most common type of epilepsy in adults." | 3.75 | Prevention of epilepsy by taurine treatments in mice experimental model. ( Auladell, C; Camins, A; Duque, D; Junyent, F; Pallàs, M; Romero, R; Utrera, J, 2009) |
| "We sought to determine whether taurine could specifically protect against coronary artery disease during an atherogenic diet and whether taurine affects the lipid profile, metabolites of methionine, and endothelial atherogenic systems." | 3.75 | High dietary taurine reduces apoptosis and atherosclerosis in the left main coronary artery: association with reduced CCAAT/enhancer binding protein homologous protein and total plasma homocysteine but not lipidemia. ( Carru, C; Hare, DL; Jin, X; Lau, E; Learmont, J; Schwartz, GD; Sutarga, K; Wijaya, BP; Wookey, PJ; Zinellu, A; Zulli, A, 2009) |
| "To study the effects of different doses of taurine (Tau) on calcium ion concentration ([Ca2+]i) and ATPase on cardiocyte membrane of diastole heart failure rats." | 3.75 | [Antagonism for different doses of taurine on calcium overload in myocardial cells of diastole heart failure rat model]. ( Qu, Y; Zhang, Q; Zhang, T; Zhang, X, 2009) |
| "To observe and compare the effect of taurine on contractions of aortic rings isolated from normal (NC) and insulin resistance (IR) Sprague-Dawley rats, and to explore its underlying mechanism(s)." | 3.74 | Effects of taurine on aortic rings isolated from fructose-fed insulin resistance Sprague-Dawley rat are changed. ( Li, J; Liang, Y; Niu, L; Wu, D; Xue, W; Zhang, M, 2008) |
| "We examined the effects of peritoneal instillation (INST, 5-ml solution) with taurolidine (TAURO) or polihexanide (POLI-LS) on intestinal microcirculation using intravital microscopy (IVM) in experimental endotoxemia (15 mg/kg lipopolysaccharide i." | 3.74 | Peritoneal instillation of taurolidine or polihexanide modulates intestinal microcirculation in experimental endotoxemia. ( Frieling, H; Gründling, M; Kanellopoulou, T; Lauer, KS; Lehmann, C; Meissner, K; Pavlovic, D; Usichenko, T; Wendt, M, 2007) |
| " Taurine may have been released by the tissues as a protective mechanism against hypoxia-induced inflammation, or in an attempt to maintain osmotic balance." | 3.74 | Taurine as a marker for foetal wellbeing? ( de Boo, HA; Harding, JE, 2007) |
| "The effects of dietary taurine on the experimental colitis induced by dextran sulfate sodium (DSS) in mice were evaluated." | 3.74 | Attenuation by dietary taurine of dextran sulfate sodium-induced colitis in mice and of THP-1-induced damage to intestinal Caco-2 cell monolayers. ( Fujisawa, M; Hori, M; Ishimoto, Y; Kakuta, S; Nambu, A; Ozaki, H; Satsu, H; Shimizu, M; Totsuka, M; Zhao, Z, 2008) |
| "The ventilatory response to hypoxia is influenced by the balance between inhibitory (GABA, glycine, and taurine) and excitatory (glutamate and aspartate) brainstem amino acid (AA) neurotransmitters." | 3.74 | Brainstem amino acid neurotransmitters and ventilatory response to hypoxia in piglets. ( Bancalari, E; Devia, CJ; Hehre, DA; Suguihara, C, 2008) |
| " We investigated whether taurine, an endogenous antioxidant and vasodilator, could attenuate the deleterious effects of endotoxin in a mouse model of sepsis." | 3.74 | The effect of taurine on mesenteric blood flow and organ injury in sepsis. ( Akbiyik, F; Atilla, P; Balkanci, ZD; Cakar, N; Erdem, A; Guc, MO; Iskit, AB; Sevgili, AM, 2008) |
| "Taurolidine is a broad-spectrum, non antibiotic antimicrobial agent, not previously tested against the common causes of bacterial keratitis." | 3.73 | Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. ( Gurkan, T; Oguz, E; Oguz, H; Ozbilge, H, 2005) |
| "0% taurolidine on the invasion of 1 x 10(5) CC531 adenocarcinoma cells." | 3.73 | Impact of taurolidine on the growth of CC531 coloncarcinoma cells in vitro and in a laparoscopic animal model in rats. ( Krüger, S; Lippert, H; Nestler, G; Pross, M; Schubert, D; Schulz, HU, 2005) |
| "A total of 130 healthy adult Wistar rats were randomly divided into 3 groups: the control group (C, without burns), the burn group (B, subjected to a 30% TBSA III degree scalding) and the treatment group (T, treated with intraperitoneal injection of taurine (400 mg/kg) immediately after scald injury)." | 3.73 | [Protective effects of taurine on myocardial injury in severely burned rats]. ( Li, GH; Wan, FS, 2005) |
| "The aim of this study was to evaluate the beta-endorphin (beta-endorphin) plasma level in Warsaw Low Preferring (WLP) and Warsaw high-preferring (WHP) rats after repeated administration of acamprosate, one of most effective drug in the treatment of alcoholism." | 3.73 | Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference. ( Cwiek, W; Czarnecka, E; Dyr, W; Zalewska-Kaszubska, J, 2005) |
| "The higher bursting pressures and tissue hydroxyproline levels in the rats given taurolidine showed the positive effect of taurolidine on anastomotic strength in secondary peritonitis." | 3.73 | Effect of peritoneal lavage with taurolidine on primary colonic anastomosis in a rat model of secondary peritonitis. ( Akkuş, A; Barişik, NO; Bildik, N; Cevik, A; Gülmen, M; Oztürk, E; Sad, O, 2006) |
| " The aim of this study was to investigate the effects of taurine on oxidative capacity and fibrosis in experimental chronic rat pancreatic fibrosis." | 3.73 | Antioxidant treatment with taurine ameliorates chronic pancreatitis in an experimental rat model. ( Akay, C; Comert, B; Deveci, S; Inal, V; Isik, AT; Mas, MR; Mas, N; Tasci, I; Yamanel, L, 2006) |
| "To explore the molecular mechanism of neural tube defects (NTDs) caused by hyperglycemia and thiadiazole and the antagonistic effect of taurine." | 3.72 | [Study of teratogenicity of hyperglycemia on neural tube defects and antagonistic effect of taurine]. ( Che, JH; Li, SR; Mao, DW; Tan, WH; Zhao, YP, 2004) |
| " One of the factors that regulate the degree of apoptosis during ischemia is the amino acid taurine." | 3.72 | Taurine inhibits apoptosis by preventing formation of the Apaf-1/caspase-9 apoptosome. ( Azuma, J; Fujio, Y; Ito, T; Matsuda, T; Schaffer, SW; Shikata, E; Takahashi, K; Takatani, T; Uozumi, Y; Yamamoto, Y, 2004) |
| "Intravenous injection of chloramine derivatives of amino acids and taurine reduced the mortality rate in mice with thrombosis induced by intravenous injection of ADP or collagen-epinephrine mixture." | 3.71 | Antithrombotic activity of N,N-dichlorotaurine on mouse model of thrombosis in vivo. ( Chudina, NA; Fesenko, OD; Murina, MA; Roshchupkin, DI; Sergienko, VI, 2002) |
| "The effects of taurine on insulin sensitivity were examined in a model rat of insulin resistance and type 2 diabetes-the Otsuka Long-Evans Tokushima Fatty (OLETF) rat." | 3.70 | Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes. ( Harada, N; Minami, A; Nakaya, Y; Niwa, Y; Ohnaka, M; Sakamoto, S, 2000) |
| "Taurine and niacin have been previously found to block the accumulation of collagen in lung in the multidose bleomycin hamster model of pulmonary fibrosis." | 3.69 | Dietary supplementation with taurine and niacin prevents the increase in lung collagen cross-links in the multidose bleomycin hamster model of pulmonary fibrosis. ( Blaisdell, RJ; Giri, SN; Schiedt, MJ, 1994) |
| "Human inhalation exposures to relatively high mass concentrations of the oxidant gas nitrogen dioxide (NO2) can result in a variety of pulmonary disorders, including life-threatening pulmonary edema, pneumonia, and bronchiolitis obliterans." | 3.69 | Lung injury following exposure of rats to relatively high mass concentrations of nitrogen dioxide. ( Archuleta, DC; Ellis, T; Gurley, LR; Lehnert, BE; Lehnert, NM; Session, WS; Stavert, DM, 1994) |
| "The early-weaned pig develops intestinal atrophy and provides a readily accessible animal model for determining the role of dietary supplementation of glutamine (Gln, a major fuel for enterocytes) in preventing intestinal damage." | 3.69 | Dietary glutamine supplementation prevents jejunal atrophy in weaned pigs. ( Knabe, DA; Meier, SA; Wu, G, 1996) |
| "The effect of taurolidine and heparin on growth of colon adenocarcinoma DHD/K12/TRb was measured in vitro and in vivo." | 3.69 | Inhibition of peritoneal tumor cell growth and implantation in laparoscopic surgery in a rat model. ( Böhm, B; Jacobi, CA; Müller, JM; Ordemann, J; Sabat, R; Zieren, HU, 1997) |
| "The therapeutic effects of 2-aminoethanesulfonic acid (taurine) were tested in animals with congestive heart failure (HF) simulated by aortic valve damage." | 3.68 | [Use of taurine in the treatment of experimental congestive heart failure]. ( Elizarova, EP; Fetisova, NI; Mit'kina, LI; Orlova, TsR; Ryff, IM, 1991) |
| " Severe hyponatremia and hypoosmolality induced profound decreases in levels of brain electrolytes, amino acids (especially taurine), and creatine." | 3.67 | Adaptive decreases in amino acids (taurine in particular), creatine, and electrolytes prevent cerebral edema in chronically hyponatremic mice: rapid correction (experimental model of central pontine myelinolysis) causes dehydration and shrinkage of brain. ( Hauhart, RE; Nelson, JS; Thurston, JH, 1987) |
| "Myocardial taurine levels were correlated with pulmonary wedge pressure (PWP) in dogs with congestive heart failure (CHF)." | 3.65 | A relation between myocardial taurine contest and pulmonary wedge pressure in dogs with heart failure. ( Bressler, R; Frangakis, CJ; Grosso, DS; Newman, WH, 1977) |
| "Taurine levels were 67% lower in vigabatrin-treated animals than in control animals." | 2.74 | Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. ( Chiron, C; Collins, SD; Coriat, C; Craft, CM; Duboc, A; Dubus, E; Dulac, O; Jammoul, F; Nabbout, R; Picaud, S; Sahel, JA; Simonutti, M; Wang, Q; Ye, W, 2009) |
| " The formation of toxic amyloid oligomers, extracellular amyloid plaques and amyloid angiopathy in brain by amyloid beta peptides are considered a part of the identified mechanism involved in disease pathogenesis." | 2.61 | Contributions of Mass Spectrometry to the Identification of Low Molecular Weight Molecules Able to Reduce the Toxicity of Amyloid-β Peptide to Cell Cultures and Transgenic Mouse Models of Alzheimer's Disease. ( Caba, IC; Luca, A; Mihai, CT; Stanciu, GD; Ştefănescu, R; Tamba, BI, 2019) |
| "Taurine is a highly abundant "amino acid" in the brain." | 2.55 | Understanding taurine CNS activity using alternative zebrafish models. ( Barcellos, LJG; Fontana, BD; Kalueff, AV; Mezzomo, NJ; Rosemberg, DB, 2017) |
| "Taurine is a sulfur-containing amino acid that is present in mammalian tissues in millimolar concentrations." | 2.52 | Role of taurine in the pathogenesis of obesity. ( Murakami, S, 2015) |
| "Atherosclerosis is the underlying mechanism of cardiovascular disease including myocardial infarctions, strokes and peripheral artery disease and remains a major cause of morbidity and mortality worldwide." | 2.50 | Taurine and atherosclerosis. ( Murakami, S, 2014) |
| "Oral taurine treatment has been studied extensively as a hypotensive agent." | 2.41 | Treatment of hypertension with oral taurine: experimental and clinical studies. ( Lombardini, JB; Militante, JD, 2002) |
| "Disease progression was investigated at 4 time points, from 9 to 18 months of age, and in 4 regions: cortex, hippocampus, striatum, and thalamus." | 1.72 | Spatio-temporal metabolic rewiring in the brain of TgF344-AD rat model of Alzheimer's disease. ( López-Gil, X; Muñoz-Moreno, E; Simões, RV; Soria, G; Tudela, R, 2022) |
| "In taurine-treated rats, superoxide dismutase activity was significantly (p < 0." | 1.62 | Taurine and Camel Milk Modulate Neurobehavioral and Biochemical Changes in Aluminum Chloride-Induced Alzheimer's Disease in Rats. ( Abdulkadir, TS; Ayo, JO; Dawud, FA; Isa, AS, 2021) |
| "With the surge in the cases of Alzheimer's disease (AD) over the years, several targets have been explored to curb the disease." | 1.56 | Dual targeting of cholinesterase and amyloid beta with pyridinium/isoquinolium derivatives. ( Chakravarty, H; Chen, WH; Ju, Y; Tam, KY, 2020) |
| "Taurine is a ubiquitous sulphur-containing amino acid present in foods such as seafood." | 1.56 | Perinatal taurine exerts a hypotensive effect in male spontaneously hypertensive rats and down-regulates endothelial oxide nitric synthase in the aortic arch. ( Burgueño, AL; Mensegue, MF; Tellechea, ML, 2020) |
| "Taurine has been reported to have neuroprotective properties against dementia, including AD." | 1.56 | Evaluation of the neuroprotective effect of taurine in Alzheimer's disease using functional molecular imaging. ( Choi, JY; Han, SJ; Jeong, YJ; Kang, KJ; Lee, HJ; Lee, KC; Lee, YJ; Nam, KR; Oh, SJ, 2020) |
| "Fragile X syndrome is an X-linked dominant disorder and the most common cause of inherited mental retardation." | 1.51 | Role of Taurine in Testicular Function in the Fragile x Mouse. ( El Idrissi, A; Lin, S, 2019) |
| "Taurine also ameliorated the visual impairments in the MNU-induced mice as evidenced by functional examinations." | 1.51 | Systemic taurine treatment provides neuroprotection against retinal photoreceptor degeneration and visual function impairments. ( Chen, W; He, M; Ma, Z; Peng, G; Qu, Y; Tao, Y; Teng, D; Yang, Q, 2019) |
| "taurine." | 1.51 | Evaluation of taurine neuroprotection in aged rats with traumatic brain injury. ( Brooks, WM; Christian, S; Gupte, R; Habiger, J; Harris, JL; Keselman, P, 2019) |
| "Hypertension was induced by oral administration of nitric oxide synthase inhibitor, N-nitro L-arginine-methyl-ester (L-NAME), at 40 mg/kg body weight to the male Wistar rats for 14 consecutive days." | 1.51 | Taurine Ameliorates Thyroid Hypofunction and Renal Injury in L-NAME-Induced Hypertensive Rats. ( Adedara, IA; Adeyemo, MO; Ajibade, TO; Alake, SE; Farombi, EO; Olajide, LO, 2019) |
| "Taurine is an amino acid with significant neuroprotective properties." | 1.51 | Taurine Treatment Provides Neuroprotection in a Mouse Model of Manganism. ( Abdoli, N; Ghanbarinejad, V; Heidari, R; Niknahad, H; Ommati, MM, 2019) |
| "Taurine treatment normalized the expression levels of γ-glutamyl ligase C/M, GS, OPLAH, and glyoxalase-1, and reversed HCU-induced deficits in protein glutathionylation by acting to double GSH levels relative to controls." | 1.48 | Taurine treatment prevents derangement of the hepatic γ-glutamyl cycle and methylglyoxal metabolism in a mouse model of classical homocystinuria: regulatory crosstalk between thiol and sulfinic acid metabolism. ( Aivazidis, S; Allen, RH; Harris, PS; Jiang, H; Kim, E; Maclean, KN; Petersen, DR; Roede, JR; Shearn, CT; Stabler, SP, 2018) |
| "Taurine treatment of mdx mice only altered ncRNA levels when administered from 18 days to 6 weeks of age, but a deficiency in tRNA levels was rectified earlier in mdx skeletal muscles treated from 14 days to 3 weeks." | 1.48 | Expression patterns of regulatory RNAs, including lncRNAs and tRNAs, during postnatal growth of normal and dystrophic (mdx) mouse muscles, and their response to taurine treatment. ( Butchart, LC; Filipovska, A; Grounds, MD; Rossetti, G; Terrill, JR; White, R, 2018) |
| "Taurine (TAU) is a β-amino sulfonic acid with pleiotropic roles in the brain." | 1.48 | Taurine modulates acute ethanol-induced social behavioral deficits and fear responses in adult zebrafish. ( Fontana, BD; Mezzomo, NJ; Müller, TE; Parker, MO; Quadros, VA; Rico, EP; Rosemberg, DB; Stefanello, FV, 2018) |
| "Taurine was found to inhibit the decrease of sucrose consumption and prevent the deficiency of spatial memory and anxiety in rats exposed to CUMS, suggesting a preventive effect of taurine on depression-like behavior." | 1.46 | Antidepressant effect of taurine in chronic unpredictable mild stress-induced depressive rats. ( Feng, Y; Hu, JM; Lin, SM; Ren, S; Tang, RY; Wu, GF; Xu, C; Yang, JC; Yang, QH; Zhou, JQ, 2017) |
| "Binge drinking is a form of abusive alcohol drinking defined by the NIAAA as a drinking to blood alcohol levels (BALs)>0." | 1.46 | High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking. ( Barkley-Levenson, A; Crabbe, JC; Hack, WR; Huang, LC; Metten, P; Ozburn, AR; Schlumbohm, JP; Spence, SE, 2017) |
| "Treatment with taurine prevents gut mucosal damage and inhibits intestinal epithelial cell apoptosis following intestinal IR in a rat." | 1.43 | Effect of taurine on intestinal recovery following intestinal ischemia-reperfusion injury in a rat. ( Aranovich, I; Ben Shahar, Y; Berkowitz, D; Bitterman, A; Bitterman, N; Chepurov, D; Coran, AG; Pollak, Y; Sukhotnik, I, 2016) |
| "Taurine treatment also reduced protein thiol oxidation and was overall more effective, as OTC treatment reduced body and muscle weight, suggesting some adverse effects of this drug." | 1.43 | Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy. ( Arthur, PG; Graves, JA; Grounds, MD; Pinniger, GJ; Terrill, JR, 2016) |
| " The results showed that high dosage of taurine administration in the early postnatal period attenuated impairment of spatial learning and memory induced by PS." | 1.43 | Taurine promotes cognitive function in prenatally stressed juvenile rats via activating the Akt-CREB-PGC1α pathway. ( Chen, G; Dang, S; Jia, N; Su, Q; Sun, Q, 2016) |
| "Taurine (50 mg/kg) was administered intravenously 30 min and 4 h again after CHI." | 1.42 | Taurine attenuates hippocampal and corpus callosum damage, and enhances neurological recovery after closed head injury in rats. ( Gu, Y; Qian, K; Sun, M; Zhao, Y, 2015) |
| "Alcoholism is one of the most prevalent neuropsychiatric diseases, having an enormous health and socioeconomic impact." | 1.40 | Acamprosate produces its anti-relapse effects via calcium. ( Fischer, WN; Gallop, MA; Grindstaff, K; Jandeleit, B; Kiefer, F; Krstew, EV; Lawrence, AJ; Spanagel, R; Vengeliene, V; Zhang, X, 2014) |
| "Treatment with taurine mediated a reduction in oxidative stress in iron‑overloaded mice, attenuated liver lipid peroxidation, elevated antioxidant enzyme activities and maintained reduced glutathione levels." | 1.40 | Taurine supplementation reduces oxidative stress and protects the liver in an iron-overload murine model. ( He, M; Liao, Z; Liu, D; Tang, L; Yi, B; Yin, D; Zhang, Z, 2014) |
| "Atherosclerosis is a multifactorial and progressive disease commonly correlated with a high fat diet." | 1.40 | Serum metabonomic analysis of apoE(-/-) mice reveals progression axes for atherosclerosis based on NMR spectroscopy. ( Guo, J; Li, J; Li, X; Liu, Y; Wang, L; Wu, T; Yang, Y; Yuan, F; Zhang, Q; Zheng, L, 2014) |
| "Taurine treatment rescued cognitive deficits in APP/PS1 mice up to the age-matching wild-type mice in Y-maze and passive avoidance tests without modifying the behaviours of cognitively normal mice." | 1.40 | Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's disease. ( Cho, SM; Cho, Y; Kang, BR; Kim, HV; Kim, HY; Kim, JW; Kim, JY; Kim, Y; Lee, S; Woo, J; Yoon, JH, 2014) |
| "Taurine has also been shown to reduce lenticular oxidative stress." | 1.39 | Effects of magnesium taurate on the onset and progression of galactose-induced experimental cataract: in vivo and in vitro evaluation. ( Abdul Rahman, TH; Agarwal, P; Agarwal, R; Ahmad Fisol, NF; Awaludin, NA; Bakar, NS; Iezhitsa, I; Mohamed Ahmed Salama, MS; Mohd Ismail, N; Ozerov, A; Spasov, A, 2013) |
| "Spinocerebellar ataxia type 1 (SCA1) is a hereditary, progressive and fatal movement disorder that primarily affects the cerebellum." | 1.39 | Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1. ( Brent Clark, H; Eberly, LE; Emir, UE; Öz, G; Vollmers, ML, 2013) |
| "Maternal obesity is associated with obesity and metabolic disorders in offspring." | 1.39 | Effects of taurine supplementation on hepatic markers of inflammation and lipid metabolism in mothers and offspring in the setting of maternal obesity. ( Gray, C; Li, M; Reynolds, CM; Sloboda, DM; Vickers, MH, 2013) |
| "Taurine is an inhibitory neurotransmitter and is one of the most abundant amino acids present in the mammalian nervous system." | 1.39 | The mechanism of taurine protection against endoplasmic reticulum stress in an animal stroke model of cerebral artery occlusion and stroke-related conditions in primary neuronal cell culture. ( Chen, PC; Gharibani, PM; Ma, Z; Menzie, J; Modi, J; Pan, C; Prentice, H; Tao, R; Wu, JY, 2013) |
| " Similarly, we showed that RGC degeneration can be induced by pharmacologically blocking the taurine-transporter with the chronic administration of a selective inhibitor, which results in a decrease in the taurine levels both in the plasma and in the retinal tissue." | 1.39 | Taurine is a crucial factor to preserve retinal ganglion cell survival. ( Cadetti, L; Degardin, J; Dubus, E; Forster, V; Froger, N; Gaucher, D; Ivkovic, I; Jammoul, F; Lorach, H; Pain, D; Picaud, S; Sahel, JA; Simonutti, M, 2013) |
| "A well-validated animal model of treatment resistant depression (congenital learned helpless rats = cLH) was investigated by hippocampal in vivo ¹H MRS with and without a 1-week course of electroconvulsive shocks (ECS), an animal model of ECT, and compared to wild type (WT) animals, while saline and clomipramine injections served as additional controls." | 1.38 | Increase of hippocampal glutamate after electroconvulsive treatment: a quantitative proton MR spectroscopy study at 9.4 T in an animal model of depression. ( Biedermann, S; Ende, G; Gass, P; Hoyer, C; Sartorius, A; Vollmayr, B; Weber-Fahr, W; Zheng, L, 2012) |
| "Taurine is a conditionally essential amino acid in humans that may be a promising therapy for treating this disease." | 1.38 | The effect of taurine on hepatic steatosis induced by thioacetamide in zebrafish (Danio rerio). ( da Rosa, DP; da Silveira, TR; Escobar, TD; Fracasso, LB; Hammes, TO; Hartmann, CR; Marroni, NP; Pedroso, GL; Porawski, M, 2012) |
| "Diabetes during pregnancy affects >5% of all pregnancies, causing reproductive abnormalities that enhance spontaneous abortion - congenital anomalies, morbidity and mortality of both mother and fetus/newborn." | 1.38 | Taurine attenuates maternal and embryonic oxidative stress in a streptozotocin-diabetic rat model. ( Shivananjappa, MM, 2012) |
| "Taurine (TAU) is an amino sulfonic acid that plays protective roles against neurochemical impairments induced by ethanol (EtOH)." | 1.38 | Behavioral effects of taurine pretreatment in zebrafish acutely exposed to ethanol. ( Blaser, RE; Braga, MM; Calcagnotto, ME; Campos, MM; Córdova, SD; de Oliveira, DL; Dias, RD; Leite, CE; Loss, CM; Mussulini, BH; Rico, EP; Rosemberg, DB; Souza, DO, 2012) |
| " The aim of this study was to show that these compounds are safe in an EpiOcular model and effective in corneas infected ex vivo." | 1.38 | N-chlorotaurine and its analogues N,N-dichloro-2,2-dimethyltaurine and N-monochloro-2,2-dimethyltaurine are safe and effective bactericidal agents in ex vivo corneal infection models. ( Anderson, M; Bechrakis, NE; Debabov, D; Eitzinger, C; Hager, T; Jekle, A; Lutz, M; Nagl, M; Schmid, E; Teuchner, B; Zuck, M, 2012) |
| "Taurine is an organic acid, which has a very important function in the human body." | 1.37 | Effects of taurine on reperfusion injury. ( Akdemir, O; Arslan, Z; Hede, Y; Lineaweaver, WC; Songur, E; Zhang, F, 2011) |
| "We modeled transient ischemic attacks and strokes in mice." | 1.37 | Early predictive biomarkers for lesion after transient cerebral ischemia. ( Berthet, C; Gruetter, R; Hirt, L; Lei, H, 2011) |
| "Taurine was added to the diet of the taurine group at a dose of 300 mg/kg/d from 12 days after conception until natural delivery." | 1.37 | Antenatal taurine supplementation for improving brain ultrastructure in fetal rats with intrauterine growth restriction. ( Chen, H; Liu, J; Liu, L, 2011) |
| "Taurine and treatment groups were given a 200 mg/kg/day dose of Taurine by oral gavage besides rat feed." | 1.37 | Is there any cardioprotective role of Taurine during cold ischemic period following global myocardial ischemia? ( Arslan, S; Cingoz, F; Demirkilic, U; Doganci, S; Gamsizkan, M; Guler, A; Jahollari, A; Sahin, MA; Yaman, H; Yucel, O, 2011) |
| "We show that disease progression in the TgP347L rabbit closely tracks human cone-sparing RP, including the cone-associated preservation of bipolar cell signaling and triggering of reprogramming." | 1.37 | Retinal remodeling in the Tg P347L rabbit, a large-eye model of retinal degeneration. ( Anderson, J; Jones, BW; Kondo, M; Lin, Y; Marc, RE; Rapp, K; Shaw, MV; Terasaki, H; Watt, CB; Yang, JH, 2011) |
| "Hydroxyproline content was also significantly lower at 14 weeks in mice treated with taurine (P = 0." | 1.36 | Taurine attenuates radiation-induced lung fibrosis in C57/Bl6 fibrosis prone mice. ( Bouchier-Hayes, DJ; Condron, C; Moriarty, M; Robb, WB; Walsh, TN, 2010) |
| "Surgical cytoreduction of peritoneal surface malignancy of colorectal origin in combination with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) has become an established treatment approach." | 1.36 | Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model. ( Atanassow, V; Braumann, C; Caldenas, S; Hartmann, J; Kilian, M; Makareinis, A; Raue, W; Schwenk, W, 2010) |
| "Taurine is a semi-essential amino acid and is successful in preserving neutrophil bactericidal function in urine." | 1.36 | Taurine modulates neutrophil function but potentiates uropathogenic E. coli infection in the murine bladder. ( Bouchier-Hayes, DJ; Casey, RG; Condron, C; Creagh, T; Kehoe, S; Toomey, D, 2010) |
| "The treatment of taurine (300mgkg(-1)d(-1)) and oat fiber (15gkg(-1)d(-1)) induced 21." | 1.36 | Inhibitory effects of taurine and oat fiber on intestinal endotoxin release in rats. ( He, P; Li, XD; Luo, M; Wan, XY; Wu, MC, 2010) |
| "Fragile X Syndrome is the most common known genetic cause of autism." | 1.36 | Taurine regulation of short term synaptic plasticity in fragile X mice. ( El Idrissi, A; L'Amoreaux, W; Neuwirth, LS, 2010) |
| "Taurine treatment resulted in a significant increase in the number and size of islets." | 1.36 | Neuro-endocrine basis for altered plasma glucose homeostasis in the Fragile X mouse. ( El Idrissi, A; L'Amoreaux, W; Sidime, F; Yan, X, 2010) |
| "Taurine treatments also prevented the alterations promoted in superoxide dismutase and catalase activities by EtOH, suggesting a modulatory role in enzymatic antioxidant defenses." | 1.36 | Taurine prevents enhancement of acetylcholinesterase activity induced by acute ethanol exposure and decreases the level of markers of oxidative stress in zebrafish brain. ( Bogo, MR; Bonan, CD; da Rocha, RF; Dias, RD; Klamt, F; Moreira, JC; Rico, EP; Rosemberg, DB; Souza, DO; Zanotto-Filho, A, 2010) |
| "Diazepam was used as a positive control." | 1.35 | Acamprosate attenuates the handling induced convulsions during alcohol withdrawal in Swiss Webster mice. ( Barron, S; Farook, JM; Krazem, A; Lewis, B; Littleton, JM; Morrell, DJ, 2008) |
| "Taurine was intravenously injected to Wistar rats 30 min before II/R; physiological saline and sham operation served as controls." | 1.35 | Taurine attenuates multiple organ injury induced by intestinal ischemia reperfusion in rats. ( Dong, X; Jiang, H; Qiao, G; Qiao, H; Sun, X; Tong, L; Zhang, F, 2008) |
| "Taurine treatment reduced fibrosis scores significantly as compared to placebo." | 1.35 | Ultrastructural changes in hepatocytes after taurine treatment in CCl4 induced liver injury. ( Comert, B; Mas, MR; Mas, N; Tasci, I; Tuncer, M, 2008) |
| " Sprague-Dawley rat dams were dosed from the first day of gestation until weaning with methylmercury (MeHg), polychlorinated biphenyls (PCBs) or organochlorines pesticides (OCs) administered either separately or together in the NCM." | 1.35 | Contribution of methylmercury, polychlorinated biphenyls and organochlorine pesticides to the toxicity of a contaminant mixture based on Canadian Arctic population blood profiles. ( Alwis, R; Black, P; Bowers, WJ; Chu, I; Kumarathasan, P; Masson, S; Mohottalage, S; Nakai, J; Pelletier, G; Vincent, R; Wade, MJ, 2009) |
| "Taurine plays a protective role against free radicals and toxins in various cells and tissues." | 1.35 | The protective effect of taurine against hepatic damage in a model of liver disease and hepatic stellate cells. ( Bouscarel, B; Honda, A; Ikegami, T; Matsuzaki, Y; Miyazaki, T, 2009) |
| "Taurine treatment alleviated the oxidative injury of the kidney, improved SOD and GSH-Px activities, as well as the mitochondrial membrane injury, with lesser crystal depositions in the kidney." | 1.35 | Taurine protected kidney from oxidative injury through mitochondrial-linked pathway in a rat model of nephrolithiasis. ( Deng, YL; Li, CY; Sun, BH, 2009) |
| "Taurolidine is an antimicrobial agent used to prevent intraabdominal adhesion formation and sepsis in experimental and clinical trials." | 1.35 | The effect of taurolidine on experimental thrombus formation. ( Akyol, H; Bingul, SM; Colak, E; Kaptanoglu, L; Kucuk, HF; Kurt, N; Torlak, OA; Yazici, F, 2008) |
| "Taurine treatment was associated with amelioration in macroscopic and microscopic colitis scores, decreased colonic MPO activity and MDA levels and increased GSH levels in TNBS-induced colitis." | 1.35 | Effect of taurine on oxidative stress and apoptosis-related protein expression in trinitrobenzene sulphonic acid-induced colitis. ( Aliş, H; Aykaç-Toker, G; Depboylu, B; Doğru-Abbasoğlu, S; Erbil, Y; Giriş, M; Olgaç, V; Uysal, M, 2008) |
| "Pre-treatment with taurine (1." | 1.35 | Tryptophan administration induces oxidative stress in brain cortex of rats. ( Amaral, MF; Dutra-Filho, CS; Feksa, LR; Feksa, PB; Koch, GD; Latini, A; Leipnitz, G; Rech, VC; Wajner, M; Wannmacher, CM, 2008) |
| "Taurine is a semi-essential amino acid that is endothelial protective and restrains excess leucocyte activity by the formation of less toxic inflammatory mediators." | 1.34 | Taurine attenuates acute hyperglycaemia-induced endothelial cell apoptosis, leucocyte-endothelial cell interactions and cardiac dysfunction. ( Bouchier-Hayes, DJ; Casey, RG; Gang, C; Joyce, M, 2007) |
| "Amyotrophic lateral sclerosis (ALS) is a fatal disease of degeneration of motor neurons." | 1.34 | Consideration of acamprosate for treatment of amyotrophic lateral sclerosis. ( Altschuler, EL; Kast, RE, 2007) |
| "Paraoxonase activity has been reported to decrease in several situations associated with atherosclerosis and oxidative stress." | 1.34 | High-dose taurine supplementation increases serum paraoxonase and arylesterase activities in experimental hypothyroidism. ( Dirican, M; Sarandöl, E; Taş, S, 2007) |
| "In an animal model of fetal malnutrition, rats received an isoenergetic, low-protein (LP) diet during gestation." | 1.33 | Nutritional regulation of proteases involved in fetal rat insulin secretion and islet cell proliferation. ( Ahn, MT; Kalbe, L; Kruhoffer, M; Leunda, A; Meulemans, C; Nerup, J; Orntoft, T; Remacle, C; Reusens, B; Sparre, T, 2005) |
| "Taurine is an amino acid able to react with hypochlorous acid, produced endogenously by neutrophils, resulting in the more stable and less toxic taurine chloramine (Tau-Cl)." | 1.33 | Inhibition of septic arthritis by local administration of taurine chloramine, a product of activated neutrophils. ( Tarkowski, A; Verdrengh, M, 2005) |
| "Taurine pretreatment also caused about 2-fold increase in GABA concentration compared to 3-NP-treated animals." | 1.33 | Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype. ( Abdel-Naim, AB; Arafa, HM; Khalifa, AE; Tadros, MG, 2005) |
| "Ischemia-reperfusion injury is of major clinical relevance during liver transplantation." | 1.33 | Taurine protects against ischemia-reperfusion injury in rabbit livers. ( Jiang, H; Li, J; Meng, F; Qiao, H; Sun, X; Tong, L, 2006) |
| "These features were accompanied by gliosis, neuronal loss, and cerebral atrophy." | 1.33 | Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation. ( Abe, K; Bergeron, C; Carlson, GA; Chishti, MA; Egashira, N; Fujiwara, M; Hanna, A; Harigaya, Y; Horne, P; Ikeda, M; Ishiguro, K; Iwasaki, K; Janus, C; Kawarabayashi, T; Kawarai, T; Matsubara, E; Mishima, K; Murakami, T; Paitel, E; Phinney, AL; Sasaki, A; Shoji, M; St George-Hyslop, P; Takahashi, M; Westaway, D; Yang, J, 2006) |
| "Two weeks after induction of hydrocephalus the taurine concentration was decreased, whereas the concentration of [1,2-13C]lactate was increased in the cerebrum and that of [1,2-13C]GABA in the brainstem." | 1.32 | Astrocyte metabolism is disturbed in the early development of experimental hydrocephalus. ( Brinker, T; Kondziella, D; Lüdemann, W; Qu, H; Sletvold, O; Sonnewald, U, 2003) |
| "As part of a wider metabonomic investigation into the early detection and discrimination of site-specific hepatotoxicity, male Sprague-Dawley rats were dosed with the model hepatotoxins allyl formate, ethionine and alpha-naphthylisothiocyanate (ANIT)." | 1.32 | An hypothesis for a mechanism underlying hepatotoxin-induced hypercreatinuria. ( Charuel, C; Clayton, TA; Everett, JR; Hanton, G; Le Net, JL; Lindon, JC; Nicholson, JK; Provost, JP, 2003) |
| "We introduced intracerebral hemorrhage in each of eight anesthetized New Zealand rabbits by injecting 0." | 1.32 | Extracellular glutamate and other amino acids in experimental intracerebral hemorrhage: an in vivo microdialysis study. ( Ali, Z; Baker, G; Guterman, LR; Hopkins, LN; Qureshi, AI; Shuaib, A; Suri, MF; Todd, K, 2003) |
| "Taurine is a sulfur containing beta-amino acid rich in human body, and our previous experiments showed that it can inhibit the deposition of the extracellular matrix in the damaged liver." | 1.32 | Effects of taurine on proliferation and apoptosis of hepatic stellate cells in vitro. ( Chen, YX; Li, S; Xie, WF; Zhang, XR, 2004) |
| "Taurolidine has significant antineoplastic activity against MM in vitro and in vivo, in part, due to tumor cell apoptosis." | 1.32 | The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. ( Calabresi, P; Monfils, B; Nici, L, 2004) |
| "Flurbiprofen treatment of ND rats replicated many of the biochemical and physiological abnormalities of EDN, i." | 1.31 | Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. ( Greene, DA; Larkin, D; Li, F; Marinescu, V; Pop-Busui, R; Stevens, MJ; Sullivan, K; Van Huysen, C, 2002) |
| "5." | 1.31 | Guanosine enhances glutamate uptake in brain cortical slices at normal and excitotoxic conditions. ( Frizzo, ME; Lara, DR; Prokopiuk, Ade S; Salbego, CG; Souza, DO; Vargas, CR; Wajner, M, 2002) |
| "Taurine and niacin treatment significantly reduced the numbers of neutrophils, lymphocytes, and macrophages in the BL + TN group and caused significant reductions in BL-induced increases in the lung hydroxyproline content at 14 and 21 days in the BL + TN group." | 1.31 | Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin. ( Giri, SN; Gurujeyalakshmi, G; Wang, Y, 2000) |
| " In consequence of these acute processes delayed cell death in the MBN and persistent loss of cholinergic fibre projections to the neocortex appear as early as 3 days following the Abeta-induced toxic insult." | 1.31 | beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. ( Abrahám, I; Harkany, T; Kónya, C; Korf, J; Laskay, G; Luiten, PG; Nyakas, C; Penke, B; Sasvári, M; Sebens, JB; Soós, K; Timmerman, W; Tóth, B; Zarándi, M, 2000) |
| "Taurine levels were increased 7 and 30 days following transection in spinal segments immediately adjacent to the lesion and were further elevated by MP treatment." | 1.31 | Spinal taurine levels are increased 7 and 30 days following methylprednisolone treatment of spinal cord injury in rats. ( Benton, RL; Miller, KE; Ross, CD, 2001) |
| "Acute pancreatitis was induced by administering three subcutaneous injections of cerulein (40 microg/kg body weight) at 1-hour intervals, while taurine was administered intravenously at graded doses (30, 100, or 300 mg/kg, respectively) following the first cerulein injection." | 1.31 | Effects of taurine on cerulein-induced acute pancreatitis in the rat. ( Ahn, BO; Hyun, JH; Kim, CD; Kim, KH; Kim, WB; Kim, YS; Lee, G; Lee, HS; Oh, TY; Son, MW, 2001) |
| "Taurine was found to be effective in (1) increasing glutathione levels that had been diminished by lead; (2) reducing malondialdehyde levels, an end-product of lipid peroxidation; (3) decreasing catalase and erythrocyte G6PD activity, which had been increased by lead exposure; and (4) improving cell survival of CHO cells." | 1.31 | Antioxidant effect of taurine against lead-induced oxidative stress. ( Ercal, N; Gürer, H; Ozgünes, H; Saygin, E, 2001) |
| "Taurine treatment significantly decreased serum LDL and VLDL cholesterol, while it significantly increased serum HDL cholesterol." | 1.31 | Effects of long-term treatment with taurine in mice fed a high-fat diet: improvement in cholesterol metabolism and vascular lipid accumulation by taurine. ( Kondo, Y; Murakami, S; Nagate, T, 2000) |
| "Alcohol relapse is a major problem in the treatment of alcohol abuse and alcoholism." | 1.31 | Central nervous system mechanisms in alcohol relapse. ( Le, AD; McBride, WJ; Noronha, A, 2002) |
| "Taurine treated rats showed levels of MDA not different from untreated rats after RS; also no differences were observed concerning enzyme concentrations and ammonia levels." | 1.30 | No beneficial effects of taurine application on oxygen free radical production after hemorrhagic shock in rats. ( Isselhard, W; Minor, T; Niessen, F, 1998) |
| "The taurine-treated animals showed reduced MPO activity (35% lower) when compared with that of the vehicle-treated animals." | 1.30 | Taurine can ameliorate inflammatory bowel disease in rats. ( Kang, HK; Kim, BK; Kim, WB; Ko, JI; Son, M, 1998) |
| "Taurine is a beta-aminosulfonic acid and is a ubiquitous amino acid whose role in the cochlea is not well established." | 1.30 | Taurine entry into perilymph of the guinea pig. ( Angelini, E; Aran, JM; Ferrary, E; Teixeira, M, 1998) |
| "Taurine is an inhibitory amino acid in the CNS." | 1.30 | Dietary supplementation with the inhibitory amino acid taurine suppresses autotomy in HA rats. ( Beery, E; Belfer, I; Davidson, E; Ratner, A; Seltzer, Z; Shir, Y, 1998) |
| "Neither streptozotocin diabetes nor taurine in the diet appeared to affect the weight of the lenses." | 1.30 | Modelling cortical cataractogenesis 21: in diabetic rat lenses taurine supplementation partially reduces damage resulting from osmotic compensation leading to osmolyte loss and antioxidant depletion. ( Dzialoszynski, T; Linklater, HA; Mitton, KP; Sanford, SE; Starkey, K; Trevithick, JR, 1999) |
| "Taurine treatment had a marked prophylactic effect on these maternal pathological changes during pregnancy, resulting in better growth in offsprings." | 1.28 | Stroke-prone spontaneously hypertensive rats as a model for toxemia of pregnancy and aggravating and preventive effects of maternal modifications during pregnancy on offspring's growth. ( Horie, R; Kitao, M; Shibukawa, T; Yamori, Y, 1990) |
| "Quinolinic acid (QA) is an endogenous excitotoxin present in mammalian brain that reproduces many of the histologic and neurochemical features of Huntington's disease (HD)." | 1.27 | Systemic approaches to modifying quinolinic acid striatal lesions in rats. ( Beal, MF; Ferrante, RJ; Kowall, NW; Martin, JB; Swartz, KJ, 1988) |
| "In view of the tendency of Friedreich's ataxia patients to exhibit increased alimentary absorption of taurine, and to demonstrate an excessive accumulation of taurine in the cerebellum and heart tissue on autopsy, fetal exposure to high taurine levels or neonatal high taurine milk ingestion may, by analogy, contribute to the slowly progressing disease process." | 1.27 | Embryonic exposure to high taurine: a possible nutritional contribution to Friedreich's ataxia. ( Bélanger, F; van Gelder, NM, 1988) |
| " This has been correlated with the effect of repeated oral dosing on the manifestations of cobalt-induced epilepsy in the rat." | 1.26 | Uptake studies of taurine in vivo and its effects on the course of experimental focal epilepsy in rats. ( Bradford, HF; Davison, AN; Osborne, RH; Wheler, GH, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 34 (9.24) | 18.7374 |
| 1990's | 32 (8.70) | 18.2507 |
| 2000's | 114 (30.98) | 29.6817 |
| 2010's | 150 (40.76) | 24.3611 |
| 2020's | 38 (10.33) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Abdulkadir, TS | 1 |
| Dawud, FA | 1 |
| Isa, AS | 1 |
| Ayo, JO | 1 |
| Yao, Z | 1 |
| Liang, G | 1 |
| Lv, ZL | 1 |
| Lan, LC | 1 |
| Zhu, FL | 1 |
| Tang, Q | 1 |
| Huang, L | 1 |
| Chen, XQ | 1 |
| Yang, MX | 1 |
| Shan, QW | 1 |
| Wang, K | 2 |
| Zhang, B | 3 |
| Tian, T | 1 |
| Shi, G | 1 |
| Zhang, C | 2 |
| Li, G | 2 |
| Huang, M | 1 |
| Öcük, Ö | 1 |
| Fırat, C | 1 |
| Yıldız, A | 1 |
| Vardı, N | 1 |
| Ulu, A | 1 |
| Abbas Ali Noma, S | 1 |
| Parlakpınar, H | 1 |
| Özhan, O | 1 |
| Stacy, A | 1 |
| Doss, HM | 1 |
| Kim, JY | 2 |
| Kim, KS | 1 |
| Huang, F | 1 |
| Zhang, T | 2 |
| Li, B | 1 |
| Wang, S | 1 |
| Xu, C | 4 |
| Huang, C | 1 |
| Lin, D | 1 |
| Muñoz-Moreno, E | 1 |
| Simões, RV | 1 |
| Tudela, R | 1 |
| López-Gil, X | 1 |
| Soria, G | 1 |
| Ping, Y | 1 |
| Shan, J | 1 |
| Liu, Y | 2 |
| Liu, F | 1 |
| Wang, L | 3 |
| Liu, Z | 1 |
| Li, J | 7 |
| Yue, D | 1 |
| Chen, X | 1 |
| Zhang, Y | 3 |
| Claeys, W | 1 |
| Van Hoecke, L | 1 |
| Geerts, A | 1 |
| Van Vlierberghe, H | 1 |
| Lefere, S | 1 |
| Van Imschoot, G | 1 |
| Van Wonterghem, E | 1 |
| Ghesquière, B | 1 |
| Vandenbroucke, RE | 1 |
| Van Steenkiste, C | 1 |
| Pannkuk, EL | 1 |
| Laiakis, EC | 1 |
| Garty, G | 1 |
| Ponnaiya, B | 1 |
| Wu, X | 1 |
| Shuryak, I | 1 |
| Ghandhi, SA | 1 |
| Amundson, SA | 1 |
| Brenner, DJ | 1 |
| Fornace, AJ | 2 |
| Yin, M | 1 |
| Zhou, D | 1 |
| Jia, F | 1 |
| Su, X | 1 |
| Li, X | 2 |
| Sun, R | 1 |
| Bejarano, E | 1 |
| Whitcomb, EA | 1 |
| Pfeiffer, RL | 1 |
| Rose, KL | 1 |
| Asensio, MJ | 1 |
| Rodríguez-Navarro, JA | 1 |
| Ponce-Mora, A | 1 |
| Canto, A | 1 |
| Almansa, I | 1 |
| Schey, KL | 1 |
| Jones, BW | 3 |
| Taylor, A | 1 |
| Rowan, S | 1 |
| Ren, X | 2 |
| Hinchie, A | 1 |
| Swomley, A | 1 |
| Powell, DK | 1 |
| Butterfield, DA | 1 |
| Ohmori, H | 1 |
| Matsumura, M | 1 |
| Komine, S | 1 |
| Kobayashi, H | 1 |
| Kobayashi, Y | 1 |
| Shiromoto, J | 1 |
| Miyakawa, S | 1 |
| Lin, S | 2 |
| El Idrissi, A | 4 |
| Chang, H | 1 |
| Lee, DH | 1 |
| Tao, Y | 1 |
| He, M | 3 |
| Yang, Q | 2 |
| Ma, Z | 4 |
| Qu, Y | 2 |
| Chen, W | 3 |
| Peng, G | 1 |
| Teng, D | 1 |
| Barış, VÖ | 1 |
| Gedikli, E | 1 |
| Yersal, N | 1 |
| Müftüoğlu, S | 1 |
| Erdem, A | 2 |
| Grevengoed, TJ | 2 |
| Trammell, SAJ | 1 |
| McKinney, MK | 1 |
| Petersen, N | 1 |
| Cardone, RL | 1 |
| Svenningsen, JS | 2 |
| Ogasawara, D | 1 |
| Nexøe-Larsen, CC | 1 |
| Knop, FK | 1 |
| Schwartz, TW | 1 |
| Kibbey, RG | 1 |
| Cravatt, BF | 2 |
| Gillum, MP | 2 |
| Chakravarty, H | 1 |
| Ju, Y | 1 |
| Chen, WH | 1 |
| Tam, KY | 1 |
| Mensegue, MF | 1 |
| Burgueño, AL | 1 |
| Tellechea, ML | 1 |
| Miyata, M | 1 |
| Funaki, A | 1 |
| Fukuhara, C | 1 |
| Sumiya, Y | 1 |
| Sugiura, Y | 1 |
| Nor Arfuzir, NN | 2 |
| Agarwal, R | 3 |
| Iezhitsa, I | 3 |
| Agarwal, P | 3 |
| Ismail, NM | 1 |
| Xu, H | 2 |
| Barker, RG | 2 |
| Lamb, GD | 1 |
| Murphy, RM | 2 |
| Cammalleri, M | 1 |
| Dal Monte, M | 1 |
| Amato, R | 1 |
| Bagnoli, P | 1 |
| Rusciano, D | 2 |
| Kim, S | 2 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Jo, K | 1 |
| Grosheva, I | 1 |
| Zheng, D | 1 |
| Levy, M | 1 |
| Polansky, O | 1 |
| Lichtenstein, A | 1 |
| Golani, O | 1 |
| Dori-Bachash, M | 1 |
| Moresi, C | 1 |
| Shapiro, H | 1 |
| Del Mare-Roumani, S | 1 |
| Valdes-Mas, R | 1 |
| He, Y | 1 |
| Karbi, H | 1 |
| Chen, M | 1 |
| Harmelin, A | 1 |
| Straussman, R | 1 |
| Yissachar, N | 1 |
| Elinav, E | 1 |
| Geiger, B | 1 |
| Baliou, S | 1 |
| Kyriakopoulos, AM | 2 |
| Spandidos, DA | 1 |
| Zoumpourlis, V | 2 |
| Xu, D | 2 |
| Liao, S | 1 |
| Lv, Y | 1 |
| Wang, J | 4 |
| Kong, L | 2 |
| Terrill, JR | 5 |
| Webb, SM | 1 |
| Arthur, PG | 4 |
| Hackett, MJ | 1 |
| Oh, SJ | 1 |
| Lee, HJ | 1 |
| Jeong, YJ | 1 |
| Nam, KR | 1 |
| Kang, KJ | 1 |
| Han, SJ | 1 |
| Lee, KC | 1 |
| Lee, YJ | 2 |
| Choi, JY | 1 |
| Freese, L | 1 |
| Fraga de Souza, M | 1 |
| Schüler Nin, M | 1 |
| Calleti, G | 1 |
| Flores Peres, V | 1 |
| Gomez, R | 2 |
| Maria Tannhauser Barros, H | 1 |
| Trammell, SA | 1 |
| Makarov, MV | 1 |
| Nielsen, TS | 1 |
| Jacobsen, JCB | 1 |
| Treebak, JT | 1 |
| Calder, PC | 1 |
| Migaud, ME | 1 |
| Tian, J | 2 |
| Song, M | 1 |
| Kaufman, DL | 2 |
| Zhu, X | 1 |
| Wang, H | 2 |
| Gasior, FM | 1 |
| Lee, C | 1 |
| Zhu, Z | 1 |
| Wang, Y | 7 |
| Justice, CN | 1 |
| O'Donnell, JM | 1 |
| Vanden Hoek, TL | 1 |
| Abuirmeileh, AN | 1 |
| Abuhamdah, SM | 1 |
| Ashraf, A | 1 |
| Alzoubi, KH | 1 |
| Lee, CC | 1 |
| Chen, WT | 1 |
| Chen, SY | 1 |
| Lee, TM | 1 |
| Stachowicz, A | 1 |
| Wiśniewska, A | 1 |
| Kuś, K | 1 |
| Białas, M | 1 |
| Łomnicka, M | 1 |
| Totoń-Żurańska, J | 1 |
| Kiepura, A | 1 |
| Stachyra, K | 1 |
| Suski, M | 1 |
| Bujak-Giżycka, B | 1 |
| Jawień, J | 1 |
| Olszanecki, R | 1 |
| Lan, R | 1 |
| Wan, Z | 1 |
| Xu, Y | 1 |
| Wang, Z | 1 |
| Fu, S | 1 |
| Zhou, Y | 1 |
| Lin, X | 2 |
| Han, X | 2 |
| Luo, Z | 1 |
| Miao, J | 2 |
| Yin, Y | 1 |
| Abbasian, N | 1 |
| Ghaderi-Najafabadi, M | 1 |
| Watson, E | 1 |
| Brown, J | 1 |
| Yu Si, L | 1 |
| Bursnall, D | 1 |
| Pawluczyk, I | 1 |
| Seymour, AM | 1 |
| Bevington, A | 1 |
| Chen, J | 2 |
| Xue, X | 1 |
| Cai, J | 1 |
| Jia, L | 1 |
| Sun, B | 1 |
| Zhao, W | 1 |
| Sevin, G | 1 |
| Kerry, Z | 1 |
| Sozer, N | 1 |
| Ozsarlak-Sozer, G | 1 |
| Stefanello, FV | 2 |
| Müller, TE | 3 |
| Franscescon, F | 2 |
| Quadros, VA | 2 |
| Souza, TP | 1 |
| Canzian, J | 1 |
| Leitemperger, J | 1 |
| Loro, VL | 1 |
| Rosemberg, DB | 6 |
| Cui, X | 1 |
| Navneet, S | 1 |
| Roon, P | 1 |
| Xian, M | 1 |
| Smith, SB | 1 |
| Nam, SY | 2 |
| Kim, HM | 2 |
| Jeong, HJ | 2 |
| Wu, GF | 1 |
| Ren, S | 1 |
| Tang, RY | 1 |
| Zhou, JQ | 1 |
| Lin, SM | 1 |
| Feng, Y | 1 |
| Yang, QH | 1 |
| Hu, JM | 1 |
| Yang, JC | 1 |
| Dallak, M | 1 |
| Chen, VC | 2 |
| Hsu, TC | 2 |
| Chen, LJ | 2 |
| Chou, HC | 1 |
| Weng, JC | 1 |
| Tzang, BS | 2 |
| Zhang, HH | 1 |
| Tao, YN | 1 |
| Jiang, MY | 1 |
| Xia, CM | 1 |
| Shen, LL | 1 |
| Wang, MY | 1 |
| Zhu, DN | 1 |
| Crabbe, JC | 1 |
| Ozburn, AR | 1 |
| Metten, P | 1 |
| Barkley-Levenson, A | 1 |
| Schlumbohm, JP | 1 |
| Spence, SE | 1 |
| Hack, WR | 1 |
| Huang, LC | 1 |
| Mezzomo, NJ | 2 |
| Fontana, BD | 3 |
| Kalueff, AV | 1 |
| Barcellos, LJG | 1 |
| Abad, N | 1 |
| Rosenberg, JT | 1 |
| Roussel, T | 1 |
| Grice, DC | 1 |
| Harrington, MG | 1 |
| Grant, SC | 1 |
| Kim, HW | 1 |
| Blomkalns, AL | 1 |
| Ogbi, M | 1 |
| Thomas, M | 1 |
| Gavrila, D | 1 |
| Neltner, BS | 1 |
| Cassis, LA | 1 |
| Thompson, RW | 1 |
| Weiss, RM | 1 |
| Lindower, PD | 1 |
| Blanco, VM | 1 |
| McCormick, ML | 1 |
| Daugherty, A | 1 |
| Fu, X | 1 |
| Hazen, SL | 1 |
| Stansfield, BK | 1 |
| Huo, Y | 1 |
| Fulton, DJ | 1 |
| Chatterjee, T | 1 |
| Weintraub, NL | 1 |
| Song, X | 1 |
| Fiati Kenston, SS | 1 |
| Zhao, J | 2 |
| Maclean, KN | 2 |
| Jiang, H | 4 |
| Aivazidis, S | 1 |
| Kim, E | 1 |
| Shearn, CT | 1 |
| Harris, PS | 1 |
| Petersen, DR | 1 |
| Allen, RH | 1 |
| Stabler, SP | 2 |
| Roede, JR | 1 |
| Lunde-Young, R | 1 |
| Davis-Anderson, K | 1 |
| Naik, V | 1 |
| Nemec, M | 1 |
| Wu, G | 2 |
| Ramadoss, J | 1 |
| Woo, CW | 1 |
| Kwon, JI | 1 |
| Kim, KW | 1 |
| Kim, JK | 1 |
| Jeon, SB | 1 |
| Jung, SC | 1 |
| Choi, CG | 1 |
| Kim, ST | 1 |
| Kim, J | 1 |
| Ham, SJ | 1 |
| Shim, WH | 1 |
| Sung, YS | 1 |
| Ha, HK | 1 |
| Choi, Y | 1 |
| Woo, DC | 1 |
| Qi, C | 1 |
| Liu, L | 3 |
| Zhao, L | 1 |
| Cui, W | 1 |
| Tian, Y | 1 |
| Liu, B | 1 |
| Hutson, RL | 1 |
| Thompson, RL | 1 |
| Bantel, AP | 1 |
| Tessier, CR | 1 |
| Wyckelsma, VL | 1 |
| Leão, VF | 1 |
| Ferreira, LLDM | 1 |
| Melo, CM | 1 |
| Bonfleur, ML | 2 |
| da Silva, LL | 1 |
| Carneiro, EM | 3 |
| Raimundo, JM | 1 |
| Ribeiro, RA | 2 |
| Che, Y | 1 |
| Hou, L | 1 |
| Sun, F | 1 |
| Liu, X | 2 |
| Piao, F | 1 |
| Zhang, D | 1 |
| Li, H | 2 |
| Wang, Q | 3 |
| Butchart, LC | 1 |
| Rossetti, G | 1 |
| White, R | 1 |
| Filipovska, A | 1 |
| Grounds, MD | 4 |
| Guzzetti, S | 1 |
| Calzari, L | 1 |
| Buccarello, L | 1 |
| Cesari, V | 1 |
| Toschi, I | 1 |
| Cattaldo, S | 1 |
| Mauro, A | 1 |
| Pregnolato, F | 1 |
| Mazzola, SM | 1 |
| Russo, S | 1 |
| García-Ayuso, D | 2 |
| Di Pierdomenico, J | 1 |
| Hadj-Said, W | 2 |
| Marie, M | 1 |
| Agudo-Barriuso, M | 2 |
| Vidal-Sanz, M | 2 |
| Picaud, S | 5 |
| Villegas-Pérez, MP | 2 |
| Bian, Y | 1 |
| Zhang, M | 2 |
| Gupte, R | 1 |
| Christian, S | 1 |
| Keselman, P | 1 |
| Habiger, J | 1 |
| Brooks, WM | 1 |
| Harris, JL | 1 |
| Sidek, S | 1 |
| Spasov, A | 2 |
| Ozerov, A | 2 |
| Mohd Ismail, N | 2 |
| Chiu, CC | 1 |
| Jin, R | 1 |
| Xiao, AY | 1 |
| Liu, S | 2 |
| Wang, M | 2 |
| Thirupathi, A | 1 |
| Freitas, S | 1 |
| Sorato, HR | 1 |
| Pedroso, GS | 1 |
| Effting, PS | 1 |
| Damiani, AP | 1 |
| Andrade, VM | 1 |
| Nesi, RT | 1 |
| Gupta, RC | 1 |
| Muller, AP | 1 |
| Pinho, RA | 1 |
| Adedara, IA | 1 |
| Alake, SE | 1 |
| Olajide, LO | 1 |
| Adeyemo, MO | 1 |
| Ajibade, TO | 1 |
| Farombi, EO | 1 |
| Parker, MO | 1 |
| Rico, EP | 3 |
| Ommati, MM | 1 |
| Heidari, R | 1 |
| Ghanbarinejad, V | 1 |
| Abdoli, N | 1 |
| Niknahad, H | 1 |
| Dang, H | 1 |
| Wallner, M | 1 |
| Olsen, R | 1 |
| Sekar, S | 1 |
| Grandjean, J | 1 |
| Garnell, JF | 1 |
| Willems, R | 1 |
| Duytschaever, H | 1 |
| Seramani, S | 1 |
| Su, H | 1 |
| Ver Donck, L | 1 |
| Bhakoo, KK | 1 |
| Phinney, WN | 1 |
| Keating, AK | 1 |
| Hurt, KJ | 1 |
| Chiquita, S | 1 |
| Ribeiro, M | 1 |
| Castelhano, J | 1 |
| Oliveira, F | 1 |
| Sereno, J | 1 |
| Batista, M | 1 |
| Abrunhosa, A | 1 |
| Rodrigues-Neves, AC | 1 |
| Carecho, R | 1 |
| Baptista, F | 1 |
| Gomes, C | 1 |
| Moreira, PI | 1 |
| Ambrósio, AF | 1 |
| Castelo-Branco, M | 1 |
| Bertoncello, KT | 1 |
| Filho, GLB | 1 |
| Ştefănescu, R | 1 |
| Stanciu, GD | 1 |
| Luca, A | 1 |
| Caba, IC | 1 |
| Tamba, BI | 1 |
| Mihai, CT | 1 |
| Chen, DQ | 1 |
| Cao, G | 2 |
| Chen, H | 2 |
| Argyopoulos, CP | 1 |
| Yu, H | 2 |
| Su, W | 1 |
| Chen, L | 1 |
| Samuels, DC | 1 |
| Zhuang, S | 1 |
| Bayliss, GP | 1 |
| Zhao, S | 1 |
| Yu, XY | 1 |
| Vaziri, ND | 1 |
| Liu, D | 2 |
| Mao, JR | 1 |
| Ma, SX | 1 |
| Shang, YQ | 1 |
| Kang, H | 1 |
| Ye, F | 1 |
| Cheng, XH | 1 |
| Li, XR | 1 |
| Zhang, L | 2 |
| Meng, MX | 1 |
| Guo, Y | 1 |
| Zhao, YY | 1 |
| Liu, H | 1 |
| Liu, J | 3 |
| Fu, W | 1 |
| Oja, SS | 2 |
| Saransaari, P | 1 |
| Awaludin, NA | 1 |
| Ahmad Fisol, NF | 1 |
| Bakar, NS | 1 |
| Abdul Rahman, TH | 1 |
| Mohamed Ahmed Salama, MS | 1 |
| Akay, C | 2 |
| Yaman, H | 2 |
| Oztosun, M | 1 |
| Cakir, E | 1 |
| Yildirim, AO | 1 |
| Eyi, YE | 1 |
| Agilli, M | 1 |
| Akgul, EO | 1 |
| Aydin, I | 1 |
| Kaldirim, U | 1 |
| Tuncer, SK | 1 |
| Eken, A | 2 |
| Oztas, E | 1 |
| Poyrazoglu, Y | 1 |
| Yasar, M | 1 |
| Ozkan, Y | 1 |
| Suzuki, Y | 1 |
| Kaneko, R | 1 |
| Nomura, M | 1 |
| Naito, H | 1 |
| Kitamori, K | 1 |
| Nakajima, T | 2 |
| Ogawa, T | 1 |
| Hattori, H | 1 |
| Seno, H | 1 |
| Ishii, A | 1 |
| Boyatzis, A | 1 |
| Emir, UE | 1 |
| Brent Clark, H | 1 |
| Vollmers, ML | 1 |
| Eberly, LE | 1 |
| Öz, G | 1 |
| Spanagel, R | 6 |
| Vengeliene, V | 2 |
| Jandeleit, B | 1 |
| Fischer, WN | 1 |
| Grindstaff, K | 1 |
| Zhang, X | 4 |
| Gallop, MA | 1 |
| Krstew, EV | 1 |
| Lawrence, AJ | 1 |
| Kiefer, F | 1 |
| Li, M | 2 |
| Reynolds, CM | 1 |
| Sloboda, DM | 1 |
| Gray, C | 1 |
| Vickers, MH | 1 |
| Guler, L | 1 |
| Tavlasoglu, M | 1 |
| Yucel, O | 2 |
| Guler, A | 2 |
| Sahin, MA | 2 |
| Kurkluoglu, M | 1 |
| Sirin, Y | 1 |
| Gamsizkan, M | 2 |
| Dakak, M | 1 |
| Gurkok, S | 1 |
| Genc, O | 1 |
| Su, Y | 1 |
| Fan, W | 2 |
| Wen, X | 1 |
| Wang, W | 1 |
| Wu, Q | 3 |
| Huang, H | 2 |
| Szwergold, BS | 1 |
| Miller, CB | 1 |
| Nishimura, T | 1 |
| Higuchi, K | 1 |
| Sai, Y | 1 |
| Sugita, Y | 1 |
| Yoshida, Y | 1 |
| Tomi, M | 1 |
| Wada, M | 1 |
| Wakayama, T | 1 |
| Tamura, A | 1 |
| Tsukita, S | 1 |
| Soga, T | 1 |
| Nakashima, E | 1 |
| Zhang, Z | 2 |
| Yi, B | 1 |
| Liao, Z | 1 |
| Tang, L | 1 |
| Yin, D | 1 |
| Yang, Y | 1 |
| Zheng, L | 4 |
| Wu, T | 1 |
| Zhang, Q | 2 |
| Yuan, F | 1 |
| Guo, J | 1 |
| Gu, Y | 3 |
| Zhao, Y | 3 |
| Qian, K | 1 |
| Sun, M | 3 |
| Alhouayek, M | 1 |
| Bottemanne, P | 1 |
| Subramanian, KV | 1 |
| Lambert, DM | 1 |
| Makriyannis, A | 1 |
| Cani, PD | 1 |
| Muccioli, GG | 1 |
| Lu, H | 2 |
| Liu, C | 1 |
| Zhu, W | 2 |
| Zheng, S | 1 |
| Wan, F | 1 |
| Rasmussen, AD | 1 |
| Truchot, N | 1 |
| Pickersgill, N | 1 |
| Thale, ZI | 1 |
| Rosolen, SG | 1 |
| Botteron, C | 1 |
| Kim, HY | 1 |
| Kim, HV | 1 |
| Yoon, JH | 1 |
| Kang, BR | 1 |
| Cho, SM | 1 |
| Lee, S | 2 |
| Kim, JW | 1 |
| Cho, Y | 1 |
| Woo, J | 1 |
| Kim, Y | 2 |
| Sierra-Paredes, G | 1 |
| Loureiro, AI | 1 |
| Wright, LC | 1 |
| Sierra-Marcuño, G | 1 |
| Soares-da-Silva, P | 1 |
| Aydos, TR | 1 |
| Başar, MM | 1 |
| Kul, O | 1 |
| Atmaca, HT | 1 |
| Uzunalıoğlu, T | 1 |
| Kisa, Ü | 1 |
| Efe, OE | 1 |
| Chumakov, I | 2 |
| Nabirotchkin, S | 2 |
| Cholet, N | 2 |
| Milet, A | 2 |
| Boucard, A | 1 |
| Toulorge, D | 2 |
| Pereira, Y | 1 |
| Graudens, E | 1 |
| Traoré, S | 1 |
| Foucquier, J | 2 |
| Guedj, M | 2 |
| Vial, E | 1 |
| Callizot, N | 1 |
| Steinschneider, R | 1 |
| Maurice, T | 1 |
| Bertrand, V | 1 |
| Scart-Grès, C | 1 |
| Hajj, R | 2 |
| Cohen, D | 2 |
| Murakami, S | 6 |
| Kim, W | 1 |
| Kim, HU | 1 |
| Lee, HN | 1 |
| Kim, SH | 3 |
| Kim, C | 1 |
| Cha, YN | 1 |
| Joe, Y | 1 |
| Chung, HT | 1 |
| Jang, J | 1 |
| Kim, K | 1 |
| Suh, YG | 1 |
| Jin, HO | 1 |
| Lee, JK | 1 |
| Surh, YJ | 1 |
| Ito, T | 4 |
| Azuma, J | 3 |
| Schaffer, SW | 5 |
| Chesney, RW | 1 |
| Makarova, LM | 2 |
| Pogoreliy, VE | 2 |
| Novikova, NA | 2 |
| Oleynikova, ON | 2 |
| Makarova, TI | 1 |
| Kim, SY | 1 |
| You, JS | 1 |
| Chang, KJ | 1 |
| Moon, PD | 1 |
| Kim, MH | 1 |
| Lim, HS | 1 |
| Oh, HA | 1 |
| Han, NR | 1 |
| Kim, MJ | 1 |
| Misini, B | 1 |
| Freinbichler, W | 1 |
| Colivicchi, MA | 1 |
| Bisilimi, K | 1 |
| Linert, W | 1 |
| Tipton, KF | 1 |
| Della Corte, L | 1 |
| Gharibani, P | 1 |
| Modi, J | 2 |
| Menzie, J | 2 |
| Alexandrescu, A | 1 |
| Tao, R | 2 |
| Prentice, H | 2 |
| Wu, JY | 2 |
| Russo, R | 1 |
| Adornetto, A | 1 |
| Cavaliere, F | 1 |
| Varano, GP | 1 |
| Morrone, LA | 1 |
| Corasaniti, MT | 1 |
| Bagetta, G | 1 |
| Nucci, C | 1 |
| Yoshikawa, N | 1 |
| Ito, H | 1 |
| Bakrania, B | 1 |
| Du Toit, EF | 1 |
| Wagner, KH | 1 |
| Headrick, JP | 1 |
| Bulmer, AC | 1 |
| Brener, O | 1 |
| Dunkelmann, T | 1 |
| Gremer, L | 1 |
| van Groen, T | 1 |
| Mirecka, EA | 1 |
| Kadish, I | 1 |
| Willuweit, A | 1 |
| Kutzsche, J | 1 |
| Jürgens, D | 1 |
| Rudolph, S | 1 |
| Tusche, M | 1 |
| Bongen, P | 1 |
| Pietruszka, J | 1 |
| Oesterhelt, F | 1 |
| Langen, KJ | 1 |
| Demuth, HU | 1 |
| Janssen, A | 1 |
| Hoyer, W | 1 |
| Funke, SA | 1 |
| Nagel-Steger, L | 1 |
| Willbold, D | 1 |
| Sukhotnik, I | 1 |
| Aranovich, I | 1 |
| Ben Shahar, Y | 1 |
| Bitterman, N | 1 |
| Pollak, Y | 1 |
| Berkowitz, D | 1 |
| Chepurov, D | 1 |
| Coran, AG | 1 |
| Bitterman, A | 1 |
| Laffaire, J | 1 |
| Robelet, S | 1 |
| Mitry, R | 1 |
| Pinniger, GJ | 1 |
| Graves, JA | 1 |
| Zhong, M | 1 |
| Liu, T | 1 |
| Han, H | 1 |
| Zhang, G | 1 |
| Wei, M | 1 |
| Hu, S | 1 |
| Capogrosso, RF | 2 |
| Cozzoli, A | 2 |
| Mantuano, P | 1 |
| Camerino, GM | 1 |
| Massari, AM | 1 |
| Sblendorio, VT | 2 |
| De Bellis, M | 1 |
| Tamma, R | 1 |
| Giustino, A | 1 |
| Nico, B | 2 |
| Montagnani, M | 1 |
| De Luca, A | 2 |
| Logotheti, S | 1 |
| Khoury, N | 1 |
| Vlahopoulos, SA | 1 |
| Skourti, E | 1 |
| Papaevangeliou, D | 1 |
| Liloglou, T | 1 |
| Gorgoulis, V | 1 |
| Budunova, I | 1 |
| Cai, Y | 1 |
| Mo, L | 1 |
| Huang, Z | 1 |
| Rahmeier, FL | 1 |
| Zavalhia, LS | 1 |
| Tortorelli, LS | 1 |
| Huf, F | 1 |
| Géa, LP | 1 |
| Meurer, RT | 1 |
| Machado, AC | 1 |
| Fernandes, MDC | 1 |
| Mei, X | 1 |
| Yuan, J | 1 |
| Lai, X | 1 |
| Froger, N | 3 |
| Ivkovic, I | 2 |
| Jiménez-López, M | 1 |
| Dubus, É | 4 |
| Dégardin-Chicaud, J | 1 |
| Simonutti, M | 4 |
| Quénol, C | 1 |
| Neveux, N | 1 |
| Sahel, JA | 4 |
| Jia, N | 1 |
| Sun, Q | 1 |
| Su, Q | 1 |
| Dang, S | 1 |
| Chen, G | 1 |
| Singh, K | 1 |
| Trivedi, R | 1 |
| Haridas, S | 1 |
| Manda, K | 1 |
| Khushu, S | 1 |
| Van den Bossche, L | 1 |
| Hindryckx, P | 1 |
| Devisscher, L | 1 |
| Devriese, S | 1 |
| Van Welden, S | 1 |
| Holvoet, T | 1 |
| Vilchez-Vargas, R | 1 |
| Vital, M | 1 |
| Pieper, DH | 1 |
| Vanden Bussche, J | 1 |
| Vanhaecke, L | 1 |
| Van de Wiele, T | 1 |
| De Vos, M | 1 |
| Laukens, D | 1 |
| Yu, R | 1 |
| Cao, L | 2 |
| Manna, P | 2 |
| Sinha, M | 2 |
| Sil, PC | 2 |
| Farook, JM | 1 |
| Krazem, A | 1 |
| Lewis, B | 1 |
| Morrell, DJ | 1 |
| Littleton, JM | 1 |
| Barron, S | 1 |
| Xue, W | 1 |
| Wu, D | 1 |
| Niu, L | 1 |
| Liang, Y | 1 |
| Zhang, F | 2 |
| Tong, L | 2 |
| Qiao, H | 2 |
| Dong, X | 1 |
| Qiao, G | 1 |
| Sun, X | 2 |
| Benesova, J | 1 |
| Hock, M | 1 |
| Butenko, O | 1 |
| Prajerova, I | 1 |
| Anderova, M | 1 |
| Chvatal, A | 1 |
| Tasci, I | 2 |
| Mas, N | 2 |
| Mas, MR | 2 |
| Tuncer, M | 1 |
| Comert, B | 2 |
| Gupta, T | 1 |
| Syed, YM | 1 |
| Revis, AA | 1 |
| Miller, SA | 1 |
| Martinez, M | 1 |
| Cohn, KA | 1 |
| Demeyer, MR | 1 |
| Patel, KY | 1 |
| Brzezinska, WJ | 1 |
| Rhodes, JS | 1 |
| Junyent, F | 2 |
| Utrera, J | 2 |
| Romero, R | 2 |
| Pallàs, M | 2 |
| Camins, A | 2 |
| Duque, D | 1 |
| Auladell, C | 2 |
| Pelletier, G | 1 |
| Masson, S | 1 |
| Wade, MJ | 1 |
| Nakai, J | 1 |
| Alwis, R | 1 |
| Mohottalage, S | 1 |
| Kumarathasan, P | 1 |
| Black, P | 1 |
| Bowers, WJ | 1 |
| Chu, I | 1 |
| Vincent, R | 1 |
| Tsang, TM | 1 |
| Haselden, JN | 1 |
| Holmes, E | 1 |
| Jammoul, F | 2 |
| Nabbout, R | 1 |
| Coriat, C | 1 |
| Duboc, A | 1 |
| Craft, CM | 1 |
| Ye, W | 1 |
| Collins, SD | 1 |
| Dulac, O | 1 |
| Chiron, C | 1 |
| Sakurai, T | 2 |
| Tomoike, H | 1 |
| Sakono, M | 1 |
| Nasu, T | 1 |
| Fukuda, N | 1 |
| Boukarrou, L | 1 |
| Dokin, C | 1 |
| Brown, WT | 1 |
| Shimizu, M | 2 |
| Zhao, Z | 2 |
| Ishimoto, Y | 2 |
| Satsu, H | 2 |
| Miyazaki, T | 1 |
| Bouscarel, B | 1 |
| Ikegami, T | 1 |
| Honda, A | 1 |
| Matsuzaki, Y | 1 |
| Win-Shwe, TT | 1 |
| Mitsushima, D | 1 |
| Yamamoto, S | 1 |
| Funabashi, T | 1 |
| Fujimaki, H | 1 |
| Lakshmi Devi, S | 1 |
| Anuradha, CV | 3 |
| Zulli, A | 1 |
| Lau, E | 1 |
| Wijaya, BP | 1 |
| Jin, X | 1 |
| Sutarga, K | 1 |
| Schwartz, GD | 1 |
| Learmont, J | 1 |
| Wookey, PJ | 1 |
| Zinellu, A | 1 |
| Carru, C | 1 |
| Hare, DL | 1 |
| Maciejak, P | 1 |
| Szyndler, J | 1 |
| Turzyńska, D | 1 |
| Sobolewska, A | 1 |
| Taracha, E | 1 |
| Skórzewska, A | 1 |
| Lehner, M | 1 |
| Bidziński, A | 1 |
| Hamed, A | 1 |
| Wisłowska-Stanek, A | 1 |
| Płaźnik, A | 1 |
| Li, CY | 1 |
| Deng, YL | 1 |
| Sun, BH | 1 |
| Das, J | 1 |
| Ghosh, J | 1 |
| Robb, WB | 1 |
| Condron, C | 2 |
| Moriarty, M | 1 |
| Walsh, TN | 1 |
| Bouchier-Hayes, DJ | 3 |
| Yang, SO | 1 |
| Kim, HS | 1 |
| Park, T | 1 |
| Choi, HK | 1 |
| Raue, W | 1 |
| Kilian, M | 1 |
| Braumann, C | 2 |
| Atanassow, V | 1 |
| Makareinis, A | 1 |
| Caldenas, S | 1 |
| Schwenk, W | 1 |
| Hartmann, J | 1 |
| Casey, RG | 2 |
| Kehoe, S | 1 |
| Toomey, D | 1 |
| Creagh, T | 1 |
| Akira, K | 2 |
| Mitome, H | 1 |
| Imachi, M | 2 |
| Shida, Y | 1 |
| Miyaoka, H | 1 |
| Hashimoto, T | 2 |
| Mason, BJ | 2 |
| Heyser, CJ | 1 |
| Wan, XY | 1 |
| Luo, M | 1 |
| Li, XD | 1 |
| He, P | 1 |
| Wu, MC | 1 |
| Men, X | 1 |
| Han, S | 1 |
| Gao, J | 1 |
| Pu, J | 1 |
| Olive, MF | 1 |
| Rolland, JF | 1 |
| Longo, V | 1 |
| Simonetti, S | 1 |
| Leonardi-Essmann, F | 1 |
| Sommer, WH | 1 |
| Marston, HM | 1 |
| Lee, IO | 1 |
| Lim, ES | 1 |
| de Oliveira, CA | 1 |
| Latorraca, MQ | 1 |
| de Mello, MA | 1 |
| Neuwirth, LS | 1 |
| L'Amoreaux, W | 2 |
| Yan, X | 1 |
| Sidime, F | 1 |
| Brozoski, TJ | 1 |
| Caspary, DM | 1 |
| Bauer, CA | 1 |
| Richardson, BD | 1 |
| da Rocha, RF | 1 |
| Zanotto-Filho, A | 1 |
| Dias, RD | 2 |
| Bogo, MR | 1 |
| Bonan, CD | 1 |
| Moreira, JC | 1 |
| Klamt, F | 1 |
| Souza, DO | 3 |
| Zhao, LC | 1 |
| Zhang, XD | 1 |
| Liao, SX | 1 |
| Gao, HC | 1 |
| Wang, HY | 1 |
| Lin, DH | 1 |
| Nardelli, TR | 1 |
| Balbo, SL | 1 |
| Vanzela, EC | 1 |
| Boschero, AC | 1 |
| Chang, YY | 1 |
| Chou, CH | 1 |
| Chiu, CH | 1 |
| Yang, KT | 1 |
| Lin, YL | 1 |
| Weng, WL | 1 |
| Chen, YC | 1 |
| Gao, X | 1 |
| Yang, X | 1 |
| Akdemir, O | 1 |
| Hede, Y | 1 |
| Lineaweaver, WC | 1 |
| Arslan, Z | 1 |
| Songur, E | 1 |
| Berthet, C | 1 |
| Lei, H | 1 |
| Gruetter, R | 1 |
| Hirt, L | 1 |
| Doganci, S | 1 |
| Jahollari, A | 1 |
| Cingoz, F | 1 |
| Arslan, S | 1 |
| Demirkilic, U | 1 |
| Porquet, D | 1 |
| de Lemos, L | 1 |
| Terada, T | 1 |
| Hara, K | 1 |
| Haranishi, Y | 1 |
| Sata, T | 1 |
| Kondo, M | 1 |
| Terasaki, H | 1 |
| Watt, CB | 2 |
| Rapp, K | 1 |
| Anderson, J | 1 |
| Lin, Y | 1 |
| Shaw, MV | 1 |
| Yang, JH | 1 |
| Marc, RE | 2 |
| Manna, SK | 1 |
| Patterson, AD | 1 |
| Krausz, KW | 1 |
| Idle, JR | 1 |
| Gonzalez, FJ | 1 |
| Biedermann, S | 1 |
| Weber-Fahr, W | 1 |
| Hoyer, C | 1 |
| Vollmayr, B | 1 |
| Gass, P | 1 |
| Ende, G | 1 |
| Sartorius, A | 1 |
| Zhang, J | 2 |
| Yu, X | 1 |
| Zou, S | 1 |
| Schwienbacher, M | 1 |
| Treml, B | 1 |
| Pinna, A | 1 |
| Geiger, R | 1 |
| Reinstadler, H | 1 |
| Pircher, I | 1 |
| Schmidl, E | 1 |
| Willomitzer, C | 1 |
| Neumeister, J | 1 |
| Pilch, M | 1 |
| Hauer, M | 1 |
| Hager, T | 2 |
| Sergi, C | 1 |
| Scholl-Bürgi, S | 1 |
| Giese, T | 1 |
| Löckinger, A | 1 |
| Nagl, M | 4 |
| Hammes, TO | 1 |
| Pedroso, GL | 1 |
| Hartmann, CR | 1 |
| Escobar, TD | 1 |
| Fracasso, LB | 1 |
| da Rosa, DP | 1 |
| Marroni, NP | 1 |
| Porawski, M | 1 |
| da Silveira, TR | 1 |
| MacKay, DS | 1 |
| Brophy, JD | 1 |
| McBreairty, LE | 1 |
| McGowan, RA | 1 |
| Bertolo, RF | 1 |
| Shi, X | 1 |
| Yao, D | 1 |
| Chen, C | 1 |
| Shivananjappa, MM | 1 |
| Gaucher, D | 2 |
| Arnault, E | 1 |
| Husson, Z | 1 |
| Gondouin, P | 1 |
| Dherbécourt, D | 1 |
| Degardin, J | 2 |
| Fouquet, S | 1 |
| Benahmed, MA | 1 |
| Elbayed, K | 1 |
| Namer, IJ | 1 |
| Massin, P | 1 |
| Braga, MM | 1 |
| Loss, CM | 1 |
| Córdova, SD | 1 |
| Mussulini, BH | 1 |
| Blaser, RE | 1 |
| Leite, CE | 1 |
| Campos, MM | 1 |
| Calcagnotto, ME | 1 |
| de Oliveira, DL | 1 |
| Guo, JX | 1 |
| Chang, P | 1 |
| Pałucha-Poniewiera, A | 1 |
| Pilc, A | 1 |
| Wang, XF | 1 |
| Teng, HY | 1 |
| Yang, N | 1 |
| Teuchner, B | 2 |
| Eitzinger, C | 1 |
| Lutz, M | 1 |
| Schmid, E | 1 |
| Bechrakis, NE | 1 |
| Zuck, M | 1 |
| Jekle, A | 1 |
| Debabov, D | 1 |
| Anderson, M | 1 |
| Zhuo, L | 1 |
| Liao, M | 1 |
| Huang, Q | 1 |
| Wei, L | 1 |
| Huang, R | 1 |
| Zhang, S | 1 |
| Gharibani, PM | 1 |
| Pan, C | 1 |
| Chen, PC | 1 |
| Cadetti, L | 1 |
| Lorach, H | 1 |
| Pain, D | 1 |
| Forster, V | 1 |
| Budhram, R | 2 |
| Pandya, KG | 2 |
| Lau-Cam, CA | 3 |
| Mathew, E | 1 |
| Barletta, MA | 1 |
| Clark, G | 1 |
| Han, L | 1 |
| Zhao, D | 1 |
| Pop-Busui, R | 1 |
| Marinescu, V | 1 |
| Van Huysen, C | 1 |
| Li, F | 2 |
| Sullivan, K | 1 |
| Greene, DA | 1 |
| Larkin, D | 2 |
| Stevens, MJ | 3 |
| Schuhmann, MU | 1 |
| Stiller, D | 1 |
| Skardelly, M | 1 |
| Thomas, S | 1 |
| Samii, M | 1 |
| Brinker, T | 2 |
| Değim, Z | 1 |
| Celebi, N | 1 |
| Sayan, H | 1 |
| Babül, A | 1 |
| Erdoğan, D | 1 |
| Take, G | 1 |
| Militante, JD | 1 |
| Lombardini, JB | 3 |
| Murina, MA | 1 |
| Fesenko, OD | 1 |
| Sergienko, VI | 1 |
| Chudina, NA | 1 |
| Roshchupkin, DI | 1 |
| Frizzo, ME | 1 |
| Lara, DR | 1 |
| Prokopiuk, Ade S | 1 |
| Vargas, CR | 1 |
| Salbego, CG | 1 |
| Wajner, M | 2 |
| Kondziella, D | 1 |
| Qu, H | 1 |
| Lüdemann, W | 1 |
| Sletvold, O | 1 |
| Sonnewald, U | 1 |
| Clayton, TA | 1 |
| Lindon, JC | 1 |
| Everett, JR | 1 |
| Charuel, C | 1 |
| Hanton, G | 1 |
| Le Net, JL | 1 |
| Provost, JP | 1 |
| Nicholson, JK | 1 |
| Opitz, I | 2 |
| van der Veen, HC | 1 |
| Ablassmaier, B | 1 |
| Führer, K | 1 |
| Jacobi, CA | 2 |
| Qureshi, AI | 1 |
| Ali, Z | 1 |
| Suri, MF | 1 |
| Shuaib, A | 1 |
| Baker, G | 1 |
| Todd, K | 1 |
| Guterman, LR | 1 |
| Hopkins, LN | 1 |
| Frederick, JM | 1 |
| Baehr, W | 1 |
| Chen, CK | 1 |
| Levine, EM | 1 |
| Milam, AH | 1 |
| Lavail, MM | 1 |
| Tenner, TE | 1 |
| Zhang, XJ | 1 |
| Giri, SN | 4 |
| Zwingmann, C | 2 |
| Chatauret, N | 1 |
| Rose, C | 1 |
| Leibfritz, D | 1 |
| Butterworth, RF | 1 |
| Chen, YX | 1 |
| Zhang, XR | 1 |
| Xie, WF | 1 |
| Li, S | 1 |
| Mao, DW | 1 |
| Zhao, YP | 1 |
| Li, SR | 1 |
| Che, JH | 1 |
| Tan, WH | 1 |
| Nandhini, AT | 1 |
| Takatani, T | 1 |
| Takahashi, K | 1 |
| Uozumi, Y | 1 |
| Shikata, E | 1 |
| Yamamoto, Y | 1 |
| Matsuda, T | 1 |
| Fujio, Y | 1 |
| Kingston, R | 1 |
| Kelly, CJ | 1 |
| Murray, P | 1 |
| O'Brien, CP | 1 |
| Nici, L | 1 |
| Monfils, B | 1 |
| Calabresi, P | 1 |
| Oguz, H | 1 |
| Ozbilge, H | 1 |
| Oguz, E | 1 |
| Gurkan, T | 1 |
| Gao, GD | 1 |
| Zheng, J | 1 |
| Sun, LZ | 1 |
| Long, C | 1 |
| Nestler, G | 1 |
| Schulz, HU | 1 |
| Schubert, D | 1 |
| Krüger, S | 1 |
| Lippert, H | 1 |
| Pross, M | 1 |
| Kalbe, L | 1 |
| Leunda, A | 1 |
| Sparre, T | 1 |
| Meulemans, C | 1 |
| Ahn, MT | 1 |
| Orntoft, T | 1 |
| Kruhoffer, M | 1 |
| Reusens, B | 1 |
| Nerup, J | 1 |
| Remacle, C | 1 |
| Wan, FS | 1 |
| Li, GH | 1 |
| Zalewska-Kaszubska, J | 2 |
| Cwiek, W | 1 |
| Dyr, W | 2 |
| Czarnecka, E | 2 |
| Li, C | 1 |
| Zeng, Q | 1 |
| Dai, T | 1 |
| Hu, D | 1 |
| Huang, K | 1 |
| Wang, X | 1 |
| Li, D | 1 |
| Chen, Z | 1 |
| Li, Y | 1 |
| Sharma, R | 1 |
| Verdrengh, M | 1 |
| Tarkowski, A | 1 |
| Dahchour, A | 1 |
| Lallemand, F | 1 |
| Ward, RJ | 1 |
| De Witte, P | 1 |
| Sarria, AJ | 1 |
| Surra, JC | 1 |
| Acin, S | 1 |
| Carnicer, R | 1 |
| Navarro, MA | 1 |
| Arbones-Mainar, JM | 1 |
| Guillen, N | 1 |
| Martinez-Gracia, MV | 1 |
| Arnal, C | 1 |
| Osada, J | 1 |
| Egli, M | 2 |
| Tadros, MG | 1 |
| Khalifa, AE | 1 |
| Abdel-Naim, AB | 1 |
| Arafa, HM | 1 |
| Franconi, F | 1 |
| Loizzo, A | 1 |
| Ghirlanda, G | 1 |
| Seghieri, G | 1 |
| Bilodeau, M | 1 |
| Heilig, M | 1 |
| Baran, H | 1 |
| Abatan, OI | 1 |
| Kim, H | 1 |
| Burnett, D | 1 |
| Obrosova, IG | 2 |
| Akkuş, A | 1 |
| Gülmen, M | 1 |
| Cevik, A | 1 |
| Bildik, N | 1 |
| Sad, O | 1 |
| Oztürk, E | 1 |
| Barişik, NO | 1 |
| Romanowski, EG | 1 |
| Yates, KA | 1 |
| Irschick, EU | 1 |
| Gordon, YJ | 1 |
| Gervais, F | 1 |
| Paquette, J | 1 |
| Morissette, C | 1 |
| Krzywkowski, P | 1 |
| Yu, M | 1 |
| Azzi, M | 1 |
| Lacombe, D | 1 |
| Kong, X | 1 |
| Aman, A | 1 |
| Laurin, J | 1 |
| Szarek, WA | 1 |
| Tremblay, P | 1 |
| Mozaffari, MS | 1 |
| Patel, C | 1 |
| Abdelsayed, R | 1 |
| Meng, F | 1 |
| Isik, AT | 1 |
| Yamanel, L | 1 |
| Inal, V | 1 |
| Deveci, S | 1 |
| Zeybek, A | 2 |
| Ercan, F | 2 |
| Cetinel, S | 2 |
| Cikler, E | 2 |
| Sağlam, B | 2 |
| Sener, G | 2 |
| Murakami, T | 1 |
| Paitel, E | 1 |
| Kawarabayashi, T | 1 |
| Ikeda, M | 1 |
| Chishti, MA | 1 |
| Janus, C | 1 |
| Matsubara, E | 1 |
| Sasaki, A | 1 |
| Kawarai, T | 1 |
| Phinney, AL | 1 |
| Harigaya, Y | 1 |
| Horne, P | 1 |
| Egashira, N | 1 |
| Mishima, K | 1 |
| Hanna, A | 1 |
| Yang, J | 1 |
| Iwasaki, K | 1 |
| Takahashi, M | 1 |
| Fujiwara, M | 1 |
| Ishiguro, K | 1 |
| Bergeron, C | 1 |
| Carlson, GA | 1 |
| Abe, K | 1 |
| Westaway, D | 1 |
| St George-Hyslop, P | 1 |
| Shoji, M | 1 |
| Soyka, M | 1 |
| Roesner, S | 1 |
| Frieling, H | 1 |
| Lauer, KS | 1 |
| Gründling, M | 1 |
| Usichenko, T | 1 |
| Meissner, K | 1 |
| Kanellopoulou, T | 1 |
| Lehmann, C | 1 |
| Wendt, M | 1 |
| Pavlovic, D | 1 |
| Gang, C | 1 |
| Joyce, M | 1 |
| Lardinois, D | 1 |
| Arni, S | 1 |
| Hillinger, S | 1 |
| Vogt, P | 1 |
| Odermatt, B | 1 |
| Rousson, V | 1 |
| Weder, W | 1 |
| Kast, RE | 1 |
| Altschuler, EL | 1 |
| de Boo, HA | 1 |
| Harding, JE | 1 |
| Fujisawa, M | 1 |
| Hori, M | 1 |
| Totsuka, M | 1 |
| Nambu, A | 1 |
| Kakuta, S | 1 |
| Ozaki, H | 1 |
| Dirican, M | 1 |
| Taş, S | 1 |
| Sarandöl, E | 1 |
| Navneet, AK | 1 |
| Appukuttan, TA | 1 |
| Pandey, M | 1 |
| Mohanakumar, KP | 1 |
| Bahadir, I | 1 |
| Oncel, M | 1 |
| Kement, M | 1 |
| Sahip, Y | 1 |
| Kaptanoglu, L | 1 |
| Kucuk, HF | 1 |
| Colak, E | 1 |
| Kurt, N | 1 |
| Bingul, SM | 1 |
| Akyol, H | 1 |
| Torlak, OA | 1 |
| Yazici, F | 1 |
| Tarhan, OR | 1 |
| Barut, I | 1 |
| Sezik, M | 1 |
| Hehre, DA | 1 |
| Devia, CJ | 1 |
| Bancalari, E | 1 |
| Suguihara, C | 1 |
| Górska, D | 1 |
| Sevgili, AM | 1 |
| Akbiyik, F | 1 |
| Atilla, P | 1 |
| Cakar, N | 1 |
| Balkanci, ZD | 1 |
| Iskit, AB | 1 |
| Guc, MO | 1 |
| Giriş, M | 1 |
| Depboylu, B | 1 |
| Doğru-Abbasoğlu, S | 1 |
| Erbil, Y | 1 |
| Olgaç, V | 1 |
| Aliş, H | 1 |
| Aykaç-Toker, G | 1 |
| Uysal, M | 1 |
| Liu, HY | 1 |
| Chi, FL | 1 |
| Gao, WY | 1 |
| Feksa, LR | 1 |
| Latini, A | 1 |
| Rech, VC | 1 |
| Feksa, PB | 1 |
| Koch, GD | 1 |
| Amaral, MF | 1 |
| Leipnitz, G | 1 |
| Dutra-Filho, CS | 1 |
| Wannmacher, CM | 1 |
| Zhao, XD | 1 |
| Zhou, XP | 1 |
| Liu, HH | 1 |
| Li, BM | 1 |
| Hu, XW | 1 |
| Li, FQ | 1 |
| You, BM | 1 |
| Craig, CR | 2 |
| Matuk, Y | 1 |
| Nagy, K | 1 |
| Bátkai, L | 1 |
| Tálas, M | 1 |
| Feuer, L | 1 |
| Kontro, P | 1 |
| Platt, J | 1 |
| Jones, RA | 1 |
| Bucknall, RA | 1 |
| Durelli, L | 2 |
| Mutani, R | 3 |
| Harris, TM | 1 |
| Nance, CS | 1 |
| Sheppard, LB | 1 |
| Fox, RR | 1 |
| Golden, GT | 2 |
| Fariello, RG | 2 |
| Barnett, KC | 1 |
| Curtis, R | 1 |
| Yamori, Y | 3 |
| Ikeda, K | 1 |
| Kihara, M | 1 |
| Nara, Y | 2 |
| Horie, R | 3 |
| Reddy, GS | 1 |
| Wilcken, DE | 1 |
| Frigyesi, TL | 1 |
| Benjamin, LE | 1 |
| Steele, RD | 1 |
| Blaisdell, RJ | 1 |
| Schiedt, MJ | 1 |
| Montalbetti, L | 1 |
| Rozza, A | 1 |
| Rizzo, V | 1 |
| Favalli, L | 1 |
| Scavini, C | 1 |
| Lanza, E | 1 |
| Savoldi, F | 1 |
| Racagni, G | 1 |
| Scelsi, R | 1 |
| Trachtman, H | 1 |
| Sturman, JA | 1 |
| Perry, VL | 1 |
| Young, RS | 1 |
| Aquila, WJ | 1 |
| During, MJ | 1 |
| Lehnert, BE | 1 |
| Archuleta, DC | 1 |
| Ellis, T | 1 |
| Session, WS | 1 |
| Lehnert, NM | 1 |
| Gurley, LR | 1 |
| Stavert, DM | 1 |
| Nakashima, T | 1 |
| Shima, T | 1 |
| Sakamoto, Y | 1 |
| Seto, Y | 1 |
| Sano, A | 1 |
| Iwai, M | 1 |
| Okanoue, T | 1 |
| Kashima, K | 1 |
| Nakata, N | 1 |
| Kato, H | 1 |
| Kogure, K | 1 |
| Matsumura, J | 1 |
| Neri, K | 1 |
| Rege, RV | 1 |
| Meier, SA | 1 |
| Knabe, DA | 1 |
| Overstreet, DH | 1 |
| Zieglgänsberger, W | 1 |
| Bac, P | 1 |
| Herrenknecht, C | 1 |
| Pagès, N | 1 |
| Dupont, C | 1 |
| Durlach, J | 1 |
| Ordemann, J | 1 |
| Böhm, B | 1 |
| Zieren, HU | 1 |
| Sabat, R | 1 |
| Müller, JM | 1 |
| Gurujeyalakshmi, G | 2 |
| Hollinger, MA | 1 |
| Nonaka, M | 1 |
| Yoshimine, T | 1 |
| Kohmura, E | 1 |
| Wakayama, A | 1 |
| Yamashita, T | 1 |
| Hayakawa, T | 1 |
| Yoshida, WB | 1 |
| Alasio, T | 1 |
| Mazziotta, R | 1 |
| Qin, F | 1 |
| Kashani, M | 1 |
| Dardik, H | 1 |
| Becker, R | 1 |
| Niessen, F | 1 |
| Isselhard, W | 1 |
| Minor, T | 1 |
| Son, M | 1 |
| Ko, JI | 1 |
| Kim, WB | 2 |
| Kang, HK | 1 |
| Kim, BK | 1 |
| Angelini, E | 1 |
| Teixeira, M | 1 |
| Aran, JM | 1 |
| Ferrary, E | 1 |
| Belfer, I | 1 |
| Davidson, E | 1 |
| Ratner, A | 1 |
| Beery, E | 1 |
| Shir, Y | 1 |
| Seltzer, Z | 1 |
| Konukoglu, D | 1 |
| Iynem, H | 1 |
| Ziylan, E | 1 |
| Hengster, P | 1 |
| Semenitz, E | 1 |
| Gottardi, W | 1 |
| Kornhuber, J | 1 |
| Mitton, KP | 1 |
| Linklater, HA | 1 |
| Dzialoszynski, T | 1 |
| Sanford, SE | 1 |
| Starkey, K | 1 |
| Trevithick, JR | 1 |
| Melani, A | 1 |
| Pantoni, L | 1 |
| Corsi, C | 1 |
| Bianchi, L | 1 |
| Monopoli, A | 1 |
| Bertorelli, R | 1 |
| Pepeu, G | 1 |
| Pedata, F | 1 |
| Kondo, Y | 3 |
| Tomisawa, K | 1 |
| Nagate, T | 3 |
| Balakrishnan, SD | 1 |
| Nakaya, Y | 1 |
| Minami, A | 1 |
| Harada, N | 1 |
| Sakamoto, S | 1 |
| Niwa, Y | 1 |
| Ohnaka, M | 1 |
| Kodama, M | 1 |
| Tsukada, H | 1 |
| Ooya, M | 1 |
| Onomura, M | 1 |
| Saito, T | 1 |
| Fukuda, K | 1 |
| Nakamura, H | 1 |
| Taniguchi, T | 1 |
| Tominaga, M | 1 |
| Hosokawa, M | 1 |
| Fujita, J | 1 |
| Seino, Y | 1 |
| Volz, J | 1 |
| Volz-Köster, S | 1 |
| Kanis, S | 1 |
| Klee, D | 1 |
| Ahlert, C | 1 |
| Melchert, F | 1 |
| Hölter, SM | 1 |
| Harkany, T | 1 |
| Abrahám, I | 1 |
| Timmerman, W | 1 |
| Laskay, G | 1 |
| Tóth, B | 1 |
| Sasvári, M | 1 |
| Kónya, C | 1 |
| Sebens, JB | 1 |
| Korf, J | 1 |
| Nyakas, C | 1 |
| Zarándi, M | 1 |
| Soós, K | 1 |
| Penke, B | 1 |
| Luiten, PG | 1 |
| Koob, GF | 1 |
| McCourt, M | 1 |
| Wang, JH | 1 |
| Sookhai, S | 1 |
| Redmond, HP | 1 |
| Yao, FS | 1 |
| Caserta, MT | 1 |
| Wyrwicz, AM | 1 |
| Benton, RL | 1 |
| Ross, CD | 1 |
| Miller, KE | 1 |
| Mankovskaya, IN | 1 |
| Serebrovskaya, TV | 1 |
| Swanson, RJ | 1 |
| Vavilova, GL | 1 |
| Kharlamova, ON | 1 |
| Zemgulis, V | 1 |
| Ronquist, G | 1 |
| Bjerner, T | 1 |
| Henze, A | 1 |
| Waldenström, A | 1 |
| Thelin, S | 1 |
| Wikström, G | 1 |
| Boening, JA | 1 |
| Lesch, OM | 1 |
| Wolffgramm, J | 1 |
| Narita, M | 1 |
| Sinclair, D | 1 |
| Wiesbeck, GA | 1 |
| Ahn, BO | 1 |
| Kim, KH | 1 |
| Lee, G | 1 |
| Lee, HS | 1 |
| Kim, CD | 1 |
| Kim, YS | 1 |
| Son, MW | 1 |
| Oh, TY | 1 |
| Hyun, JH | 1 |
| Fürst, P | 1 |
| Gürer, H | 1 |
| Ozgünes, H | 1 |
| Saygin, E | 1 |
| Ercal, N | 1 |
| Fathallah, L | 1 |
| Cortijo, J | 1 |
| Blesa, S | 1 |
| Martinez-Losa, M | 1 |
| Mata, M | 1 |
| Seda, E | 1 |
| Santangelo, F | 1 |
| Morcillo, EJ | 1 |
| Takenaga, T | 1 |
| Imada, K | 1 |
| Otomo, S | 1 |
| Zemlyanoy, A | 1 |
| Lupachyov, YU | 1 |
| Tyaptin, A | 1 |
| Torkounov, P | 1 |
| Varlashova, M | 1 |
| Novosyolova, N | 1 |
| Smith, CP | 1 |
| Somogyi, GT | 1 |
| Bird, ET | 1 |
| Chancellor, MB | 1 |
| Boone, TB | 1 |
| McBride, WJ | 1 |
| Le, AD | 1 |
| Noronha, A | 1 |
| Kitajima, H | 1 |
| Dawson, R | 1 |
| Biasetti, M | 1 |
| Messina, S | 1 |
| Dominy, J | 1 |
| Smith, AR | 1 |
| Rossi-Fanelli, F | 1 |
| Freund, H | 1 |
| Fischer, JE | 1 |
| Azari, J | 1 |
| Reisine, T | 1 |
| Barbeau, A | 2 |
| Yamamura, HI | 1 |
| Huxtable, R | 1 |
| Pfirrmann, RW | 1 |
| Leslie, GB | 1 |
| Quattrocolo, G | 1 |
| Delsedime, M | 2 |
| Buffa, C | 1 |
| Fassio, F | 1 |
| Valentini, C | 1 |
| Fumero, S | 1 |
| Wheler, GH | 1 |
| Osborne, RH | 1 |
| Bradford, HF | 1 |
| Davison, AN | 1 |
| Iritani, N | 1 |
| Ohtaka, M | 1 |
| Ooshima, A | 1 |
| Newman, WH | 1 |
| Frangakis, CJ | 1 |
| Grosso, DS | 1 |
| Bressler, R | 1 |
| Contreras, NE | 1 |
| Gordon, RE | 1 |
| Heller, RF | 2 |
| Mangum, JB | 1 |
| Everitt, JI | 1 |
| Bonner, JC | 1 |
| Moore, LR | 1 |
| Brody, AR | 1 |
| Orlova, TsR | 1 |
| Elizarova, EP | 1 |
| Ryff, IM | 1 |
| Fetisova, NI | 1 |
| Mit'kina, LI | 1 |
| Shibukawa, T | 1 |
| Kitao, M | 1 |
| Bocock, MA | 1 |
| Zlotkin, SH | 1 |
| Beal, MF | 1 |
| Kowall, NW | 1 |
| Swartz, KJ | 1 |
| Ferrante, RJ | 1 |
| Martin, JB | 1 |
| Feeney-Burns, L | 1 |
| Neuringer, M | 1 |
| Gao, CL | 1 |
| Mironova, EM | 1 |
| Pavlova, ON | 1 |
| Ronkina, TI | 1 |
| McNeal, RB | 1 |
| van Gelder, NM | 1 |
| Bélanger, F | 1 |
| Al-Zaid, NS | 1 |
| Thurston, JH | 1 |
| Hauhart, RE | 1 |
| Nelson, JS | 1 |
| Donaldson, J | 1 |
| Bergamini, L | 1 |
| Fariello, R | 1 |
| Hartman, ER | 1 |
| Cohen, AI | 1 |
| McDaniel, M | 1 |
| Orr, H | 1 |
| Philbrick, DJ | 1 |
| Hill, DC | 1 |
| Subbiah, MT | 1 |
| Kottke, BA | 1 |
| Carlo, IA | 1 |
| Weaver, KM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women With High Anxiety: an Experimental Medicine Study[NCT01187511] | Phase 2 | 44 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics[NCT01227980] | Phase 2 | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics[NCT00605904] | Phase 2 | 37 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Efficacy of Subgingivally Placed Amnion Membrane With and Without Taurine as an Adjunct to Scaling and Root Planing in the Treatment of Chronic Periodontitis[NCT04772508] | 45 participants (Actual) | Interventional | 2020-12-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.6932 |
| Placebo | 14.6126 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.7646 |
| Placebo | 10.413 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.4075 |
| Placebo | 13.0412 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.6218 |
| Placebo | 12.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 13.9789 |
| Placebo | 15.946 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.9075 |
| Placebo | 12.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.6218 |
| Placebo | 11.6603 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.9075 |
| Placebo | 13.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 12.1376 |
| Placebo | 13.1086 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.7805 |
| Placebo | 10.6194 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.7091 |
| Placebo | 13.1432 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.3519 |
| Placebo | 12.1432 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 14.1376 |
| Placebo | 16.9051 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.2805 |
| Placebo | 12.0956 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 12.2091 |
| Placebo | 10.3813 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 13.1376 |
| Placebo | 10.0004 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 100 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 12.977 |
| Placebo | 12.0475 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 15.1645 |
| Placebo | 12.0116 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 20 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 18.4145 |
| Placebo | 15.2497 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 40 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 20.352 |
| Placebo | 18.0116 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 70 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 13.7895 |
| Placebo | 13.0592 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.8582 |
| Placebo | 8.7076 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 11 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.4777 |
| Placebo | 7.041 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.5443 |
| Placebo | 6.6122 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 18 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.011 |
| Placebo | 5.4219 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.611 |
| Placebo | 5.7835 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 25 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.3112 |
| Placebo | 5.1362 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.2231 |
| Placebo | 4.5648 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.2365 |
| Placebo | 4.2791 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 4 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.6777 |
| Placebo | 5.9457 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.6078 |
| Placebo | 6.66 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 10.002 |
| Placebo | 8.7759 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 11 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.3187 |
| Placebo | 6.2997 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.6521 |
| Placebo | 8.0633 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 18 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.0521 |
| Placebo | 6.5855 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.0521 |
| Placebo | 5.9353 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 25 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 4.8092 |
| Placebo | 4.9188 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.149 |
| Placebo | 4.2997 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 4.8071 |
| Placebo | 4.2045 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 4 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.2521 |
| Placebo | 7.1569 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.6366 |
| Placebo | 6.9188 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.5572 |
| Placebo | 12.2152 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 11 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.7 |
| Placebo | 8.8468 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.7 |
| Placebo | 7.3205 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 18 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.2715 |
| Placebo | 6.9521 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.2715 |
| Placebo | 6.531 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 25 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 4.6286 |
| Placebo | 6.6363 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 3.6083 |
| Placebo | 6.5836 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 3.7666 |
| Placebo | 6.531 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 4 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.9858 |
| Placebo | 9.7942 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.1286 |
| Placebo | 8.7942 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | Units on a scale (Mean) |
|---|---|
| Pexacerfont | 16.6 |
| Placebo | 12.9 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | Units on a scale (Mean) |
|---|---|
| Pexacerfont | 12.7 |
| Placebo | 10.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 16.5 |
| Placebo | 11.8 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 15 |
| Placebo | 12.1 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 18.7 |
| Placebo | 14.5 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 13.7 |
| Placebo | 12.3 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 13.5 |
| Placebo | 12 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 13.7 |
| Placebo | 11.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 16.8 |
| Placebo | 12.5 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 12.9 |
| Placebo | 10.2 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 15.3 |
| Placebo | 12.2 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.9 |
| Placebo | 11.6 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 17.8 |
| Placebo | 14.4 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.3 |
| Placebo | 11.6 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.9 |
| Placebo | 11.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | Units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.6 |
| Placebo | 11.2 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
| Intervention | Units on a scale (Mean) |
|---|---|
| Acamprosate | 3.460 |
| Placebo | 5.416 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
| Intervention | Units on a scale (Mean) |
|---|---|
| Acamprosate | 1.704 |
| Placebo | 1.766 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
| Intervention | Units on a scale (Mean) |
|---|---|
| Acamprosate | 3.613 |
| Placebo | 3.606 |
26 reviews available for taurine and Disease Models, Animal
| Article | Year |
|---|---|
Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review).
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Cell Proliferation; Disease Models, Animal | 2020 |
Understanding taurine CNS activity using alternative zebrafish models.
Topics: Animals; Antioxidants; Brain Diseases; Disease Models, Animal; Taurine; Zebrafish | 2017 |
Molecular mechanisms of nickel induced neurotoxicity and chemoprevention.
Topics: Animals; Carnitine; Cell Line; Chemoprevention; Disease Models, Animal; DNA Damage; DNA, Mitochondri | 2017 |
Contributions of Mass Spectrometry to the Identification of Low Molecular Weight Molecules Able to Reduce the Toxicity of Amyloid-β Peptide to Cell Cultures and Transgenic Mouse Models of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line; Cell Survival; Disaccharides; Disease | 2019 |
Taurine and epilepsy.
Topics: Amino Acids; Animals; Disease Models, Animal; Epilepsy; Humans; Neurotransmitter Agents; Taurine | 2013 |
Role of taurine in the pathogenesis of obesity.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Animals; Anti-Obesity Agents; Bile Acids and Salts; Disease | 2015 |
The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Cognition; Diarrhea; Disease Models, Animal; D | 2010 |
Mechanisms of insulin secretion in malnutrition: modulation by amino acids in rodent models.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Diabetes Mellitus, Type 2; Dietary Supplement | 2011 |
The potential usefulness of taurine on diabetes mellitus and its complications.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Disease Models, Animal; Glycation | 2012 |
The effect of taurine on cholesterol metabolism.
Topics: Animals; Bile Acids and Salts; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Disease Models, Ani | 2012 |
Taurine and atherosclerosis.
Topics: Animals; Atherosclerosis; Disease Models, Animal; Humans; Hyperlipidemias; Myocardial Infarction; Ta | 2014 |
Treatment of hypertension with oral taurine: experimental and clinical studies.
Topics: Administration, Oral; Animals; Blood Pressure; Central Nervous System; Disease Models, Animal; Human | 2002 |
The therapeutic role of taurine in ischaemia-reperfusion injury.
Topics: Animals; Antioxidants; Ascorbic Acid; Clinical Trials as Topic; Disease Models, Animal; Free Radical | 2004 |
Understanding the role of dietary components on atherosclerosis using genetic engineered mouse models.
Topics: Alcohol Drinking; Allergy and Immunology; Animals; Antioxidants; Apolipoproteins E; Arginine; Arteri | 2006 |
Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Disease Models, Anim | 2005 |
Taurine supplementation and diabetes mellitus.
Topics: Adult; Animals; Child; Diabetes Mellitus; Dietary Supplements; Disease Models, Animal; Female; Human | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
New pharmacological approaches for the treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Carbamazepine; Depression; Disease Models, Ani | 2006 |
Retinitis pigmentosa and retinal degeneration in animals: a review.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Calcium; Disease Models, Animal; Dogs; Eye Proteins; G | 1984 |
The current status of taurine in epilepsy.
Topics: Animals; Brain; Disease Models, Animal; Epilepsy; Humans; Taurine | 1983 |
Taurine and experimental kidney disease.
Topics: Animals; Cell Division; Cell Line; Diabetic Nephropathies; Disease Models, Animal; Kidney Diseases; | 1994 |
Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
Topics: Acamprosate; Alcoholism; Animals; Behavior, Animal; Calcium Channels; Disease Models, Animal; Humans | 1997 |
Animal models of craving for ethanol.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Behavior, Addictive; Conditioning, Opera | 2000 |
Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Disease Models, Anim | 2001 |
Conditionally indispensable amino acids (glutamine, cyst(e)ine, tyrosine, arginine, ornithine, taurine) in enteral feeding and the dipeptide concept.
Topics: Amino Acids, Essential; Animals; Arginine; Cysteine; Disease Models, Animal; Enteral Nutrition; Glut | 2000 |
Taurine and related amino acids in seizure disorders--current controversies.
Topics: Amino Acids; Animals; Anticonvulsants; Clinical Trials as Topic; Disease Models, Animal; Epilepsy; g | 1985 |
2 trials available for taurine and Disease Models, Animal
| Article | Year |
|---|---|
Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity.
Topics: Amino Acids; Analysis of Variance; Animals; Child, Preschool; Disease Models, Animal; Dose-Response | 2009 |
Taurine and related amino acids in seizure disorders--current controversies.
Topics: Amino Acids; Animals; Anticonvulsants; Clinical Trials as Topic; Disease Models, Animal; Epilepsy; g | 1985 |
341 other studies available for taurine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Taurine and Camel Milk Modulate Neurobehavioral and Biochemical Changes in Aluminum Chloride-Induced Alzheimer's Disease in Rats.
Topics: Acetylcholinesterase; Aluminum Chloride; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; C | 2021 |
Taurine Reduces Liver Damage in Non-Alcoholic Fatty Liver Disease Model in Rats by Down-Regulating IL-9 and Tumor Growth Factor TGF-β.
Topics: Animals; Disease Models, Animal; Down-Regulation; Interleukin-9; Intestinal Mucosa; Liver; Liver Cir | 2021 |
Taurine protects dopaminergic neurons in paraquat-induced Parkinson's disease mouse model through PI3K/Akt signaling pathways.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Mice; Mice, Inbred C57BL; Paraquat; Parkinson | 2022 |
Effects of taurine and apocynin on the zone of stasis.
Topics: Animals; Antioxidants; Burns; Disease Models, Animal; Inflammation; Rats; Rats, Sprague-Dawley; Taur | 2022 |
Remembrance of infections past.
Topics: Animals; Disease Models, Animal; Gastrointestinal Microbiome; Gastrointestinal Tract; Host-Pathogen | 2022 |
Taurine Supplementation Inhibits the Expression of Atrogin-1 and MURF-1, Protein Degradation Marker Genes, in Skeletal Muscle of C26-Induced Cachexia Mouse Model.
Topics: Animals; Cachexia; Dietary Supplements; Disease Models, Animal; Mice; Muscle, Skeletal; Muscular Atr | 2022 |
NMR-based metabolomic analysis for the effects of moxibustion on imiquimod-induced psoriatic mice.
Topics: Alanine; Animals; Asparagine; Aspartic Acid; Cytokines; Disease Models, Animal; Glucose; Histidine; | 2023 |
Spatio-temporal metabolic rewiring in the brain of TgF344-AD rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Brain; Choline; Creatine; Disease Models, Animal; Disease Progression; G | 2022 |
Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8
Topics: Amino Acids; Animals; Antibodies, Monoclonal; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cyt | 2023 |
A mouse model of hepatic encephalopathy: bile duct ligation induces brain ammonia overload, glial cell activation and neuroinflammation.
Topics: Ammonia; Animals; Bile Acids and Salts; Bile Ducts; Brain; Choline; Disease Models, Animal; Glutamin | 2022 |
Variable Dose Rates in Realistic Radiation Exposures: Effects on Small Molecule Markers of Ionizing Radiation in the Murine Model.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Radiation; Female; Male; Metabolomics; | 2023 |
Metabolomics analysis of the potential mechanism of Yi-Guan-Jian decoction to reverse bone loss in glucocorticoid-induced osteoporosis.
Topics: Alkaline Phosphatase; Animals; Disease Models, Animal; Glucocorticoids; Male; Metabolomics; Mice; Mi | 2023 |
Unbalanced redox status network as an early pathological event in congenital cataracts.
Topics: Animals; Cataract; Disease Models, Animal; Glutathione; Humans; Mice; Mice, Transgenic; Mutant Prote | 2023 |
Profiles of brain oxidative damage, ventricular alterations, and neurochemical metabolites in the striatum of PINK1 knockout rats as functions of age and gender: Relevance to Parkinson disease.
Topics: Animals; Aspartic Acid; Biomarkers; Brain; Corpus Striatum; Disease Models, Animal; Female; Gene Kno | 2019 |
The Production of a Rat Model That Inhibits Phosphoenolpyruvate Carboxykinase (PEPCK), a Rate-Limiting Enzyme of Hepatic Gluconeogenesis.
Topics: Animals; Blood Glucose; Disease Models, Animal; Gluconeogenesis; Intracellular Signaling Peptides an | 2019 |
Role of Taurine in Testicular Function in the Fragile x Mouse.
Topics: Animals; Cyclin-Dependent Kinase 5; Dietary Supplements; Disease Models, Animal; Fragile X Mental Re | 2019 |
Pleiotropic Effects of Taurine on Nematode Model for Down Syndrome.
Topics: Animals; Caenorhabditis elegans; Calcium; Disease Models, Animal; Down Syndrome; Endoplasmic Reticul | 2019 |
Systemic taurine treatment provides neuroprotection against retinal photoreceptor degeneration and visual function impairments.
Topics: Animals; Apoptosis; Disease Models, Animal; Female; Injections, Intraperitoneal; Injections, Intrave | 2019 |
Protective effect of taurine against doxorubicin-induced cardiotoxicity in rats: echocardiographical and histological findings.
Topics: Animals; Antibiotics, Antineoplastic; Cardiotoxicity; Disease Models, Animal; Doxorubicin; Echocardi | 2019 |
Topics: Amidohydrolases; Amino Acid Substitution; Animals; Blood Glucose; Disease Models, Animal; Eating; Et | 2019 |
Dual targeting of cholinesterase and amyloid beta with pyridinium/isoquinolium derivatives.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Catalytic Domain; Cell Line | 2020 |
Perinatal taurine exerts a hypotensive effect in male spontaneously hypertensive rats and down-regulates endothelial oxide nitric synthase in the aortic arch.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Disease Models, Animal; Down-Regu | 2020 |
Taurine attenuates hepatic steatosis in a genetic model of fatty liver disease.
Topics: Acetyl-CoA Carboxylase; Animals; Disease Models, Animal; Fatty Liver; Female; Glutathione Transferas | 2020 |
Magnesium acetyltaurate protects against endothelin-1 induced RGC loss by reducing neuroinflammation in Sprague dawley rats.
Topics: Animals; Apoptosis; Blotting, Western; Disease Models, Animal; Endothelin-1; Female; Glaucoma; Intra | 2020 |
Elevated MMP2 abundance and activity in mdx mice are alleviated by prenatal taurine supplementation.
Topics: Animals; Dietary Supplements; Disease Models, Animal; Female; Male; Matrix Metalloproteinase 2; Matr | 2020 |
A Dietary Combination of Forskolin with Homotaurine, Spearmint and B Vitamins Protects Injured Retinal Ganglion Cells in a Rodent Model of Hypertensive Glaucoma.
Topics: Animals; Colforsin; Dietary Supplements; Disease Models, Animal; Female; Glaucoma; Intraocular Press | 2020 |
Creatine and taurine mixtures alleviate depressive-like behaviour in Drosophila melanogaster and mice via regulating Akt and ERK/BDNF pathways.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Catecholamines; | 2020 |
High-Throughput Screen Identifies Host and Microbiota Regulators of Intestinal Barrier Function.
Topics: Animals; Caco-2 Cells; Citrobacter rodentium; Colitis; Colon; Dextran Sulfate; Disease Models, Anima | 2020 |
NMR-based metabolomics approach reveals effects of antioxidant nutrients in sepsis-induced changes in rat liver injury.
Topics: Animals; Antioxidants; Ascorbic Acid; Disease Models, Animal; Glutathione; Liver Diseases; Magnetic | 2020 |
Investigation of the effect of taurine supplementation on muscle taurine content in the mdx mouse model of Duchenne muscular dystrophy using chemically specific synchrotron imaging.
Topics: Animals; Dietary Supplements; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Mu | 2020 |
Evaluation of the neuroprotective effect of taurine in Alzheimer's disease using functional molecular imaging.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Disease Models, Animal; Hippocampus; Human | 2020 |
Elevated GABA levels in the medial prefrontal cortex and lower estrogen levels abolish cocaine sensitization behavior in ovariectomized female rats.
Topics: Animals; Behavior, Animal; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Dopamine Upta | 2020 |
An abundant biliary metabolite derived from dietary omega-3 polyunsaturated fatty acids regulates triglycerides.
Topics: Amidohydrolases; Animals; Bile; Disease Models, Animal; Docosahexaenoic Acids; Fatty Acids, Omega-3; | 2021 |
Homotaurine limits the spreading of T cell autoreactivity within the CNS and ameliorates disease in a model of multiple sclerosis.
Topics: Animals; Antigen Presentation; Antigen-Presenting Cells; Cell Proliferation; Central Nervous System; | 2021 |
TAT delivery of a PTEN peptide inhibitor has direct cardioprotective effects and improves outcomes in rodent models of cardiac arrest.
Topics: Animals; Brain; Cardiotonic Agents; Disease Models, Animal; Glutamic Acid; Heart Arrest; Mice; Myoca | 2021 |
Protective effect of caffeine and/or taurine on the 6-hydroxydopamine-induced rat model of Parkinson's disease: Behavioral and neurochemical evidence.
Topics: Animals; Apomorphine; Behavior, Animal; Caffeine; Corpus Striatum; Disease Models, Animal; Dopamine; | 2021 |
Taurine Alleviates Sympathetic Innervation by Inhibiting NLRP3 Inflammasome in Postinfarcted Rats.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Inflammasomes; Inflammation; Interleukin- | 2021 |
Diminazene Aceturate Stabilizes Atherosclerotic Plaque and Attenuates Hepatic Steatosis in apoE-Knockout Mice by Influencing Macrophages Polarization and Taurine Biosynthesis.
Topics: Angiotensin I; Angiotensin-Converting Enzyme 2; Animals; Apolipoproteins E; Atherosclerosis; Diet, H | 2021 |
Taurine Reprograms Mammary-Gland Metabolism and Alleviates Inflammation Induced by
Topics: AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Energy Metabolism; Epithelial Cells; | 2021 |
Hepatic cysteine sulphinic acid decarboxylase depletion and defective taurine metabolism in a rat partial nephrectomy model of chronic kidney disease.
Topics: Animals; Carboxy-Lyases; Cysteine Dioxygenase; Dietary Supplements; Disease Models, Animal; Glutamin | 2021 |
Protective effect of taurine on sepsis‑induced lung injury via inhibiting the p38/MAPK signaling pathway.
Topics: Acute Lung Injury; Animals; Disease Models, Animal; Imidazoles; Lung; Male; Malondialdehyde; MAP Kin | 2021 |
Taurine supplementation protects lens against glutathione depletion.
Topics: Animals; Buthionine Sulfoximine; Cataract; Dietary Supplements; Disease Models, Animal; Female; Glut | 2021 |
Taurine modulates behavioral effects of intermittent ethanol exposure without changing brain monoamine oxidase activity in zebrafish: Attenuation of shoal- and anxiety-like responses, and abolishment of memory acquisition deficit.
Topics: Animals; Anxiety; Behavior, Animal; Brain; Disease Models, Animal; Ethanol; Female; Humans; Male; Me | 2021 |
Analysis of MTHFR, CBS, Glutathione, Taurine, and Hydrogen Sulfide Levels in Retinas of Hyperhomocysteinemic Mice.
Topics: Animals; Disease Models, Animal; Gene Expression Regulation; Glutathione; Hydrogen Sulfide; Hyperhom | 2017 |
The potential protective role of taurine against experimental allergic inflammation.
Topics: Animals; Caspase 1; Cell Line; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; | 2017 |
Antidepressant effect of taurine in chronic unpredictable mild stress-induced depressive rats.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dopamine; Fibroblast Growth Fact | 2017 |
A synergistic protective effect of selenium and taurine against experimentally induced myocardial infarction in rats.
Topics: Animals; bcl-2-Associated X Protein; Biomarkers; Disease Models, Animal; Drug Synergism; Electrocard | 2017 |
Effects of taurine on resting-state fMRI activity in spontaneously hypertensive rats.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; C-Reactive Protein; Disease Models, Animal; | 2017 |
The protective effects of electro-acupuncture in thoracic surgery on trauma stressed rats involve the rostral ventrolateral medulla and supraoptic nucleus.
Topics: Action Potentials; Animals; Disease Models, Animal; Electroacupuncture; Glutamic Acid; Male; Medulla | 2017 |
High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking.
Topics: Acamprosate; Animals; Baclofen; Binge Drinking; Darkness; Disease Models, Animal; Ethanol; Female; M | 2017 |
Metabolic assessment of a migraine model using relaxation-enhanced
Topics: Animals; Brain; Brain Chemistry; Disease Models, Animal; Lactic Acid; Magnetic Resonance Imaging; Ma | 2018 |
Role of myeloperoxidase in abdominal aortic aneurysm formation: mitigation by taurine.
Topics: Angiotensin II; Animals; Antioxidants; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Calcium Chlorid | 2017 |
Taurine treatment prevents derangement of the hepatic γ-glutamyl cycle and methylglyoxal metabolism in a mouse model of classical homocystinuria: regulatory crosstalk between thiol and sulfinic acid metabolism.
Topics: Amino Acids; Aminobutyrates; Animals; Cystathionine beta-Synthase; Disease Models, Animal; Female; g | 2018 |
Regional dysregulation of taurine and related amino acids in the fetal rat brain following gestational alcohol exposure.
Topics: Animals; Brain; Cerebellum; Cerebral Cortex; Disease Models, Animal; Ethanol; Female; Fetal Alcohol | 2018 |
The administration of hydrogen sulphide prior to ischemic reperfusion has neuroprotective effects in an acute stroke model.
Topics: Animals; Apoptosis; Aspartic Acid; Brain Ischemia; Disease Models, Animal; Glutamic Acid; Humans; Hy | 2017 |
Taurine Protects Primary Neonatal Cardiomyocytes Against Apoptosis Induced by Hydrogen Peroxide.
Topics: Animals; Animals, Newborn; Apoptosis; Blotting, Western; Calcium; Calcium-Calmodulin-Dependent Prote | 2018 |
Acamprosate rescues neuronal defects in the Drosophila model of Fragile X Syndrome.
Topics: Acamprosate; Animals; Animals, Genetically Modified; Behavior, Animal; Calbindins; Disease Models, A | 2018 |
Mitochondrial content is preserved throughout disease progression in the mdx mouse model of Duchenne muscular dystrophy, regardless of taurine supplementation.
Topics: Animals; Citrate (si)-Synthase; Dietary Supplements; Disease Models, Animal; Disease Progression; El | 2018 |
Taurine supplementation prevents endothelial dysfunction and attenuates structural changes in aortas from hypothalamic obese rats.
Topics: Animals; Aorta, Thoracic; Dietary Supplements; Disease Models, Animal; Endothelium, Vascular; Hypoth | 2019 |
Taurine protects dopaminergic neurons in a mouse Parkinson's disease model through inhibition of microglial M1 polarization.
Topics: alpha-Synuclein; Animals; Disease Models, Animal; Dopaminergic Neurons; Gait; Gene Expression; Male; | 2018 |
Expression patterns of regulatory RNAs, including lncRNAs and tRNAs, during postnatal growth of normal and dystrophic (mdx) mouse muscles, and their response to taurine treatment.
Topics: Animals; Disease Models, Animal; Female; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; | 2018 |
Taurine Administration Recovers Motor and Learning Deficits in an Angelman Syndrome Mouse Model.
Topics: Angelman Syndrome; Animals; Disease Models, Animal; Female; gamma-Aminobutyric Acid; Learning; Male; | 2018 |
Taurine Depletion Causes ipRGC Loss and Increases Light-Induced Photoreceptor Degeneration.
Topics: Animals; beta-Alanine; Cell Survival; Disease Models, Animal; Light; Photoreceptor Cells, Vertebrate | 2018 |
Taurine protects against knee osteoarthritis development in experimental rat models.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage Diseases; Cartilage, Articular; Disease | 2018 |
Evaluation of taurine neuroprotection in aged rats with traumatic brain injury.
Topics: Animals; Brain Injuries, Traumatic; Disease Models, Animal; Humans; Magnetic Resonance Imaging; Male | 2019 |
Effect of Magnesium Acetyltaurate and Taurine on Endothelin1-Induced Retinal Nitrosative Stress in Rats.
Topics: Animals; Apoptosis; Disease Models, Animal; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Female; | 2018 |
Effects of taurine on striatal dopamine transporter expression and dopamine uptake in SHR rats.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Brain-Derived Neurotrophic Factor; Co | 2018 |
Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
Topics: Animals; Disease Models, Animal; Fibrinolytic Agents; Infarction, Middle Cerebral Artery; Intracrani | 2018 |
Modulatory effects of taurine on metabolic and oxidative stress parameters in a mice model of muscle overuse.
Topics: Animals; Antioxidants; Cumulative Trauma Disorders; Disease Models, Animal; Male; Mice; Mitochondria | 2018 |
Taurine Ameliorates Thyroid Hypofunction and Renal Injury in L-NAME-Induced Hypertensive Rats.
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Dietary Supplements; Disease Models, Ani | 2019 |
Taurine modulates acute ethanol-induced social behavioral deficits and fear responses in adult zebrafish.
Topics: Animals; Avoidance Learning; Central Nervous System Depressants; Disease Models, Animal; Dose-Respon | 2018 |
Taurine Treatment Provides Neuroprotection in a Mouse Model of Manganism.
Topics: Animals; Biomarkers; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Injections, Su | 2019 |
Homotaurine, a safe blood-brain barrier permeable GABA
Topics: Administration, Oral; Animals; Blood-Brain Barrier; Disease Models, Animal; GABA Agonists; Mice; Mic | 2018 |
Neuro-metabolite profiles of rodent models of psychiatric dysfunctions characterised by MR spectroscopy.
Topics: Anhedonia; Animals; Choline; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; | 2019 |
Taurine alleviates repression of betaine-homocysteine
Topics: Animals; Betaine; Betaine-Homocysteine S-Methyltransferase; Disease Models, Animal; Homocystinuria; | 2019 |
A longitudinal multimodal in vivo molecular imaging study of the 3xTg-AD mouse model shows progressive early hippocampal and taurine loss.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomarkers; Blood-Brain Barrier; Disease Models, | 2019 |
Taurine prevents memory consolidation deficits in a novel alcohol-induced blackout model in zebrafish.
Topics: Amnesia; Animals; Avoidance Learning; Disease Models, Animal; Ethanol; Female; Male; Memory Consolid | 2019 |
Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan.
Topics: Acetylcarnitine; Animals; Canavanine; Carnitine; Case-Control Studies; Disease Models, Animal; Disea | 2019 |
Proteomics analysis of fetal growth restriction and taurine‑treated fetal growth restriction rat brain tissue by 2D DIGE and MALDI‑TOF/TOF MS analysis.
Topics: Animals; Brain; Disease Models, Animal; Female; Fetal Growth Retardation; Nerve Tissue Proteins; Pro | 2019 |
Effects of magnesium taurate on the onset and progression of galactose-induced experimental cataract: in vivo and in vitro evaluation.
Topics: Administration, Oral; Administration, Topical; Animals; Calcium; Catalase; Cataract; Diabetes Mellit | 2013 |
The protective effects of taurine on experimental acute pancreatitis in a rat model.
Topics: Acute Disease; Animals; Disease Models, Animal; Interleukin-1beta; Interleukin-6; Male; Pancreatitis | 2013 |
Simple and rapid quantitation of 21 bile acids in rat serum and liver by UPLC-MS-MS: effect of high fat diet on glycine conjugates of rat bile acids.
Topics: Animals; Bile Acids and Salts; Biomarkers; Calibration; Cholesterol, Dietary; Chromatography, Liquid | 2013 |
Treatment with the cysteine precursor l-2-oxothiazolidine-4-carboxylate (OTC) implicates taurine deficiency in severity of dystropathology in mdx mice.
Topics: Acetylcysteine; Animals; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Muscular Dystrophy, | 2013 |
Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1.
Topics: Animals; Ataxin-1; Ataxins; Cerebellum; Choline; Disease Models, Animal; Disease Progression; Gene K | 2013 |
Acamprosate produces its anti-relapse effects via calcium.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Calcium; Disease Models, Animal; Dose-Response | 2014 |
Effects of taurine supplementation on hepatic markers of inflammation and lipid metabolism in mothers and offspring in the setting of maternal obesity.
Topics: Animals; Animals, Newborn; Biomarkers; Body Weight; Dietary Supplements; Disease Models, Animal; Fem | 2013 |
Taurine attenuates lung ischemia-reperfusion injury after lung transplantation in rats.
Topics: Animals; Antioxidants; Disease Models, Animal; Hypertonic Solutions; Lung; Lung Transplantation; Mal | 2014 |
Taurine improves functional and histological outcomes and reduces inflammation in traumatic brain injury.
Topics: Animals; Brain Injuries; Disease Models, Animal; Fluorescent Antibody Technique; Inflammation; Male; | 2014 |
Potential of birds to serve as pathology-free models of type 2 diabetes, part 2: do high levels of carbonyl-scavenging amino acids (e.g., taurine) and low concentrations of methylglyoxal limit the production of advanced glycation end-products?
Topics: Albumins; Animals; Arginine; Birds; Diabetes Mellitus, Type 2; Disease Models, Animal; Fructosamine; | 2014 |
Fetal growth retardation and lack of hypotaurine in ezrin knockout mice.
Topics: Animals; Cytoskeletal Proteins; Disease Models, Animal; Female; Fetal Growth Retardation; Gene Targe | 2014 |
Taurine supplementation reduces oxidative stress and protects the liver in an iron-overload murine model.
Topics: Alanine Transaminase; Animals; Apoptosis; Aspartate Aminotransferases; Catalase; Disease Models, Ani | 2014 |
Serum metabonomic analysis of apoE(-/-) mice reveals progression axes for atherosclerosis based on NMR spectroscopy.
Topics: Animals; Atherosclerosis; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Choline; Diet, High-Fat; D | 2014 |
Taurine attenuates hippocampal and corpus callosum damage, and enhances neurological recovery after closed head injury in rats.
Topics: Animals; CA1 Region, Hippocampal; CA3 Region, Hippocampal; Calcium-Binding Proteins; Calpain; Cell D | 2015 |
N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis.
Topics: Amides; Amidohydrolases; Animals; Anti-Inflammatory Agents; Arachidonic Acids; Chromatography, High | 2015 |
Taurine induces the apoptosis of breast cancer cells by regulating apoptosis-related proteins of mitochondria.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Lin | 2015 |
The effects of taurine on vigabatrin, high light intensity and mydriasis induced retinal toxicity in the pigmented rat.
Topics: Animals; Anticonvulsants; Atropine; Disease Models, Animal; Electroretinography; Male; Mydriasis; My | 2015 |
Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Blotting, Western | 2014 |
Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus.
Topics: Acute Disease; Amino Acids; Animals; Anticonvulsants; Aspartic Acid; Bridged Bicyclo Compounds, Hete | 2014 |
Effects of ozone therapy and taurine on ischemia/reperfusion-induced testicular injury in a rat testicular torsion model.
Topics: Animals; Antioxidants; Disease Models, Animal; In Situ Nick-End Labeling; Male; Oxidants, Photochemi | 2014 |
Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy.
Topics: Acamprosate; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Apop | 2015 |
Taurine Chloramine Stimulates Efferocytosis Through Upregulation of Nrf2-Mediated Heme Oxygenase-1 Expression in Murine Macrophages: Possible Involvement of Carbon Monoxide.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carbon Monoxide; Cytoskeletal Proteins; Disease Model | 2015 |
The quest for an animal model of diabetic nephropathy and the role of taurine deficiency.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Female; Hu | 2015 |
Experimental study of taurine on the cerebral dehydrogenase activity in the model of unilateral cerebral ischemia.
Topics: Animals; Brain; Brain Ischemia; Carotid Artery, Common; Cell Survival; Coronary Occlusion; Disease M | 2015 |
Experimental study of taurine antitoxic activity in the model of chronic epinephrine intoxication.
Topics: Animals; Animals, Outbred Strains; Arteries; Calcium; Cerebrum; Chronic Disease; Cytoprotection; Dis | 2015 |
N-(D-Ribopyranosyl)Taurine Sodium Salt Has Anti-obesity Effect in Diet-Induced Obesity and Taurine Deficiency Rat Model.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Body Weight; Diet; Disease Models, Animal; Eating; Ene | 2015 |
Taurine, a major amino acid of oyster, enhances linear bone growth in a mouse model of protein malnutrition.
Topics: Animals; Bone and Bones; Bone Density; Bone Development; Diet, Protein-Restricted; Dietary Supplemen | 2015 |
Continuous monitoring of highly reactive oxygen radicals during in vivo microdialysis.
Topics: Analysis of Variance; Animals; Area Under Curve; Chromatography, High Pressure Liquid; Disease Model | 2015 |
Comparison between single and combined post-treatment with S-Methyl-N,N-diethylthiolcarbamate sulfoxide and taurine following transient focal cerebral ischemia in rat brain.
Topics: Animals; Brain; Disease Models, Animal; Ditiocarb; Drug Therapy, Combination; Excitatory Amino Acid | 2015 |
Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury.
Topics: Animals; Carnosine; Cell Survival; Colforsin; Disease Models, Animal; Drug Synergism; Glaucoma; Glyc | 2015 |
Taurine deficiency, synthesis and transport in the mdx mouse model for Duchenne Muscular Dystrophy.
Topics: Animals; Biological Transport; Chromatography, High Pressure Liquid; Cysteine; Disease Models, Anima | 2015 |
Impact of taurine depletion on glucose control and insulin secretion in mice.
Topics: Animals; Blood Glucose; Body Weight; Diet, High-Fat; Disease Models, Animal; Energy Metabolism; Gene | 2015 |
Pre- or post-ischemic bilirubin ditaurate treatment reduces oxidative tissue damage and improves cardiac function.
Topics: Animals; Bilirubin; Coronary Circulation; Creatine Kinase; Disease Models, Animal; Gilbert Disease; | 2016 |
QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Carrier Proteins; Catechin; Disease Models, Anima | 2015 |
Effect of taurine on intestinal recovery following intestinal ischemia-reperfusion injury in a rat.
Topics: Animals; Blotting, Western; Disease Models, Animal; Intestines; Male; Rats; Rats, Sprague-Dawley; Re | 2016 |
Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease.
Topics: Acamprosate; Animals; Baclofen; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; | 2015 |
Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.
Topics: Animals; Disease Models, Animal; Female; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle Co | 2016 |
Duodenal-Jejunal Bypass Preferentially Elevates Serum Taurine-Conjugated Bile Acids and Alters Gut Microbiota in a Diabetic Rat Model.
Topics: Animals; Bile Acids and Salts; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Duo | 2016 |
Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of duchenne muscular dystrophy: A comparison with the gold standard, α-methyl prednisolone.
Topics: Acetophenones; Animals; Antioxidants; Disease Models, Animal; Male; Methylprednisolone; Mice; Mice, | 2016 |
N-bromotaurine surrogates for loss of antiproliferative response and enhances cisplatin efficacy in cancer cells with impaired glucocorticoid receptor.
Topics: Animals; Carcinogenesis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Models | 2016 |
Protective effects of taurine in traumatic brain injury via mitochondria and cerebral blood flow.
Topics: Animals; Blood Flow Velocity; Brain Edema; Brain Injuries, Traumatic; Cerebrovascular Circulation; D | 2016 |
The effect of taurine and enriched environment on behaviour, memory and hippocampus of diabetic rats.
Topics: Animals; Apoptosis; Behavior, Animal; Caspase 3; Diabetes Mellitus; Disease Models, Animal; Environm | 2016 |
Taurine zinc solid dispersions enhance bile-incubated L02 cell viability and improve liver function by inhibiting ERK2 and JNK phosphorylation during cholestasis.
Topics: Alanine Transaminase; Animals; Apoptosis; Aspartate Aminotransferases; Bile Ducts; Bilirubin; Cell L | 2016 |
Quantitative and Topographical Analysis of the Losses of Cone Photoreceptors and Retinal Ganglion Cells Under Taurine Depletion.
Topics: Animals; Cell Count; Disease Models, Animal; Electroretinography; Immunohistochemistry; Male; Mice; | 2016 |
Taurine promotes cognitive function in prenatally stressed juvenile rats via activating the Akt-CREB-PGC1α pathway.
Topics: Animals; Animals, Newborn; Cognition Disorders; Cyclic AMP Response Element-Binding Protein; Disease | 2016 |
Study of neurometabolic and behavioral alterations in rodent model of mild traumatic brain injury: a pilot study.
Topics: Animals; Behavior, Animal; Biomarkers; Brain Concussion; Disease Models, Animal; Hippocampus; Humans | 2016 |
Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice.
Topics: Animals; Bacteroides; Colon; Dextran Sulfate; Disease Models, Animal; Dysbiosis; Feces; Firmicutes; | 2017 |
Neuroprotection of taurine through inhibition of 12/15 lipoxygenase pathway in cerebral ischemia of rats.
Topics: Animals; Arachidonate 12-Lipoxygenase; Arachidonate 15-Lipoxygenase; Brain Edema; Brain Infarction; | 2017 |
Amelioration of cadmium-induced cardiac impairment by taurine.
Topics: Administration, Oral; Animals; Antioxidants; Biomarkers; Cadmium Chloride; Chemoprevention; Disease | 2008 |
Acamprosate attenuates the handling induced convulsions during alcohol withdrawal in Swiss Webster mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Withdrawal Seizures; Alcohols; Analysis of Variance; Animal | 2008 |
Effects of taurine on aortic rings isolated from fructose-fed insulin resistance Sprague-Dawley rat are changed.
Topics: 4-Aminopyridine; Acetylcholine; Administration, Oral; Animals; Aorta; Blood Glucose; Blood Pressure; | 2008 |
Taurine attenuates multiple organ injury induced by intestinal ischemia reperfusion in rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Disease Models, Animal; Injections, Intr | 2008 |
Quantification of astrocyte volume changes during ischemia in situ reveals two populations of astrocytes in the cortex of GFAP/EGFP mice.
Topics: Animals; Astrocytes; Cell Size; Cerebral Cortex; Disease Models, Animal; Electric Stimulation; Glial | 2009 |
Ultrastructural changes in hepatocytes after taurine treatment in CCl4 induced liver injury.
Topics: Animals; Carbon Tetrachloride; Cell Nucleus; Disease Models, Animal; Endoplasmic Reticulum; Hepatocy | 2008 |
Acute effects of acamprosate and MPEP on ethanol Drinking-in-the-Dark in male C57BL/6J mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Darkness; Disease Models, An | 2008 |
Prevention of epilepsy by taurine treatments in mice experimental model.
Topics: Analysis of Variance; Animals; Anticonvulsants; Brain; Calpain; Cell Death; Chromatography, High Pre | 2009 |
Contribution of methylmercury, polychlorinated biphenyls and organochlorine pesticides to the toxicity of a contaminant mixture based on Canadian Arctic population blood profiles.
Topics: Age Factors; Animals; Arctic Regions; Body Weight; Brain; Canada; Cerebellum; Complex Mixtures; Dise | 2009 |
Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease.
Topics: Animals; Behavior, Animal; Brain; Brain Stem; Cerebellum; Cerebral Cortex; Choline; Corpus Striatum; | 2009 |
Prevention of hypercholesterolemia and atherosclerosis in the hyperlipidemia- and atherosclerosis-prone Japanese (LAP) quail by taurine supplementation.
Topics: Animals; Atherosclerosis; Cholesterol; Disease Models, Animal; Humans; Hypercholesterolemia; Hyperli | 2010 |
Taurine improves congestive functions in a mouse model of fragile X syndrome.
Topics: Animals; Avoidance Learning; Disease Models, Animal; Fragile X Syndrome; Mice; Taurine | 2009 |
Dietary taurine attenuates dextran sulfate sodium (DSS)-induced experimental colitis in mice.
Topics: Animals; Dextran Sulfate; Diet; Disease Models, Animal; Inflammatory Bowel Diseases; Interleukin-8; | 2009 |
The protective effect of taurine against hepatic damage in a model of liver disease and hepatic stellate cells.
Topics: Animals; Base Sequence; Disease Models, Animal; DNA Primers; Liver Diseases; Male; Oxidative Stress; | 2009 |
Strain differences in extracellular amino acid neurotransmitter levels in the hippocampi of major histocompatibility complex congenic mice in response to toluene exposure.
Topics: Amino Acids; Animals; Disease Models, Animal; Extracellular Fluid; Glycine; Haplotypes; Hippocampus; | 2009 |
Mitochondrial damage, cytotoxicity and apoptosis in iron-potentiated alcoholic liver fibrosis: amelioration by taurine.
Topics: Animals; Antioxidants; Apoptosis; Cell Survival; Disease Models, Animal; DNA Fragmentation; Electron | 2010 |
High dietary taurine reduces apoptosis and atherosclerosis in the left main coronary artery: association with reduced CCAAT/enhancer binding protein homologous protein and total plasma homocysteine but not lipidemia.
Topics: Analysis of Variance; Animals; Apoptosis; CCAAT-Binding Factor; Coronary Artery Disease; Diet, Ather | 2009 |
[Antagonism for different doses of taurine on calcium overload in myocardial cells of diastole heart failure rat model].
Topics: Adenosine Triphosphatases; Animals; Calcium; Diastole; Disease Models, Animal; Female; Heart Failure | 2009 |
The effects of group III mGluR ligands on pentylenetetrazol-induced kindling of seizures and hippocampal amino acids concentration.
Topics: Alanine; Amino Acids; Aminobutyrates; Animals; Convulsants; Disease Models, Animal; Dose-Response Re | 2009 |
Taurine protected kidney from oxidative injury through mitochondrial-linked pathway in a rat model of nephrolithiasis.
Topics: Animals; Antioxidants; Disease Models, Animal; Glutathione Peroxidase; Hyperoxaluria; Kidney; Kidney | 2009 |
Arsenic-induced oxidative cerebral disorders: protection by taurine.
Topics: Acetylcholinesterase; Adenosine Triphosphatases; Amino Acids, Essential; Animals; Antioxidants; Apop | 2009 |
Taurine attenuates radiation-induced lung fibrosis in C57/Bl6 fibrosis prone mice.
Topics: Analysis of Variance; Animals; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Female; Hydroxy | 2010 |
1H-nuclear magnetic resonance spectroscopy-based metabolic assessment in a rat model of obesity induced by a high-fat diet.
Topics: Acetoacetates; Acetone; Animals; Betaine; Citric Acid; Dietary Fats; Disease Models, Animal; Glycine | 2009 |
Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chemotherapy, Adjuvant; Colonic Neoplasm | 2010 |
Taurine modulates neutrophil function but potentiates uropathogenic E. coli infection in the murine bladder.
Topics: Animals; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Female; Mice; Mice, | 2010 |
LC-NMR identification of a novel taurine-related metabolite observed in (1)H NMR-based metabonomics of genetically hypertensive rats.
Topics: Animals; Chromatography, Liquid; Disease Models, Animal; Hypertension; Magnetic Resonance Spectrosco | 2010 |
Inhibitory effects of taurine and oat fiber on intestinal endotoxin release in rats.
Topics: Animals; Avena; Dietary Fiber; Disease Models, Animal; Endotoxins; Intestines; Rats; Rats, Sprague-D | 2010 |
Taurine protects against lung damage following limb ischemia reperfusion in the rat by attenuating endoplasmic reticulum stress-induced apoptosis.
Topics: Animals; Apoptosis; Disease Models, Animal; Endoplasmic Reticulum; Ischemia; Lung; Male; Oxidative S | 2010 |
Pharmacotherapies for alcoholism: the old and the new.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Dis | 2010 |
Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy.
Topics: Animals; Chromatography, High Pressure Liquid; Creatine Kinase; Disease Models, Animal; Drug Synergi | 2011 |
Glycine transporter-1 blockade leads to persistently reduced relapse-like alcohol drinking in rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Corpus Striatum; Disease Mod | 2010 |
Intracisternal or intrathecal glycine, taurine, or muscimol inhibit bicuculline-induced allodynia and thermal hyperalgesia in mice.
Topics: Animals; Bicuculline; Disease Models, Animal; Glycine; Hot Temperature; Hyperalgesia; Injections; In | 2010 |
Taurine regulation of short term synaptic plasticity in fragile X mice.
Topics: Animals; Binding Sites; Disease Models, Animal; Electric Stimulation; Excitatory Postsynaptic Potent | 2010 |
Neuro-endocrine basis for altered plasma glucose homeostasis in the Fragile X mouse.
Topics: Animals; Blood Glucose; Calcium Channels; Dietary Supplements; Disease Models, Animal; Fragile X Men | 2010 |
Protective functions of taurine against experimental stroke through depressing mitochondria-mediated cell death in rats.
Topics: Adenosine Triphosphate; Animals; bcl-2-Associated X Protein; bcl-X Protein; Brain Ischemia; Calpain; | 2011 |
The effect of supplemental dietary taurine on tinnitus and auditory discrimination in an animal model.
Topics: Acoustic Stimulation; Animals; Auditory Perception; Auditory Threshold; Behavior, Animal; Conditioni | 2010 |
Taurine prevents enhancement of acetylcholinesterase activity induced by acute ethanol exposure and decreases the level of markers of oxidative stress in zebrafish brain.
Topics: Acetylcholinesterase; Alcohol-Induced Disorders, Nervous System; Animals; Brain; Cholinesterase Inhi | 2010 |
A metabonomic comparison of urinary changes in Zucker and GK rats.
Topics: Acids, Acyclic; Animals; Biomarkers; Creatine; Diabetes Mellitus, Type 2; Dimethylamines; Disease Mo | 2010 |
Taurine prevents fat deposition and ameliorates plasma lipid profile in monosodium glutamate-obese rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Disease Models, Animal; Fatty Acid | 2011 |
Preventive effects of taurine on development of hepatic steatosis induced by a high-fat/cholesterol dietary habit.
Topics: Animals; Cholesterol, Dietary; Cricetinae; Dietary Fats; Disease Models, Animal; Fatty Liver; Gene E | 2011 |
Neuroprotection of taurine against bilirubin-induced elevation of apoptosis and intracellular free calcium ion in vivo.
Topics: Animals; Animals, Newborn; Apoptosis; Bilirubin; Brain; Calcium; Calcium Signaling; Caspase 3; Caspa | 2011 |
Effects of taurine on reperfusion injury.
Topics: Animals; Antioxidants; Biopsy, Needle; Disease Models, Animal; Follow-Up Studies; Graft Rejection; G | 2011 |
Early predictive biomarkers for lesion after transient cerebral ischemia.
Topics: Animals; Aspartic Acid; Biomarkers; Disease Models, Animal; Glutamine; Ischemic Attack, Transient; M | 2011 |
Antenatal taurine supplementation for improving brain ultrastructure in fetal rats with intrauterine growth restriction.
Topics: Animals; Brain; Disease Models, Animal; Female; Fetal Nutrition Disorders; Male; Nervous System Malf | 2011 |
Anti-inflammatory mechanism of taurine against ischemic stroke is related to down-regulation of PARP and NF-κB.
Topics: Animals; Anti-Inflammatory Agents; Brain; Cell Death; Disease Models, Animal; Gene Expression Regula | 2012 |
Is there any cardioprotective role of Taurine during cold ischemic period following global myocardial ischemia?
Topics: Animals; Catalase; Disease Models, Animal; Dose-Response Relationship, Drug; Glutathione Peroxidase; | 2011 |
Decrease of calbindin-d28k, calretinin, and parvalbumin by taurine treatment does not induce a major susceptibility to kainic acid.
Topics: Animals; Calbindin 1; Calbindin 2; Calbindins; Calcium-Binding Proteins; Disease Models, Animal; Dis | 2011 |
Antinociceptive effect of intrathecal administration of taurine in rat models of neuropathic pain.
Topics: Analgesics; Animals; Behavior, Animal; Diabetic Neuropathies; Disease Models, Animal; Dose-Response | 2011 |
Retinal remodeling in the Tg P347L rabbit, a large-eye model of retinal degeneration.
Topics: Adult; Animals; Animals, Genetically Modified; Disease Models, Animal; Disease Progression; Electror | 2011 |
UPLC-MS-based urine metabolomics reveals indole-3-lactic acid and phenyllactic acid as conserved biomarkers for alcohol-induced liver disease in the Ppara-null mouse model.
Topics: Alcohols; Analysis of Variance; Animals; Biomarkers; Chromatography, High Pressure Liquid; Disease M | 2011 |
Increase of hippocampal glutamate after electroconvulsive treatment: a quantitative proton MR spectroscopy study at 9.4 T in an animal model of depression.
Topics: Animals; Choline; Depression; Disease Models, Animal; Electroconvulsive Therapy; gamma-Aminobutyric | 2012 |
Taurine attenuates Streptococcus uberis-induced mastitis in rats by increasing T regulatory cells.
Topics: Acetylglucosaminidase; Animals; Anti-Inflammatory Agents, Non-Steroidal; CD4 Lymphocyte Count; Disea | 2012 |
Tolerability of inhaled N-chlorotaurine in an acute pig streptococcal lower airway inflammation model.
Topics: Administration, Inhalation; Animals; Anti-Infective Agents; Bronchoalveolar Lavage Fluid; Bronchopne | 2011 |
The effect of taurine on hepatic steatosis induced by thioacetamide in zebrafish (Danio rerio).
Topics: Animals; Disease Models, Animal; Fatty Liver; Female; Lipid Metabolism; Lipid Peroxidation; Liver; M | 2012 |
Intrauterine growth restriction leads to changes in sulfur amino acid metabolism, but not global DNA methylation, in Yucatan miniature piglets.
Topics: Amino Acids, Sulfur; Animals; Animals, Inbred Strains; Animals, Newborn; Betaine-Homocysteine S-Meth | 2012 |
Identification of N-acetyltaurine as a novel metabolite of ethanol through metabolomics-guided biochemical analysis.
Topics: Acetates; Alcohol Drinking; Animals; Biomarkers; Central Nervous System Depressants; Cytochrome P-45 | 2012 |
Taurine attenuates maternal and embryonic oxidative stress in a streptozotocin-diabetic rat model.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Embry | 2012 |
Taurine deficiency damages retinal neurones: cone photoreceptors and retinal ganglion cells.
Topics: Animals; Biological Transport; Disease Models, Animal; Electroretinography; Eye Proteins; Gene Expre | 2012 |
Behavioral effects of taurine pretreatment in zebrafish acutely exposed to ethanol.
Topics: Alcoholic Intoxication; Animals; Anxiety; Behavior, Animal; Brain; Dietary Supplements; Disease Mode | 2012 |
Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test.
Topics: Acamprosate; Animals; Antidepressive Agents; Benzamides; Depression; Disease Models, Animal; Dose-Re | 2012 |
Antenatal supplementation of taurine for protection of fetal rat brain with intrauterine growth restriction from injury by reducing neuronal apoptosis.
Topics: Analysis of Variance; Animals; Animals, Newborn; Apoptosis; Arabidopsis Proteins; bcl-2-Associated X | 2012 |
N-chlorotaurine and its analogues N,N-dichloro-2,2-dimethyltaurine and N-monochloro-2,2-dimethyltaurine are safe and effective bactericidal agents in ex vivo corneal infection models.
Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Cornea; Disease Models, Animal; Eye Infecti | 2012 |
Combination therapy with taurine, epigallocatechin gallate and genistein for protection against hepatic fibrosis induced by alcohol in rats.
Topics: Actins; Alanine Transaminase; Alkaline Phosphatase; Animals; Antioxidants; Aspartate Aminotransferas | 2012 |
The mechanism of taurine protection against endoplasmic reticulum stress in an animal stroke model of cerebral artery occlusion and stroke-related conditions in primary neuronal cell culture.
Topics: Activating Transcription Factor 6; Animals; Apoptosis; Brain Ischemia; Caspase 12; Caspase 3; Cell S | 2013 |
Taurine is a crucial factor to preserve retinal ganglion cell survival.
Topics: Animals; Cell Survival; Disease Models, Animal; Glaucoma; Membrane Glycoproteins; Membrane Transport | 2013 |
Protection by taurine and thiotaurine against biochemical and cellular alterations induced by diabetes in a rat model.
Topics: Animals; Antioxidants; Blood Glucose; Catalase; Cell Shape; Cholesterol; Diabetes Mellitus, Experime | 2013 |
The effects of taurine and thiotaurine on oxidative stress in the aorta and heart of diabetic rats.
Topics: Animals; Aorta; Blood Glucose; Catalase; Cholesterol; Diabetes Mellitus, Experimental; Disease Model | 2013 |
Comparative evaluation of taurine and thiotaurine as protectants against diabetes-induced nephropathy in a rat model.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Creatinine; Diabetic Nephropathies; Disease Models, Ani | 2013 |
[Effect of zinc L-lysine and taurine against teratogenesis caused by hyperthermia].
Topics: Animals; Disease Models, Animal; Embryonic and Fetal Development; Female; Fetal Weight; Fever; Lysin | 2002 |
Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration.
Topics: Acetylcarnitine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase | 2002 |
Long-time in-vivo metabolic monitoring following experimental brain contusion using proton magnetic resonance spectroscopy.
Topics: Animals; Aspartic Acid; Basal Ganglia; Biomarkers; Brain; Brain Injuries; Disease Models, Animal; Fu | 2002 |
An investigation on skin wound healing in mice with a taurine-chitosan gel formulation.
Topics: Animals; Antioxidants; Biocompatible Materials; Chemistry, Pharmaceutical; Chitin; Chitosan; Collage | 2002 |
Antithrombotic activity of N,N-dichlorotaurine on mouse model of thrombosis in vivo.
Topics: Adenosine Diphosphate; Amino Acids; Animals; Chloramines; Disease Models, Animal; Fibrinolytic Agent | 2002 |
Guanosine enhances glutamate uptake in brain cortical slices at normal and excitotoxic conditions.
Topics: Animals; Cell Death; Cerebral Cortex; Disease Models, Animal; Dose-Response Relationship, Drug; Down | 2002 |
Astrocyte metabolism is disturbed in the early development of experimental hydrocephalus.
Topics: Acetates; Animals; Astrocytes; Biomarkers; Brain Stem; Carbon Isotopes; Disease Models, Animal; Dise | 2003 |
An hypothesis for a mechanism underlying hepatotoxin-induced hypercreatinuria.
Topics: 1-Naphthylisothiocyanate; Administration, Oral; Animals; Chemical and Drug Induced Liver Injury; Cre | 2003 |
The influence of adhesion prophylactic substances and taurolidine/heparin on local recurrence and intraperitoneal tumor growth after laparoscopic-assisted bowel resection of colon carcinoma in a rat model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cellulose, Oxidized; Colonic Neoplasms; Disease Mode | 2003 |
Extracellular glutamate and other amino acids in experimental intracerebral hemorrhage: an in vivo microdialysis study.
Topics: Analysis of Variance; Animals; Asparagine; Aspartic Acid; Brain Ischemia; Cerebral Hemorrhage; Chrom | 2003 |
Retinal remodeling triggered by photoreceptor degenerations.
Topics: Aging; Amino Acids; Animals; Animals, Genetically Modified; Cell Death; Cell Movement; Disease Model | 2003 |
Hypoglycemic effects of taurine in the alloxan-treated rabbit, a model for type 1 diabetes.
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Hypoglycem | 2003 |
The combined treatment with taurine and niacin blocks the bleomycin-induced activation of nuclear factor-kappaB and lung fibrosis.
Topics: Animals; Base Sequence; Bleomycin; Blotting, Western; Bronchoalveolar Lavage Fluid; Cytokines; Disea | 2003 |
Selective alterations of brain osmolytes in acute liver failure: protective effect of mild hypothermia.
Topics: Animals; Brain Edema; Disease Models, Animal; Glutamine; Hepatic Encephalopathy; Hypothermia, Induce | 2004 |
Effects of taurine on proliferation and apoptosis of hepatic stellate cells in vitro.
Topics: Animals; Apoptosis; Cell Division; Cells, Cultured; Disease Models, Animal; Genes, fos; Hepatocytes; | 2004 |
[Study of teratogenicity of hyperglycemia on neural tube defects and antagonistic effect of taurine].
Topics: Animals; Connexin 43; Disease Models, Animal; DNA-Binding Proteins; Female; Gene Expression Regulati | 2004 |
Hoe 140 abolishes the blood pressure lowering effect of taurine in high fructose-fed rats.
Topics: Administration, Oral; Animals; Blood Pressure; Body Weight; Bradykinin; Disease Models, Animal; Fruc | 2004 |
Taurine inhibits apoptosis by preventing formation of the Apaf-1/caspase-9 apoptosome.
Topics: Animals; Animals, Newborn; Apoptosis; Apoptotic Protease-Activating Factor 1; Blotting, Western; Cas | 2004 |
The mosaic of addiction.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior, Addictive; Disease Models, | 2004 |
The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma.
Topics: Amino Acid Chloromethyl Ketones; Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Body Weight; | 2004 |
Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model.
Topics: Administration, Topical; Animals; Anti-Infective Agents, Local; Cefazolin; Ciprofloxacin; Colony Cou | 2005 |
[Effects of taurine on early changes of excitatory amino acids in rabbit brain due to deep hypothermic circulatory arrest].
Topics: Animals; Brain Ischemia; Disease Models, Animal; Excitatory Amino Acids; Extracorporeal Circulation; | 2005 |
Impact of taurolidine on the growth of CC531 coloncarcinoma cells in vitro and in a laparoscopic animal model in rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Colonic Neoplasms; | 2005 |
Nutritional regulation of proteases involved in fetal rat insulin secretion and islet cell proliferation.
Topics: Acetylcysteine; Animals; Calcium-Binding Proteins; Calpain; Cell Proliferation; Cells, Cultured; Die | 2005 |
[Protective effects of taurine on myocardial injury in severely burned rats].
Topics: Angiotensin II; Animals; Burns; Calcium; Disease Models, Animal; Female; Male; Malondialdehyde; Myoc | 2005 |
Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; bet | 2005 |
Taurine may prevent diabetic rats from developing cardiomyopathy also by downregulating angiotensin II type2 receptor expression.
Topics: Animals; Apoptosis; Biomarkers; Blood Glucose; Blotting, Western; Cardiomyopathies; Carotid Artery, | 2005 |
Inhibition of septic arthritis by local administration of taurine chloramine, a product of activated neutrophils.
Topics: Animals; Arthritis, Infectious; Cells, Cultured; Disease Models, Animal; Down-Regulation; Female; In | 2005 |
Production of reactive oxygen species following acute ethanol or acetaldehyde and its reduction by acamprosate in chronically alcoholized rats.
Topics: Acamprosate; Acetaldehyde; Alcohol Deterrents; Alcoholism; Animals; Disease Models, Animal; Ethanol; | 2005 |
Investigations into biochemical changes of genetic hypertensive rats using 1H nuclear magnetic resonance-based metabonomics.
Topics: Animals; Citric Acid; Creatine; Creatinine; Dimethylamines; Disease Models, Animal; Hypertension; Ke | 2005 |
Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype.
Topics: Animals; Corpus Striatum; Disease Models, Animal; gamma-Aminobutyric Acid; Huntington Disease; Male; | 2005 |
Metabolic insights into the hepatoprotective role of N-acetylcysteine in mouse liver.
Topics: Acetylcysteine; Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Citric Acid Cycle; Cy | 2006 |
Alterations of taurine in the brain of chronic kainic acid epilepsy model.
Topics: Animals; Behavior, Animal; Brain; Disease Models, Animal; Epilepsy; Kainic Acid; Rats; Rats, Sprague | 2006 |
Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Type 2; Disease Models, Animal; Ganglia, Spinal; Male; Neu | 2006 |
Effect of peritoneal lavage with taurolidine on primary colonic anastomosis in a rat model of secondary peritonitis.
Topics: Anastomosis, Surgical; Animals; Anti-Infective Agents, Local; Colon; Disease Models, Animal; Female; | 2006 |
N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model.
Topics: Adenoviridae; Adenoviridae Infections; Animals; Antiviral Agents; Cidofovir; Cornea; Cytosine; Disea | 2006 |
Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloidosis; Animals; Brain; Cell Death; Cell | 2007 |
Accelerated NaCl-induced hypertension in taurine-deficient rat: role of renal function.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Baroreflex; beta-Alanine; Blood Pr | 2006 |
Taurine protects against ischemia-reperfusion injury in rabbit livers.
Topics: Animals; Disease Models, Animal; Injections, Intravenous; Kinetics; Lipid Peroxidation; Liver; Liver | 2006 |
Antioxidant treatment with taurine ameliorates chronic pancreatitis in an experimental rat model.
Topics: Animals; Antioxidants; Body Weight; Disease Models, Animal; Fibrosis; Glutathione Peroxidase; Male; | 2006 |
Taurine ameliorates water avoidance stress-induced degenerations of gastrointestinal tract and liver.
Topics: Animals; Avoidance Learning; Colon; Disease Models, Animal; Female; Gastric Mucosa; Glutathione; Ile | 2006 |
Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation.
Topics: Animals; Cerebral Cortex; Dementia; Disease Models, Animal; Gliosis; Humans; Memory Disorders; Mice; | 2006 |
Peritoneal instillation of taurolidine or polihexanide modulates intestinal microcirculation in experimental endotoxemia.
Topics: Animals; Anti-Infective Agents, Local; Biguanides; Disease Models, Animal; Endotoxemia; Gastrointest | 2007 |
Taurine attenuates acute hyperglycaemia-induced endothelial cell apoptosis, leucocyte-endothelial cell interactions and cardiac dysfunction.
Topics: Acute Disease; Animals; Apoptosis; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cell Adhe | 2007 |
Taurine ameliorates stress-induced degeneration of the urinary bladder.
Topics: Animals; Cell Count; Cystitis, Interstitial; Disease Models, Animal; Escape Reaction; Female; Free R | 2007 |
Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment.
Topics: Animals; Anti-Infective Agents, Local; Antineoplastic Agents; Cell Line, Tumor; Chemokine CCL19; Che | 2007 |
Consideration of acamprosate for treatment of amyotrophic lateral sclerosis.
Topics: Acamprosate; Animals; Calcium; Disease Models, Animal; Humans; Mice; Motor Neuron Disease; Motor Neu | 2007 |
Taurine as a marker for foetal wellbeing?
Topics: Amino Acids; Animals; Biomarkers; Disease Models, Animal; Female; Fetal Death; Fetal Development; Fe | 2007 |
Attenuation by dietary taurine of dextran sulfate sodium-induced colitis in mice and of THP-1-induced damage to intestinal Caco-2 cell monolayers.
Topics: Animals; Caco-2 Cells; Colitis; Colon; Cytokines; Dextran Sulfate; Diarrhea; Dietary Supplements; Di | 2008 |
High-dose taurine supplementation increases serum paraoxonase and arylesterase activities in experimental hypothyroidism.
Topics: Animals; Antioxidants; Aryldialkylphosphatase; Carboxylic Ester Hydrolases; Cholesterol; Cholesterol | 2007 |
Taurine fails to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Corpus Striatum; Disease Models, Anima | 2008 |
Intra-abdominal use of taurolidine or heparin as alternative products to an antiadhesive barrier (Seprafilm) in adhesion prevention: an experimental study on mice.
Topics: Abdominal Cavity; Animals; Antineoplastic Agents; Digestive System Surgical Procedures; Disease Mode | 2007 |
The effect of taurolidine on experimental thrombus formation.
Topics: Animals; Blood Coagulation; Blood Coagulation Factors; Disease Models, Animal; Fibrinolytic Agents; | 2008 |
An evaluation of normal saline and taurolidine on intra-abdominal adhesion formation and peritoneal fibrinolysis.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Female; Fibrinolysis; Hydroxyproline; Perito | 2008 |
Brainstem amino acid neurotransmitters and ventilatory response to hypoxia in piglets.
Topics: Acid-Base Equilibrium; Amino Acids; Animals; Animals, Newborn; Aspartic Acid; Blood Pressure; Carbon | 2008 |
Effect of chronic acamprosate treatment on voluntary alcohol intake and beta-endorphin plasma levels in rats selectively bred for high alcohol preference.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; beta-Endorphin; Disease Mode | 2008 |
The effect of taurine on mesenteric blood flow and organ injury in sepsis.
Topics: Animals; Blood Flow Velocity; Disease Models, Animal; Endotoxins; Free Radicals; Glutathione; Inject | 2008 |
Effect of taurine on oxidative stress and apoptosis-related protein expression in trinitrobenzene sulphonic acid-induced colitis.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Blotting, Western; Co | 2008 |
Taurine attenuates aminoglycoside ototoxicity by inhibiting inducible nitric oxide synthase expression in the cochlea.
Topics: Aminoglycosides; Animals; Cochlea; Disease Models, Animal; Down-Regulation; Drug Interactions; Evoke | 2008 |
Tryptophan administration induces oxidative stress in brain cortex of rats.
Topics: alpha-Tocopherol; Amino Acid Metabolism, Inborn Errors; Animals; Antioxidants; Brain Diseases, Metab | 2008 |
[Changes of amino acids neurotransmitters in striatum of hemi-parkinsonian rhesus monkey after high frequency stimulation of subthalamic nucleus].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Chromatography, High Pressure Li | 2007 |
Evidence for a role of neurotransmitters in the mechanism of topical convulsant models.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Aspartic Acid; Brain; Choline O-Acetyltransferase; Dis | 1984 |
Effect of glutaurine on liver tumour development and acute leukaemia induced by MC29 virus in turkey poults.
Topics: Animals; Avian Leukosis; Avian Leukosis Virus; Disease Models, Animal; Female; Glutamine; Liver Neop | 1983 |
Free amino acids in epilepsy: possible role of taurine.
Topics: Amino Acids; Animals; Brain; Cerebral Cortex; Disease Models, Animal; Electroencephalography; Epilep | 1983 |
Intraperitoneal antiseptics in experimental bacterial peritonitis.
Topics: Animals; Anti-Infective Agents, Local; Chlorhexidine; Disease Models, Animal; Escherichia coli Infec | 1984 |
Evidence for an hereditary defect in taurine transport in the ciliary epithelium of an inbred strain of rabbits.
Topics: Amino Acid Metabolism, Inborn Errors; Animals; Aqueous Humor; Biological Transport; Ciliary Body; Di | 1983 |
Penicillin spikes in rats. Limitations of a simple model for the study of anticonvulsants.
Topics: Action Potentials; Animals; Anticonvulsants; Dimethyl Sulfoxide; Disease Models, Animal; Drug Evalua | 1984 |
Retinal degenerations in the dog and cat as models for retinitis pigmentosa.
Topics: Animals; Cat Diseases; Cats; Disease Models, Animal; Dog Diseases; Dogs; Retina; Retinal Degeneratio | 1983 |
Role of sulfur amino acids in the prevention and regression of cardiovascular diseases.
Topics: Amino Acids, Sulfur; Animals; Arteriosclerosis; Blood Pressure; Cardiovascular Diseases; Cerebrovasc | 1983 |
Experimental homocysteinemia in pigs: comparison with studies in sixteen homocystinuric patients.
Topics: Adolescent; Adult; Amino Acids; Aminobutyrates; Animals; Child; Child, Preschool; Dipeptides; Diseas | 1982 |
Taurine-induced thalamocortical dissociative effects in an experimental model of epilepsy.
Topics: Action Potentials; Animals; Brain; Cats; Cerebellum; Cerebral Cortex; Disease Models, Animal; Epilep | 1981 |
Effect of portacaval shunt on sulfur amino acid metabolism in rats.
Topics: Amino Acids, Sulfur; Animals; Disease Models, Animal; Glutathione; Liver Diseases; Male; Oxidation-R | 1981 |
Dietary supplementation with taurine and niacin prevents the increase in lung collagen cross-links in the multidose bleomycin hamster model of pulmonary fibrosis.
Topics: Animals; Bleomycin; Collagen; Cricetinae; Diet; Dipeptides; Disease Models, Animal; Male; Mesocricet | 1994 |
Aminoacid recovery via microdialysis and photoinduced focal cerebral ischemia in brain cortex of rats.
Topics: Amino Acids; Animals; Apoptosis; Brain Ischemia; Cerebral Cortex; Disease Models, Animal; Glutamic A | 1995 |
Effect of experimental Escherichia coli meningitis on concentrations of excitatory and inhibitory amino acids in the rabbit brain: in vivo microdialysis study.
Topics: Amino Acids; Animals; Aspartic Acid; Blood Pressure; Brain; Cerebrovascular Circulation; Disease Mod | 1993 |
Lung injury following exposure of rats to relatively high mass concentrations of nitrogen dioxide.
Topics: Administration, Inhalation; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Lung | 1994 |
Effects of bile acids and taurine on the lipid fluidity of hepatic microsomes in normal and bile duct-ligated rats--a spin label study.
Topics: Animals; Bile Acids and Salts; Cholestasis, Intrahepatic; Disease Models, Animal; Electron Spin Reso | 1993 |
Effects of repeated cerebral ischemia on extracellular amino acid concentrations measured with intracerebral microdialysis in the gerbil hippocampus.
Topics: Amino Acids; Animals; Brain Ischemia; Disease Models, Animal; Extracellular Space; gamma-Aminobutyri | 1993 |
Hypercholeresis with cholate infusion in dogs with pigment gallstones.
Topics: Animals; Bile; Bile Acids and Salts; Bile Pigments; Cholagogues and Choleretics; Cholelithiasis; Cho | 1996 |
Dietary glutamine supplementation prevents jejunal atrophy in weaned pigs.
Topics: Alanine; Animals; Aspartic Acid; Atrophy; Diet; Disease Models, Animal; Duodenum; Epithelium; Female | 1996 |
Alternatives to naltrexone in animal models.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disease Models, Animal; Drug Evaluation, Precl | 1996 |
Reversible model of magnesium depletion induced by systemic kainic acid injection in magnesium-deficient rats: I--Comparative study of various magnesium salts.
Topics: Administration, Oral; Animals; Disease Models, Animal; Food, Fortified; Injections, Intraperitoneal; | 1996 |
Inhibition of peritoneal tumor cell growth and implantation in laparoscopic surgery in a rat model.
Topics: Adenocarcinoma; Animals; Cell Division; Colonic Neoplasms; Disease Models, Animal; Drug Combinations | 1997 |
Regulation of transforming growth factor-beta1 mRNA expression by taurine and niacin in the bleomycin hamster model of lung fibrosis.
Topics: Animals; Bleomycin; Bronchoalveolar Lavage Fluid; Collagen; Cricetinae; Diet; Disease Models, Animal | 1998 |
Changes in brain organic osmolytes in experimental cerebral ischemia.
Topics: Alanine; Amino Acids; Animals; Aspartic Acid; Brain Chemistry; Brain Ischemia; Creatine; Disease Mod | 1998 |
Effect of alpha-tocopherol, taurine and selenium on the attenuation of ischemia/reperfusion injury of splanchnic organs.
Topics: Animals; Cecum; Disease Models, Animal; Duodenum; Ileum; Jejunum; Male; Random Allocation; Rats; Rat | 1998 |
No beneficial effects of taurine application on oxygen free radical production after hemorrhagic shock in rats.
Topics: Alanine Transaminase; Animals; Antioxidants; Disease Models, Animal; Free Radicals; Hemodynamics; L- | 1998 |
Taurine can ameliorate inflammatory bowel disease in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colon; Disease Models, Animal; Eicosanoids; Inflam | 1998 |
Taurine entry into perilymph of the guinea pig.
Topics: Animals; Bile; Blood Proteins; Chlorides; Disease Models, Animal; Diuretics, Osmotic; Follow-Up Stud | 1998 |
Dietary supplementation with the inhibitory amino acid taurine suppresses autotomy in HA rats.
Topics: Administration, Oral; Amino Acids; Animals; Disease Models, Animal; Hindlimb; Male; Pain; Pain Measu | 1998 |
Antioxidant status in experimental peritonitis: effects of alpha tocopherol and taurolin.
Topics: Animals; Anti-Infective Agents; Antioxidants; Disease Models, Animal; Glutathione; Glutathione Perox | 1999 |
The postantibiotic effect of N-chlorotaurine on Staphylococcus aureus. Application in the mouse peritonitis model.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Disease Models, Animal; Mice; Peritonitis; Sta | 1999 |
[Glutamate receptor agonists and alcohol dependence. Preclinical findings].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Chronic Disease; Disease Models, Animal; Human | 1999 |
Modelling cortical cataractogenesis 21: in diabetic rat lenses taurine supplementation partially reduces damage resulting from osmotic compensation leading to osmolyte loss and antioxidant depletion.
Topics: Adenosine Triphosphate; Amino Acids; Animals; Antioxidants; Blood Glucose; Cataract; Crystallins; Di | 1999 |
Striatal outflow of adenosine, excitatory amino acids, gamma-aminobutyric acid, and taurine in awake freely moving rats after middle cerebral artery occlusion: correlations with neurological deficit and histopathological damage.
Topics: Adenosine; Animals; Arterial Occlusive Diseases; Brain Ischemia; Cerebral Cortex; Chromatography, Hi | 1999 |
Prevention of atherosclerotic lesion development in mice by taurine.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Diet, At | 1999 |
Taurine attenuates hypertension and improves insulin sensitivity in the fructose-fed rat, an animal model of insulin resistance.
Topics: Animals; Blood Glucose; Blood Pressure; Creatinine; Disease Models, Animal; Fructose; Glucose Tolera | 1999 |
Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes.
Topics: Adipose Tissue; Analysis of Variance; Animals; Blood Urea Nitrogen; Body Weight; Cholesterol; Diabet | 2000 |
Gastric mucosal damage caused by monochloramine in the rat and protective effect of taurine: endoscopic observation through gastric fistula.
Topics: Analysis of Variance; Animals; Chloramines; Disease Models, Animal; Dose-Response Relationship, Drug | 2000 |
Modulation of tumor-induced lethality after pneumoperitoneum in a mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Disease Models, Animal; Fema | 2000 |
Pharmacological validation of a new animal model of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Disease Models, Animal; Nalt | 2000 |
Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin.
Topics: Animals; Bleomycin; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Gene Expression Regulation | 2000 |
beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Aspartic Acid; Astrocytes; Basal Nucleus of Meyne | 2000 |
Taurolidine inhibits tumor cell growth in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Anti-Infective Agents, Local; Cell Death; Cell Division; Cell Survival; Col | 2000 |
In vitro 1H and 31P NMR spectroscopic evidence of multiple aberrant biochemical pathways in murine trisomy 16 brain development.
Topics: Alanine; Animals; Aspartic Acid; Biomarkers; Brain Chemistry; Choline; Creatine; Disease Models, Ani | 2000 |
Spinal taurine levels are increased 7 and 30 days following methylprednisolone treatment of spinal cord injury in rats.
Topics: Animals; Chromatography, High Pressure Liquid; Disease Models, Animal; Injections, Intravenous; Male | 2001 |
Mechanisms of taurine antihypoxic and antioxidant action.
Topics: Animals; Antioxidants; Disease Models, Animal; Drug Evaluation, Preclinical; Hypoxia; Injections, In | 2000 |
Energy-related metabolites during and after induced myocardial infarction with special emphasis on the reperfusion injury after extracorporeal circulation.
Topics: Adenosine; Animals; Chromatography, High Pressure Liquid; Dialysis Solutions; Disease Models, Animal | 2001 |
Effects of taurine on cerulein-induced acute pancreatitis in the rat.
Topics: Acute Disease; Amylases; Animals; Ceruletide; Disease Models, Animal; Interleukin-1; Lung Diseases; | 2001 |
Antioxidant effect of taurine against lead-induced oxidative stress.
Topics: Animals; Antioxidants; Chelating Agents; CHO Cells; Cricetinae; Disease Models, Animal; Lead Poisoni | 2001 |
Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy.
Topics: Aldehydes; Animals; Ascorbic Acid; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diab | 2001 |
Effects of taurine on pulmonary responses to antigen in sensitized Brown-Norway rats.
Topics: Airway Resistance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigens; Asthma; Bronchoalveol | 2001 |
Effects of long-term treatment with taurine in mice fed a high-fat diet: improvement in cholesterol metabolism and vascular lipid accumulation by taurine.
Topics: Animals; Aorta; Arteriosclerosis; Body Weight; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Dietary | 2000 |
Hypolipidemic effect of taurine in golden Syrian hamsters.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Cricetinae; Dietary Fats; Dietary Supplements; Disease M | 2000 |
The treatment of ammonia poisoning by taurine in combination with a broncholytic drug.
Topics: Administration, Inhalation; Ammonia; Animals; Antidotes; Antioxidants; Bronchodilator Agents; Diseas | 2000 |
Neurogenic bladder model for spinal cord injury: spinal cord microdialysis and chronic urodynamics.
Topics: Animals; Catheters, Indwelling; Disease Models, Animal; Female; Glutamic Acid; Glycine; Microdialysi | 2002 |
Central nervous system mechanisms in alcohol relapse.
Topics: Acamprosate; Alcoholism; Animals; Behavior; Central Nervous System; Corticotropin-Releasing Hormone; | 2002 |
Taurine suppresses development of atherosclerosis in Watanabe heritable hyperlipidemic (WHHL) rabbits.
Topics: Acyl Coenzyme A; Animals; Aorta, Thoracic; Arteriosclerosis; Blood Pressure Determination; Cholester | 2002 |
The cytoprotective role of taurine in exercise-induced muscle injury.
Topics: Amino Acids; Animals; Creatine Kinase; Cytoprotection; Dietary Supplements; Disease Models, Animal; | 2002 |
Sulfur-containing amino acids in experimental hepatic coma in the dog and the monkey.
Topics: Amino Acids, Branched-Chain; Amino Acids, Sulfur; Animals; Brain Chemistry; Disease Models, Animal; | 1979 |
The Syrian golden hamster: a model for the cardiomyopathy of Friedreich's ataxia.
Topics: Animals; Calcium; Cardiomyopathies; Cricetinae; Disease Models, Animal; Friedreich Ataxia; Iron; Mag | 1979 |
The anti-endotoxin activity of Taurolin in experimental animals.
Topics: Animals; Anti-Bacterial Agents; Bacteroides fragilis; Disease Models, Animal; Endotoxins; Escherichi | 1979 |
Relationships between electroencephalographic pattern and biochemical picture of the cobalt epileptogenic lesion after cortical superfusion with taurine.
Topics: Amino Acids; Animals; Anticonvulsants; Cats; Cerebral Cortex; Cobalt; Disease Models, Animal; Drug E | 1977 |
Uptake studies of taurine in vivo and its effects on the course of experimental focal epilepsy in rats.
Topics: Animals; Blood-Brain Barrier; Cerebral Cortex; Cobalt; Disease Models, Animal; Drug Evaluation, Prec | 1977 |
Hypertension and atherogenesis in animal models - a new aspect on the relationship [proceedings].
Topics: Animals; Arteriosclerosis; Blood Pressure; Cerebrovascular Disorders; Cholesterol; Disease Models, A | 1979 |
A relation between myocardial taurine contest and pulmonary wedge pressure in dogs with heart failure.
Topics: Animals; Blood Pressure; Cardiac Catheterization; Disease Models, Animal; Dogs; Heart Failure; Heart | 1977 |
[Biochemistry of epilepsy: the experimental audiogenic model].
Topics: Animals; Choline O-Acetyltransferase; Disease Models, Animal; Ear, Middle; gamma-Aminobutyric Acid; | 1977 |
Taurine protection of lungs in hamster models of oxidant injury: a morphologic time study of paraquat and bleomycin treatment.
Topics: Animals; Antioxidants; Bleomycin; Cricetinae; Diet; Disease Models, Animal; Fresh Water; Lung Diseas | 1992 |
Co-culture of primary pulmonary cells to model alveolar injury and translocation of proteins.
Topics: alpha-Macroglobulins; Animals; Biological Transport; Cell Membrane Permeability; Cells, Cultured; Co | 1990 |
[Use of taurine in the treatment of experimental congestive heart failure].
Topics: Animals; Chronic Disease; Disease Models, Animal; Drug Evaluation, Preclinical; Heart Failure; Hemod | 1991 |
Stroke-prone spontaneously hypertensive rats as a model for toxemia of pregnancy and aggravating and preventive effects of maternal modifications during pregnancy on offspring's growth.
Topics: Animals; Birth Weight; Blood Pressure; Cerebrovascular Disorders; Disease Models, Animal; Embryonic | 1990 |
Hepatic sulfur amino acid metabolism in rats with chronic renal failure.
Topics: Amino Acids, Sulfur; Animals; Anorexia; Creatinine; Cystathionine beta-Synthase; Cystathionine gamma | 1990 |
Systemic approaches to modifying quinolinic acid striatal lesions in rats.
Topics: 2-Amino-5-phosphonovalerate; Allopurinol; Amino Acids; Animals; Antioxidants; Baclofen; Corpus Stria | 1988 |
Macular pathology in monkeys fed semipurified diets.
Topics: Animals; Cell Count; Dietary Proteins; Disease Models, Animal; Female; Fluorescein Angiography; Long | 1989 |
[The early diagnosis, evaluation of treatment results and modelling of certain aspects of the pathogenesis of retinal dystrophy].
Topics: Adult; Aged; Animals; Conjunctiva; Disease Models, Animal; Drug Evaluation; Drug Evaluation, Preclin | 1989 |
Embryonic exposure to high taurine: a possible nutritional contribution to Friedreich's ataxia.
Topics: Animals; Brain; Chick Embryo; Chickens; Disease Models, Animal; Dose-Response Relationship, Drug; Fr | 1988 |
Effect of taurine on the lung collagen content in myopathic hamsters.
Topics: Animals; Cardiomyopathies; Collagen; Cricetinae; Disease Models, Animal; Lung; Mesocricetus; Referen | 1988 |
Adaptive decreases in amino acids (taurine in particular), creatine, and electrolytes prevent cerebral edema in chronically hyponatremic mice: rapid correction (experimental model of central pontine myelinolysis) causes dehydration and shrinkage of brain.
Topics: Acclimatization; Adenine Nucleotides; Amino Acids; Animals; Brain; Brain Edema; Creatine; Demyelinat | 1987 |
Zinc, taurine, and epilepsy.
Topics: Adenosine Triphosphatases; Adult; Aminobutyrates; Animals; Behavior, Animal; Brain; Cerebral Cortex; | 1974 |
Effects of taurine on cortical acute epileptic foci.
Topics: Animals; Anticonvulsants; Cats; Cerebral Cortex; Cobalt; Disease Models, Animal; Electroencephalogra | 1974 |
Concentration of amino acids in the brain of cobalt-epileptic rat.
Topics: Alanine; Amino Acids; Animals; Aspartic Acid; Brain Chemistry; Cerebral Cortex; Cobalt; Disease Mode | 1973 |
Absolute levels of some free amino acids in normal and biologically fractionated retinas.
Topics: Adaptation, Ocular; Alanine; Amino Acids; Aminobutyrates; Animals; Autoanalysis; Dark Adaptation; Di | 1973 |
Development of malnutrition in rats.
Topics: Amino Acids; Animal Nutritional Physiological Phenomena; Animals; Blood Protein Electrophoresis; Blo | 1974 |
Bile salts of spontaneously atherosclerosis-susceptible white Carneau pigeon.
Topics: Animals; Arteriosclerosis; Bile; Bile Acids and Salts; Bird Diseases; Chromatography, Gas; Chromatog | 1971 |